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ABSTRACT 
Streptococcus pyogenes causes an estimated 616 million pharyngitis cases per year 
and a variety of invasive diseases such as necrotising fasciitis and toxic shock 
syndrome. The human nasopharynx is the major reservoir for all S. pyogenes 
infection, including severe invasive disease. A combination of biophotonic imaging 
(BPI) and direct nasal sampling techniques were used to longitudinally measure the 
in vivo carriage of S. pyogenes, looking at the effects of virulence factor expression 
on carriage and transmission and to enable vaccine evaluation. 
Direct nasal sampling demonstrated that the two component regulatory system, 
CovR/S, is required for infection and transmission from the nasopharynx.  The 
fitness cost conferred by covR/S mutation in the nasopharynx may explain why S. 
pyogenes with altered covR/S have not become prevalent in community infections 
despite conferring a selective advantage in invasive infection.  
Bioluminescent S. pyogenes strains expressing the luxABCDE operon demonstrated 
a growth deficit independent of the target site for integration in vitro that manifested 
as a fitness cost during infection in vivo.  Notwithstanding this, bioluminescence 
expression permitted longitudinal quantitation of S. pyogenes within the nasopharynx 
using BPI. Intramuscular vaccination with heat killed streptococci or the 
streptococcal chemokine protease SpyCEP conferred protection against pharyngeal 
infection in this model. 
These longitudinal techniques allow for S. pyogenes to be tracked in the 
nasopharynx non-invasively, and allow for new insights into the pathogenesis of this 
disease. 
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CHAPTER 1. INTRODUCTION 
1.1. STREPTOCOCCUS PYOGENES 
Streptococcus pyogenes is a Gram positive bacterium that primarily afflicts the 
nasopharynx, and is responsible for an estimated 616 million new cases of 
pharyngitis worldwide every year [1]. It was first named in relation to pyogenic 
osteomyelitis and wound infections [2], and was later found to be the causative 
bacterium of septicaemia [3], erysipelas, puerperal sepsis [3], necrotising fasciitis [4] 
and scarlet fever [5].  The links between streptococcal infection and the onset of 
rheumatic heart disease [6], and glomerulonephritis were later understood to be 
immune sequelae triggered by an initial infection with S. pyogenes [7,8]. The 
worldwide mortality from these diseases, taken together, is estimated to be 517,000 
deaths per year [1].  
S. pyogenes is also the cause of contagious skin conditions such as impetigo, which 
is found mainly in populations where such disease is endemic and exposure is 
common [9]. Although S. pyogenes is associated with 30-40% of cases of paediatric 
pharyngitis, the bacterium can occur asymptomatically within the nasopharynx at a 
rate of 12% within children [10],  and at much lower rates in adults [11]. S. pyogenes 
is an exclusively human pathogen and is known to utilise a number of strategies to 
survive in different niches within the human body. 
Streptococci were first differentiated from other bacteria based on their shape and 
structure when observed under the microscope [3]. S. pyogenes in particular was 
notable for causing β-haemolysis on the surface of blood agar plates. Further work 
differentiated it from other β-haemolytic streptococci based on the surface expressed 
group A carbohydrate. Genetic tools have provided even more insight into the vast 
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diversity that exists within the S. pyogenes population. During the course of its 
evolution, S. pyogenes has acquired an array of accessory gene elements, such as 
phages and phage-like elements that allow it to colonise the human host, and the 
tissues within [12,13]. These often carry important virulence factors. The presence of 
these virulence factors and the regulation thereof form the basis for the diversity of 
different diseases encoded by S. pyogenes. 
1.2. THE MOLECULAR BASIS OF STREPTOCOCCAL ADHESION AND INVASION. 
S. pyogenes encodes a variety of different surface expressed factors which play 
important roles in the binding and invasion of host cells.  In S. pyogenes, relevant 
surface proteins are exported across the cytoplasmic membrane via the Sec 
pathway. These are localised within a distinct region of the cell membrane known as 
the Exportal, which contains factors that enable the folding and maturation of 
secreted proteins [14]. Proteins to be expressed on the bacterial surface often 
demonstrate an LPXTG sequence motif within the C-terminal domain, which is 
recognised by bacterial sortases that anchor it to the peptidoglycan cell wall [15]. 
The M protein, identified by Rebecca Lancefield and colleagues in the late 1930’s 
was one of the first such proteins to be described for S. pyogenes [16]. 
However, S. pyogenes also produces a number of polysaccharides on its surface 
that also play important roles in bacterial adhesion [17].  Lipoteichoic acid is one 
such example. This carbohydrate binds to host membrane phospholipids, fibronectin 
and the CD14 receptors, which enable S. pyogenes to bind weakly to a variety of 
human cell types [18,19]. This interaction brings the host cell membrane and 
streptococcal surface antigens into close proximity, allowing for a second more 
strongly adherent and more specific streptococcal surface protein receptor to bind, 
20 
 
such as M-protein. There are multiple variants of M-proteins, encoded by emm 
genes in different strains of S. pyogenes, that bind to host factors such as CD46, 
laminin and fibronectin [19]. S. pyogenes also possesses a number of different 
adhesins which bind to fibronectin, such as sfb1, Fbp54, Fbp29, serum opacity factor 
and glyceraldehyde-3-phosphate dehydrogenase. In addition to this, S. pyogenes 
produces a hyaluronic acid capsule that enables binding to the CD44 receptor on 
epithelial cells [20]. 
The interaction between these adhesion factors and the host cell cytoskeleton 
[21,22] can induce the internalisation of S. pyogenes within epithelial cells, 
theoretically enabling the long term persistence of S. pyogenes within target tissues 
[23]. This internalisation prevents the detection of S. pyogenes by the host immune 
system and may protect bacteria from β lactam antibiotics. 
S. pyogenes also encodes the FCT pilus (also known as the T-antigen [24] ) that 
consists of a backbone protein , with an ancillary protein at the tip which mediates its 
binding [25] to factors such as gp340. This compound is found in saliva [26] and 
gp340 binding promotes aggregation and streptococcal biofilm formation. Biofilms 
confer protection to S. pyogenes against antibiotics and host clearance [27].  
These adhesion molecules are important for S .pyogenes during superficial tissue 
infections on the skin or within the nasopharynx. To invade sterile sites and deeper 
issues, S. pyogenes employs a different set of strategies to disseminate within these 
tissues and to combat the immune response. 
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1.3. VIRULENCE FACTORS ENABLE S. PYOGENES TO EVADE THE IMMUNE 
SYSTEM. 
The production of virulence factors by S. pyogenes enables it to evade the immune 
system. The key to immune defence against S. pyogenes is the initiation of 
neutrophil-mediated killing that requires opsonisation by complement and 
immunoglobulin. Often, these virulence factors can be directly secreted via specific 
ABC transporters [28], or through the previously mentioned Sec pathway. They can 
also be expressed as surface proteins, which later undergo cleavage and release 
specific portions to interact with the immune system. 
Amongst the first secreted virulence factors to be described were the streptolysins, 
due to their β-haemolytic activity [29]. Streptolysin O forms pores in membranes, 
which can allow for the entry of virulence factors such as NADase [30], Whilst these 
can induce cytolysis of red blood cells and neutrophils, at lower concentrations they 
have been shown to interfere with phagocytosis [31].  
Cationic host antimicrobial peptides (AMP) such as LL37, derived from cathelicidin, 
have lytic activity against streptococci and are found in secretions from the upper 
respiratory tract as well as within neutrophil granules. It is therefore essential that S. 
pyogenes can combat AMPs and defensins, which is achieved by production of 
enzymes that can bind, cleave and inactivate these factors, such as the 
‘streptococcal inhibitor of complement (SIC) [32].  
The relative importance of the various complement pathways to S. pyogenes 
immunity is not clear cut. The complement cascade can recognise S. pyogenes via 
the classical pathway through interaction of C1q with antibody bound to the 
streptococcal surface. Some studies suggest that C1q can directly bind to S. 
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pyogenes and can facilitate its clearance without the need for classical pathway 
activation [33]. S. pyogenes can also be detected by complement through the 
recognition of mannose sugars on the streptococcal surface of by the mannose 
binding lectin pathway. The complement protein C3 is recruited in the process of 
both these pathways, and can independently initiate the downstream antibacterial 
activities of the complement cascade via an alternative pathway. This involves the 
deposition of C3b that recruits other complement factors to form a C3 convertase, 
leading to bacterial opsonisation and neutrophil phagocytosis [34,35]. S. pyogenes 
can interfere with the complement pathway through binding of endogenous host 
complement inhibitors, such as complement factor H and C4BP which naturally act 
to inhibit C3 convertase [36–39]. M-protein also binds to fibrinogen [40], which has 
been suggested as a way for allowing the deposition of fibrin on the surface of S. 
pyogenes, thus preventing recognition by the complement cascade [41]. 
The SIC produced by emm1 S. pyogenes strains appears to bind and inhibit the 
function of a number of complement components including C3, and prevents the 
mobilisation of C5-9 proteins into the membrane attack complex (MAC). The 
significance of this is unknown as the MAC has no known antibacterial activity in 
Gram positive bacteria [42]. The chemoattractant activity of C5a is disrupted by S. 
pyogenes via the C5a peptidase scpA [43,44]. 
The chemoattractant CXCL8/IL-8, and its murine counterparts MIP-2 and KC, act to 
recruit neutrophils to areas of S. pyogenes invasion. S. pyogenes encodes a serine 
protease SpyCEP (Genomic annotation Spy0416, also known as cepA, and ScpC) 
which cleaves these chemoattractants as well as the entire repertoire of human CXC 
(neutrophil-active) chemokines [45–47], and prevents the recruitment of neutrophils 
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to the site of infection. There is also evidence that SpyCEP facilitates the 
internalisation of S. pyogenes into endothelial cells [48]. 
S. pyogenes also encodes a range of DNases, such as Sda1, which are believed to 
be protective against neutrophil extracellular traps [49]. Neutrophil extracellular traps 
are extrusions of a DNA/histone matrix purported to capture bacteria and expose 
them to bactericidal agents. DNases have been shown to break down this matrix, 
and prevent the neutrophil killing of S. pyogenes. 
M-protein binds and activates plasminogen [50,51], causing it to be degraded to 
plasmin, which can break down fibrin clots and connective tissue [50] and enable S. 
pyogenes to disseminate within the deep tissues of the body. Although severe 
infection with S. pyogenes can trigger disseminated intravascular coagulation, it 
produces a number of additional virulence factors, such as streptokinase, that 
interact with the coagulation cascade and can activate the contact system leading to 
generation of bradykinin, which is a local vasodilator and participant in inflammation 
[52].  
S. pyogenes also utilises molecular mimicry to avoid recognition by the immune 
system. The tertiary coiled-coil structure of M-protein has immune cross reactivity 
with myosin and tropomyosin antigens found in the heart and is believed to play a 
specific role in rheumatic heart disease [53,54]. Cross-reacting antibodies are 
believed to trigger endothelial and valvular damage and the ensuing immune 
sensitisation which can then result in cell-mediated autoimmunity and rheumatic 
heart disease [55].   
Capsular hyaluronic acid, in addition to aiding adhesion, also provides a degree of 
camouflage against the human immune system, as this compound is also produced 
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naturally by the human host.  Unlike other streptococcal capsular polysaccharides, 
very little antibody is observed in response to the S. pyogenes hyaluronic acid 
capsule. S. pyogenes strains isolated from more invasive diseases tend to produce 
more hyaluronic acid than those isolated from non-invasive disease. This increased 
production of hyaluronic acid induces enhanced resistance to phagocytosis [56,57].  
Superantigens are secreted proteins produced by S. pyogenes that, unlike 
conventional antigenic peptides, bind to the Vβ chain of a restricted proportion of T-
cell receptors when presented on HLA class II molecules without requirement for 
processing or specificity [58]. Superantigens are selective for different subsets of T-
lymphocytes based on the type of Vβ receptor. As S. pyogenes can produce up to 11 
different superantigens, with most strains producing 4-5 such toxins,  this interaction 
causes the widespread activation of T cells, leading to marked cytokine production, 
systemic inflammation and, in severe cases, streptococcal toxic shock syndrome. 
SpeB (streptococcal pyrogenic exotoxin) is a cysteine proteinase that is also 
believed to aid the dissemination of S. pyogenes during infection. It cleaves a 
number of immune products such as complement factors [59] and immunoglobulins 
[60]. In addition to this, it cleaves a number of streptococcal proteins, such as M-
protein, the superantigen, streptococcal mitogenic exotoxin Z (smeZ) [61],  and C5a 
peptidase [62]. The importance of immunoglobulin in recognition of S. pyogenes is 
underlined by the number of virulence factors expressed to prevent it. In addition to 
SpeB, proteases such as IdeS and EndoS cleave and inactivate antibodies, while 
the bacterial cell wall also expresses immunoglobulin binding proteins that capture 
the Fc segments of immunoglobulins, effectively neutering the ability to opsonise 
bacteria or interact with neutrophil Fc receptors [63]. The diverse virulence factors 
produced by S. pyogenes enable the bacterium to survive in sterile regions of the 
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body, and are responsible for the more severe disease manifestations caused by S. 
pyogenes. 
1.4. TISSUE TROPISM 
The array of different diseases caused by S. pyogenes can broadly be described in 
two classes; non-invasive diseases, such as those that affect the skin and the 
nasopharynx, and invasive diseases which affect deeper tissues and sterile regions 
of the body. These different manifestations can to some extent be explained by the 
genetic factors governing the survival strategies utilised by S. pyogenes in these 
diverse environments. 
1.4.1. THE ROLE OF EMM TYPES IN DETERMINING TISSUE TROPISM 
The two main targets for non-invasive S. pyogenes disease are the skin and the 
upper respiratory tract. The strains of S. pyogenes which infect the skin tend to 
cause a different spectrum of disease and different phenotype to the strains which 
cause disease in the upper respiratory tract [64].  
Historically, clinical isolates of S. pyogenes were differentiated by their variant of 
surface expressed M-protein [65,66] due to its relative heterogeneity. Currently, 
isolates are identified based on emm genotype, as emm is the gene encoding the M 
protein [67].  There are over 200 known emm types, but these tend to group 
structurally into five pattern groups, A-E, based upon the 3’ sequence and their 
chromosomal location. The emm patterns broadly map to the tissue tropism patterns 
of the strains of S. pyogenes that express them. Strains with patterns A-C generally 
infect the upper respiratory tract, pattern D strains primarily infect the skin and 
strains with Pattern E can infect both of these niches [68,69].   
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However, the M-protein is only one of many different gene products that play roles in 
the adhesion of S. pyogenes to different tissues. Many of these factors are known to 
share genetic linkage to specific emm patterns and participate in disease initiation, 
such as serum opacity factor and the FCT pilus [68,70]. The emm type can therefore 
be considered as an indicator of the niche occupied by different strains of S. 
pyogenes. The epidemiology of S. pyogenes infection is broadly similar in western 
developed nations. A study of circulating pharyngitis isolates in the USA revealed 
that the most common circulating emm types tend to be emm1, emm12 and emm28 
(Figure 1.1) [71]. This is broadly the experience within the UK, however there are no 
published data pertaining to pharyngitis isolates. The most common emm types in 
the UK based on 2009 data from Imperial College were emm types 1, 3, 6, 12, 28, 
75, and 89, (Figure 1.1.) although the relative importance of emm3 has waned in the 
last two years (Sriskandan, unpublished data).  
 Despite the broad spectrum of recognised emm types, the repertoire of emm types 
causing both invasive and non-invasive infections is in fact surprisingly limited in the 
industrialised world. This is in contrast to less-developed nations and indigenous 
communities where there is a greater diversity in the prevalent emm types [72,73].   
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Figure 0-1.1. Diversity of circulating emm types associated with pharyngitis within the USA and the UK 
Figure 1.1. Diversity of circulating emm types associated with pharyngitis 
within the USA and the UK. Proportions of different emm types collected from 
cases of non-invasive pharyngitis in multiple hospitals in the USA. Those emm types 
which accounted for <1% of the total collected isolates were classified as “rare” 
isolates (A). Based on data from [71]. Diversity of circulating emm types associated 
with pharyngitis in West London April-November 2009 (B). Data from Imperial 
College Healthcare Trust (Sriskandan, unpublished) 
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Post streptococcal auto-immune sequelae such as rheumatic heart disease, which is 
characterised by fever and valvular cardiac and joint inflammation, can be triggered 
by  S. pyogenes associated with specific emm types [74]. It has been suggested that 
strains of S. pyogenes with specific tropisms to the upper respiratory tract tend to 
cause rheumatic heart disease, and strains with a tropism to the skin tend to cause 
glomerulonephritis [64]. The molecular and immunological events leading to acute 
rheumatic fever and post-streptococcal glomerulonephritis are not known, and 
specific antigens that are targeted by cross-reacting antibodies or T cells remain 
controversial.   
Despite emm-specific niche adaptations, S. pyogenes across multiple emm classes 
have the capacity to invade deeper tissues and cause invasive disease. The gene 
regulators which control the expression of these factors play a major role in 
determining the phenotype of S. pyogenes during invasive infection. 
1.4.2. REGULATION OF VIRULENCE 
The timing of the expression of virulence factors that enable survival of S. pyogenes 
in deeper tissues is controlled by virulence regulators (Table 1.1). Two component 
regulatory systems enable S. pyogenes to detect stimuli within the external 
environment and to respond to them. They play a crucial role in niche adaptation, 
such as SptR/S which aids survival within saliva [75], and promoting the expression 
of adhesion factors in the initial stages of colonisation. RofA, and the related nra, are 
a set of stand-alone response regulators which increase the production of fibronectin 
and collagen binding proteins and repress virulence factors such as streptolysin S 
and  SpeB,  [76] in response to the presence of oxygen [77].    
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Table 0-1.1. Virulence regulation 
Regulator 
Targets 
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Streptolysin S ↓  ↑ ↑  ↓   ↓  ↓ ↓ 
Streptolysin O      ↓  ↑ ↑ ↑   
SpeA    ↑     ↑   ↓ 
SpeB ↑   ↑   ↑  ↑  ↓ ↓ 
SpeH      ↓  ↑     
Streptokinase ↓ ↑    ↓       
Hyaluronic Acid ↓     ↓ ↓ ↓ ↑    
SpyCEP ↓       ↑ ↓    
C5a peptidase ↓    ↑   ↑  ↑   
Sda1 ↓        ↓    
SIC    ↑ ↑     ↑   
EndoS ↓        ↓    
Fibronectin binding 
protein 
 ↑ ↑  ↑      ↑ ↓ 
NADase ↓     ↓       
IdeS ↓   ↑  ↓  ↑     
Mac-2          ↑   
M-protein     ↑ ↓       
Lipoteichoic Acid          ↑   
covR/S      ↑  ↓ ↑    
FasBCAX      ↑       
Ihk-Irr      ↑       
SptR/S        ↓     
Mga      ↓  ↑ ↑ ↑ ↓ ↓ 
Rgg ↓ ↓           
codY        ↓     
TrxR ↓            
RivR ↓            
References [78] [79] [80] [75] [81] [82,83] [84] [85] [86] [76] [76] [76] 
Table 1.1. Virulence regulation. ↑= Positive regulation. ↓= Negative regulation  
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The first virulence regulatory system described for S. pyogenes was mga, which is a 
stand-alone multi-gene activator for which a partner sensor kinase or regulator has 
not been found. Mga promotes the expression of the highly important anti-phagocytic 
M-protein [87], in addition to streptococcal inhibitor of complement [88], C5a 
peptidase [89] and a number of other genes within a contiguous operon. 
The covR/S system (also known as CsrR/S) is known to regulate the transcription of 
15% of all the chromosomal genes possessed by S. pyogenes [78]. Due to its broad 
coverage of the genome, and its role in repressing an array of important virulence 
factors, it has been extensively studied. It represses the expression of a number of 
important virulence factors, such as the hyaluronic acid capsule, DNases, and 
SpyCEP.  While covR/S can suppress SpeB protease production in some S. 
pyogenes strains [78,90] deletion of covR/S has been shown to prevent SpeB 
production in most strains, in particular emm1 S. pyogenes [91,92]. There is 
therefore a reciprocal relationship between SpeB expression and expression of most 
other virulence factors that are primarily concerned with the prevention of neutrophil-
mediated killing. Although covR/S primarily plays a role in pathogenicity by varying 
the phosphorylation status of the repressor component covR through kinase activity 
of the sensor component, covS, mutations in either component can have a marked 
irreversible impact on phenotype. 
Under ‘normal’ situations in the nasopharynx, it is hypothesised that CovR/S is 
active; the sensor kinase results in phosphorylation of CovR, which in turn represses 
expression of virulence factors. It is also believed that exposure to ‘danger’ signals , 
perhaps from incoming neutrophils, or exposure to blood, results in CovS acquiring 
phosphatase activity resulting in the de-phosphorylation of CovR. Consequently this 
leads to the de-repression of virulence factors, such as capsule and SpyCEP, 
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allowing S. pyogenes to defend itself from attack, The signalling molecules 
recognised by CovS are not characterised but may include Mg++  and LL37 [93,94].  
Mutations in the covS gene are associated with a de-repression of these same 
virulence factors, leading to a “hypervirulent” phenotype that is associated with 
invasive streptococcal diseases observed in humans [91,95].  These mutations are 
known to be selected for during invasive infection in response to immune pressure 
[49,96] and can be identified in samples from deep tissues in mice where S. 
pyogenes has progressed from a superficial to a more invasive infection, 
demonstrating a predicted phenotype change to match the acquired genotype [91]. 
Interestingly, strains of S. pyogenes exhibiting this hypervirulent phenotype have 
impaired biofilm formation [97]. Mutations in covR have even more impressive 
phenotypic effects, increasing the expression of virulence factors such as SpyCEP 
by 100-1000 fold [45]. Such mutants have been found in cases of invasive infection, 
but these mutants are not prevalent in the community and have not been identified in 
outbreak settings [45]. This suggests that the potential for invasiveness is a latent 
trait that is broadly expressed across all emm patterns, but does not become fixed in 
circulating strains due to the fitness costs it incurs during superficial infection. 
Despite the fact that covR/S mutations appear to favour invasive infection, albeit with 
likely fitness costs in some settings, there are no data showing that covR/S mutation 
is deleterious to nasopharyngeal infection. One of the aims of this project was to 
determine if covR/S mutation might impact on nasopharyngeal infection using a 
properly characterised murine model. 
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1.5. TRANSMISSION 
 The understanding of the factors governing the transmission of S. pyogenes in the 
human population primarily stems from observational epidemiological studies rather 
than experimental work.  The survival of S. pyogenes in saliva [98] likely forms the 
basis for the transmission of S. pyogenes from the respiratory tract. In the process of 
coughing or sneezing, saliva is converted into airborne infectious droplets [99].  The 
range and maintenance of S. pyogenes as an aerosol is limited by the size of the 
airborne droplets produced during infection [100]. 
The dispersal distance of S. pyogenes by coughing is believed to be limited 
compared with sneezing. The spread of bacteria via these routes is dependent on 
the concentration of bacteria within the saliva, and individuals with high numbers of 
S. pyogenes within their saliva tend to also have more bacteria in other body 
regions, such as the hands and lower face [101]. Increased physical activity has also 
been associated with increased aerosolisation [101,102] and crowding is known to 
be a determining factor in the frequency of transmission in rheumatic heart disease 
outbreaks [103,104].  There are also reports of transmission and outbreaks from 
vaginal [105,106] and anal carriers of S. pyogenes [107], although these are 
uncommon reservoirs of infection. 
Studies suggest that fomites, such as contaminated bedding and environmental dust 
particles are not a significant reservoir for streptococcal infection [108,109], as their 
drying in the environment inhibits infectivity. However nosocomial outbreaks have 
been linked to contaminated ‘wet’ fomites such as bath and shower fittings, 
particularly in maternity units [110]. This has led to a recognition that chlorine-based 
cleaning of such surfaces is a pre-requisite in prevention of nosocomial outbreaks, 
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as originally proposed over a century ago [111]. S. pyogenes outbreaks have also 
been traced to contaminated food [112,113], but these are uncommon. 
As noted earlier, a significant portion of the population carries S. pyogenes 
asymptomatically in the respiratory tract.  After the onset of disease, S. pyogenes 
can persist within the respiratory tract in what has been termed a “carrier state” 
which can potentially last for up to 19 weeks after the initial infection [114,115]. This 
may be due to the internalisation of S. pyogenes within cells of the nasopharynx [23]. 
This may explain the recurrence of infection even after penicillin treatment, in spite of 
S. pyogenes remaining susceptible to this antibiotic. However, the contribution of this 
carrier state to S. pyogenes spread within the population is debatable, as there is 
some evidence to suggest that carriers do not harbour streptococci in high numbers, 
and do not transmit as effectively as compared to patients at the peak of 
symptomatic infection [116].  
1.6. VACCINATION 
Rebecca Lancefield described streptococcal M protein as a potentially protective 
antigen that, when extracted crudely from a broth culture of S. pyogenes, could 
induce protective immunity against challenge with the same strain [16]. The 
heterogeneity of S. pyogenes surface proteins has unfortunately proven to be a 
formidable barrier against the development of a vaccine. Early attempts to develop a 
vaccine using attenuated or dead bacteria were unsuccessful [117,118]. The primary 
safety concern for devising a vaccine against S. pyogenes is its immune cross 
reactivity with the host. This effect could be triggered by the inoculation of dead 
bacteria or specific antigens, leading to rheumatic carditis [119,120]. Indeed, one 
early vaccine trial utilising M-protein was implicated in the onset of rheumatic heart 
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disease in its participants [122,123] and this finding has held back vaccine research 
by decades.  
In spite of this, vaccinations based on M1 [124,125] have demonstrated some 
protective efficacy, although similar work based on M3 and M12 was not as 
successful [126]. Further work found that protective antibodies in humans were 
raised to the variant N-terminal portion of the protein [127]. This poses problems with 
vaccine coverage when one considers that there are over 200 potentially variant M 
proteins. 
 A 26-valent M-protein based vaccine of S. pyogenes theoretically provided coverage 
against 90% of S. pyogenes strains circulating in the US [128]. However it lacked 
sufficient coverage against S. pyogenes strains circulating in developing countries, 
where rheumatic heart disease is an endemic problem [129].  Another approach to 
target a broad spectrum of M-proteins is to immunise against conserved C-terminal 
regions of the protein [130,131].  This is the basis for the J8 vaccine, which has been 
shown to be protective in small animal models, and provides better coverage for 
developing countries [132]. However the problems of coverage and potential immune 
sequelae associated with M-proteins has led other candidates to be explored for use 
in a vaccine.  
Adhesion factors have been evaluated for use in a vaccine to prevent S. pyogenes 
pharyngitis. The group A carbohydrate is conserved among multiple emm types of S. 
pyogenes and has been shown to be protective in animal models, but is setback by 
its cross reactivity with human heart antigens [133,134]. Vaccine candidates based 
on fibronectin binding proteins such as Fbp 54 [135], sfb1 [136–138] have also 
shown promising results in murine models of infection.  The streptococcal T-antigen, 
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which comprises part of the pilus structure [24], has also been suggested as a 
vaccine candidate as it is more conserved compared to M-protein [24]. 
Another strategy is to use streptococcal virulence factors as the basis for vaccines. 
The advantage of targeting virulence factors is that they are generally highly 
conserved, due to their essential role in streptococcal infections. The streptolysins 
are known to be immunogenic, with the anti-streptolysin O antibody titre often being 
used as an indicator for a previous S. pyogenes infection. In recent work, detoxified 
forms of streptolysin O have shown protective efficacy in mice [139]. A vaccine 
candidate against streptolysin S has been found to prevent haemolysis, but did not 
increase opsonophagocytosis [140].  
 Superantigens such as SpeA and SpeC have been explored as the basis for 
vaccines, as these toxins play important roles in invasive disease. Vaccines based 
on superantigenes have been shown to confer protection in rabbit models of 
streptococcal toxic shock syndrome through mitigating the toxic effects of the 
disease, rather than facilitating bacterial clearance [141,142]. 
 In general however, cell wall-associated antigens are favoured because antibodies 
directed to such targets are likely to assist in opsonisation of the bacterium in 
addition to possibly neutralising the virulence activity of the target. Many such 
antigens are characterised by the LPXTG sortase anchoring motif at the C terminus 
of the protein.  
A recombinant vaccine based on C5a peptidase has been shown to elicit an 
antibody response and protection in some mouse models of infection [143]. An 
additional advantage of this vaccine candidate is the cross reactivity with a C5a 
peptidase produced by Streptococcus agalactiae [144]. 
36 
 
The SpyCEP protein is conserved in S. pyogenes, and has been identified via 
proteomic and genomic approaches as a viable candidate for vaccination [145,146].  
Vaccination with SpyCEP has been shown to enhance survival in an invasive mouse 
model of respiratory infection [146]. It also prevents bacterial dissemination in an 
invasive model of soft tissue infection caused by either S. pyogenes or 
Streptococcus equi which expresses a homologous enzyme known as SeCEP [147]. 
It is likely that future anti-streptococcal vaccines may comprise several antigenic 
components including proteins such as SpyCEP and C5a peptidase. 
A variety of new proteomic approaches have been utilised to screen for surface 
expressed proteins of S. pyogenes [146], using human sera to specifically detect 
immunogenic candidates [145,148]. Whilst many of these vaccines have shown 
efficacy in animal models, there are questions as to how appropriately these 
surrogate hosts have been used to model human infection. Specifically, there is a 
pressing need for a vaccine against S. pyogenes that protects against pharyngeal 
infection, yet the majority of vaccines evaluated are tested in more invasive animal 
models.  To some extent, this is due to the methods by which vaccines are 
evaluated. In general, the elicitation of a protective antibody response, and the 
prevention of deaths in animal models have been the outcomes used to judge the 
efficacy of vaccines, rather than bacterial clearance (Table 1.2.) 
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Table 0-2. Outcomes utilised to evaluate vaccine candidates 
Protein  Vaccine 
Candidate 
Model Antibody 
production 
Demonstrated 
protection in vivo 
Demonstrated reduction 
in Streptococcal numbers 
Reference 
M-protein 26-valent 
(StreptAvax) 
Humans Yes   [149] 
Rabbits Yes   [128] 
Hexavalent Mice Yes Yes   [150] 
Mice Yes Yes  [151] 
Rabbits  Yes    [152] 
30-valent Rabbits Yes   [153] 
M5 Mice Yes Yes Yes [130] 
Salmonella 
expressing M5 
Mice Yes Yes  [154] 
Vaccinia 
expressing M6 
Mice  Yes Yes Yes [155] 
M6 Mice  Yes Yes  Yes  [156] 
Mice Yes Yes Yes [157] 
M24 Humans, 
Mice, Rabbits 
Yes  Yes  [127] 
J-8 Mice Yes Yes Yes [158] 
Mice Yes Yes  [159] 
Mice Yes Yes Yes [160] 
Mice Yes Yes  [161] 
J-14  Mice Yes No   [151] 
Mice Yes   [131] 
Mice Yes  Yes Yes [158] 
Mice Yes Yes Yes [162] 
Mice Yes Yes  [163] 
Lipoteichoic acid Mice Yes Yes  Yes [164] 
Spy0269 Spy0269 (27-849) Mice Yes Yes  [148] 
Spy0269 Mice Yes Yes  [145] 
Internalin A (spy1361) Mice Yes Yes  [148] 
Spy0872 Mice Yes Yes  [145] 
DacA (spy0292) Mice Yes Yes  [145] 
Spy0895 Mice Yes Yes  [145] 
Spy1536 Mice Yes Yes  [145] 
Spy0488 Mice Yes Yes  [145] 
Spy1727 Mice Yes Yes  [145] 
MraW (spy1666) Mice Yes Yes  [145] 
Spy0019 Spy0019 Mice Yes Yes  [148] 
Spy0019 /Alum Mice Yes No  [165] 
Sse esterase Sse Mice  Yes Yes  [165] 
SpeA SpeA mutants Rabbit Yes Yes  [141] 
SpeA-B fusion 
protein 
Mouse Yes Yes  [166] 
SpeB SpeA-B fusion 
protein 
Mouse Yes Yes  [166] 
SpeC SpeC mutants Rabbit Yes Yes  [142] 
SOF Recombinant SOF 
peptides 
Rabbit, 
Mouse 
Yes Yes  [167] 
Streptolysin S SLS(10-30) KLH Rabbit Yes   [140] 
Streptolysin O Recombinant SLO 
(32-571) 
Mouse Yes Yes  [148] 
Mutant SLO Mouse Yes Yes  [139] 
FbaA GST-FbaA Mouse Yes Yes  [168] 
SIB35 rSIB35 Mouse Yes Yes  [169] 
C5a peptidase Recombinant 
SCPAw 
Mouse Yes  Yes [144] 
Mouse Yes  Yes [170] 
ΔSCPA49 Mouse Yes Yes Yes [143] 
SpyCEP Recombinant 
SpyCEP (34-898) 
Mouse Yes Yes  [148] 
SpyCEP Mouse Yes Yes  [145] 
SpyCEP Mouse Yes Yes  [146] 
Recombinant 
SpyCEP (35-587) 
Mouse Yes  Yes [147] 
Sfb1 FNBR Mouse Yes Yes  [159] 
Sfb1 –CTB Mouse Yes No  No  [136] 
Fbp54 rFBP54 Mouse Yes Yes  [135] 
Streptococcal 
Haemoprotein 
Receptor 
rSHR Mouse Yes Yes  [171] 
Table 1.2. Outcomes utilised to evaluate vaccine candidates 
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One of the aims of this project was to develop an improved model of S. pyogenes 
upper respiratory tract infection that could be used to screen and evaluate novel 
vaccine candidates. 
1.7. ANIMAL MODELS FOR STREPTOCOCCAL INFECTION AND COLONISATION 
Much of the current understanding of S. pyogenes pathogenesis has been gained 
through the utilisation of animal models. Different models have been used in the past 
to examine different diseases caused by S. pyogenes infection. Early studies 
recognised that rabbits and white mice were more susceptible to S. pyogenes 
infection than other species of animals [3,172].  Mice have become the standard 
model organism for streptococcal infection, due to degree of characterisation, 
genetic tractability, relative inexpensiveness and recognised similarities to the 
human immune system [173]. 
However, the infectious capability of S. pyogenes in many animal hosts, particularly 
mice, is limited. One of the ways to circumvent this is to adapt S. pyogenes to animal 
hosts through passaging. This selects for strains which thrive in the niche in which 
they have been passaged, and produces S. pyogenes strains that are more 
infectious to animals [174]. It has been shown that  emm1 S. pyogenes passaged 
through an invasive model of infection, acquired mutations within a number of genes, 
including covR/S [96]. Whilst such strains have been useful, the degree to which 
they change in order to adapt to their new environment may compromise their 
relevance to the human host. However, whilst these models may have specific 
limitations, they can reveal interesting new aspects of S. pyogenes pathogenesis if 
properly applied. 
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1.7.1.  ANIMAL MODELS OF SKIN AND SOFT TISSUE INFECTIONS 
A number of different animal species and techniques have been utilised to model S. 
pyogenes skin infections.  S. pyogenes does not survive for long on the surface of 
human skin [175], and minor trauma may be required  to establish an infection [176]. 
Many models have involved subcutaneous or intradermal instillation of bacteria into 
surrogate hosts such as hamsters [177,178] or mice [179] to replicate recognised 
features of streptococcal skin infections. A modification of this infection model 
involved the injection of an air sac at the site of infection to enable the analysis of 
immune responses in vivo by sampling of fluid within the space [180]. These 
produced symptoms in animals that were comparable to humans by bypassing the 
natural barrier of the skin with an injection of a large inoculum. Recently, Svensson 
and colleagues grafted human foetal foreskin tissue onto SCID mice to produce a 
so-called ‘humanised’ mouse model to more accurately reflect the infection process 
that is believed to occur in humans [181]. 
However, the subcutaneous model of infection has additional applications, such as 
the modelling of soft tissue infections. Subcutaneous models of infection have been 
applied to investigate questions relating to the functions of virulence factors [182] 
and their regulation [90]; often lesion size is measured as a parameter of  infection 
progression since a dermonecrotic ulcer or abscess can develop. A flaw in such 
experiments is that the lesion size may relate more to the neutrophil influx than 
bacterial abundance. 
Intramuscular infection models are often used to investigate necrotising fasciitis, due 
to the characteristic lesions they produce, the size of which relates to the degree of 
damage occurring within the organ [183]. This model allowed for an estimation of 
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disease severity of S. pyogenes infection by examining the size of the lesions 
produced, although this too may be biased by neutrophil influx [184]. Hence most 
investigators choose to quantify bacterial counts at the site of infection, as an 
objective parameter of infection burden. Nonetheless, such measurement requires 
the sacrifice of the animal and the timing of measurement may mean that crucial 
events are missed. To enhance the amount of information gleaned from such 
experiments, all tissues, including the draining inguinal lymph node, can be 
harvested for culture [46]. Inevitably, investigators rely on the use of multiple time 
points to ensure differences between experimental groups are not missed, although 
this leads to the use of large numbers of animals.  
Due to their evolutionary proximity to man, primates have also been infected 
intramuscularly to simulate necrotising fasciitis [185,186]. These animals developed 
streptococcal toxic shock syndrome, similar to the disease progression observed in 
humans. However, primates are seldom utilised for primary research, as their cost of 
maintenance means they cannot be used in high numbers. 
The zebrafish, Danio rerio, has been explored as an alternative surrogate host to 
model soft tissue infection in a higher throughput manner. Intramuscular infection of 
the zebrafish with S. pyogenes produces a soft tissue infection that has some 
similarities to necrotising fasciitis [187].  The immune systems of the zebrafish and 
human have enough in common for them to be informative of S. pyogenes virulence 
in vivo [188,189].  
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1.7.2. ANIMAL MODELS OF SEPTICAEMIA AND TOXIC SHOCK SYNDROME 
Whilst the dissemination of S. pyogenes from the site of a skin or soft tissue infection 
can occur, leading to a systemic infection similar to bacteraemia, the injection of 
bacteria directly into the circulation through intravenous and intraperitoneal routes 
has also been utilised to directly examine systemic infection. These models of 
infection have been used for passaging [96], and testing vaccine [160,174] and 
antibiotic efficacy. 
However, the drawback of these models is that mice are relatively resistant to 
infection compared with the human situation. It has been shown that different strains 
of mice exhibit different susceptibilities to infection [192,193]. The sex of the mice 
[194,195], and their age [196] have also been suggested as determinants of 
systemic infection. 
Another issue with mouse models of bacterial infection is that they cannot produce 
superantigen responses, which are based on the binding of HLA class II subsets that 
do not occur in mice. One solution is the use of primate models, which are close 
enough to mimic human responses [190]. However, these models still have the 
previously discussed resource issues. An alternative approach is the use of human-
transgenic mouse models that express the DQ segment of the MHC molecule to 
enable superantigen activation [191]. 
1.7.3 MODELS OF RESPIRATORY INFECTION 
The primary site of S. pyogenes colonisation in humans is within the upper 
respiratory tract. There have been a number of studies in which S. pyogenes 
tonsillitis has been induced in human subjects. Initial work involved the inoculation 
with secretions from patients [117] and later involved the transfer of S. pyogenes in 
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broth to the tonsils via a cotton applicator [124–126]. Whilst not initially evident, the 
symptoms of S. pyogenes infection were observed to manifest 24-48 hours post 
infection [109].  It is also important to note that these early methods of experimental 
inoculation did not necessarily produce infection in all of the unvaccinated subjects 
[126]. 
It has been recognised in previous work that baboons can become naturally infected 
with S. pyogenes [197,198]. Indeed, a number of primate species have been utilised 
to study pharyngitis, such as chimpanzees [199], baboons [200], cynomolgus [201] 
and rhesus macaques [202], via intranasal instillation, or direct deposition on the 
tonsils. Whilst S. pyogenes colonises these animals effectively, and can result in 
symptomatic tonsillitis, there are some drawbacks to their use. 
Primates are rarely culled at the ends of such experiments; often they receive a 
course of treatment to clear S. pyogenes [202], thus the animals are not dissected at 
the end of experiments (although there are exceptions [203]).  Temperature, blood 
samples, veterinary scoring and throat swabs provide the primary methods for 
studying the progression of infection in these animals. 
These difficulties, in addition to the challenging ethical issues and high costs of 
primate maintenance mean that there is a requirement for a higher throughput model 
for nasopharyngeal infection that can be used to screen vaccine candidates. Mice 
have been commonly used to model respiratory infection, as they consume few 
resources, and the conserved nature of the mammalian nasopharynx ensures that 
they are relevant models [204,205]. 
However, it is important to recognise that there are some notable differences 
between the rodent and human nasopharynx. The structure of the nasopharynx 
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consists of nares, the openings through which air enters, which are lined with tough 
squamous epithelium and are broadly similar between all mammalian species [206]. 
The major differences in the structure of the nose come from the complexity of the 
ethmoturbinates (a scrolled tissue located in the caudal nasopharynx) and the 
relatively higher proportion of olfactory epithelium in the rodent nasopharynx [205]. 
Rodents also possess nasal associated lymphoid tissue (NALT) which acts as an 
immune inductive site in response to inhaled antigens. Whilst NALT has been 
observed in monkeys and humans, it is fundamentally different in structure to those 
observed in mice [207,208]. Instead, tonsils are believed to be the human analogue 
for this tissue [209]. Although rodents do not possess tonsils, some work has shown 
that the NALT becomes colonised by S. pyogenes in a similar way to human tonsils 
[210]. 
A number of methods have been utilised to induce infection in mice. Mice have been 
observed to become infected from S. pyogenes at an estimated density of ~150 
colony forming units (CFU) per ml of air that was made airborne through the use of a 
nebuliser and specialised cage system [211]. This infection technique produced 
variable outcomes, with no infection occurring at all in some instances making viable 
comparisons between treatments difficult [212]. This unreliability and the need for 
specialised equipment are the reasons why this method did not become more widely 
utilised. 
A simpler intranasal model was devised using the instillation of inoculum in solution 
into the nares of a mouse [213]. This model has been more widely adopted to study 
respiratory infection.  A number of works suggest that inoculum volumes of greater 
than 5μl [214] or 10μl [215] distribute to the lungs, which may cause pneumonia, 
whereas others state that volumes of 20μl [216] or even 50μl [217] are retained 
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within the upper respiratory tract. These models of infection have been used to 
provide insight into infection in the upper respiratory tract [217–219], as well as more 
severe diseases like pneumonia [220]. However, since the dose distribution varies 
between studies, many of the models used to study upper respiratory tract infection 
may also induce severe infection. The various models of respiratory infection that 
have been used to investigate S. pyogenes are summarised in Table 1.3. with 
particular reference to the dose volumes and number of infecting CFU. 
It has been observed that S. pyogenes is a poor pathogen of rodents compared to 
the primary human host.  A number of works have adapted strains of S. pyogenes to 
the mouse by passaging them through an intraperitoneal model of infection (Table 
1.3.). An emm50 strain of S. pyogenes that was recovered from mice during an 
epizootic outbreak in a mouse colony has been widely used [221]. However, this 
strain was later shown to have a deletion in the mga locus [222], a major virulence 
regulator which is important for human infection. 
A number of methods have been utilised to assess infection progression in the upper 
respiratory tract. Alginate swabs have been used to take throat cultures, but S. 
pyogenes cannot survive for very long on these swabs [223], and only low numbers 
of the bacteria tend to be recovered. As a result, swabs tend to be used to determine 
the presence or absence of S. pyogenes [224] but often not for quantitative 
assessments of bacterial numbers.  Another method which has been widely used is 
the monitoring of death as an outcome of infection, but this tends to be a 
characteristic of invasive infections and cannot be used to measure survivable 
colonisation. The dissection of the relevant organs can also be used to monitor 
infection. The lungs and the spleen are useful to monitor the progression of 
pneumonia and the attendant bacteraemia. The NALT, which has been postulated 
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as the primary focus of colonisation, has been dissected out as a means to assess 
nasal carriage. The dissection and culture of the whole nasal tract is the best method 
to directly assess the numbers of S. pyogenes, although the dissection as described 
in some work would only allow for the extraction of the anterior nasal passages 
[144]. The various outcomes that have been measured to study upper respiratory 
tract infection are also described in Table 1.3. 
Currently, there are a number of models of respiratory tract infection, few of which 
focus on infection exclusively in the upper respiratory tract, and there are even fewer 
techniques with the ability to monitor S. pyogenes colonisation non-invasively in 
living mice.  However, in recent years, a new technique has been developed which 
may enable the direct quantitative monitoring of S. pyogenes infection through non-
invasive means, which shall be described in more detail below. 
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Table 1.3. Intranasal models of infection 0-3models of infection 
Dose 
Volume 
Mouse 
Adapted 
emm 
type 
CFU Host Sex 
Age 
(weeks) 
Monitoring 
method 
Sampled Tissues Ref 
5-10μl Yes 
1,3,5,6, 
19,24,50 
10
1
-10
8
 CD1 F 7-10 
+ Throat cultures, 
Death 
 [224] 
5μl Yes Untyped 10
8 
AKR N/M 3-7  
Cervical Lymph Nodes*, 
Lungs*, Anterior Nasal Tract * 
[225] 
10μl Yes 50 10
5 
CD1 N/M 12 Throat cultures  [221] 
10μl No 1 10
7 BALB/c & 
C57BL/6 
F 5-6  NALT [230] 
10μl No 24 10
5
-10
7 
BALB/c F 11-14 
+ Throat cultures, 
Death 
 [20] 
10μl Yes 24 10
7 
BALB/c F 11-14 
+
 
Throat culture, 
Death 
 [130] 
10μl No 24 10
7 
BALB/c F 24 Death  [150] 
10μl No 24 10
7 
BALB/c F 11-14 
+
 
Throat culture, 
Death 
 [164] 
10μl-20μl Yes 50 10
3
-10
8 C3HeB/FeJ 
 
F 4-6 
Throat cultures, 
 
Trachea, Lungs, Nasal 
washings, Meningeal swabs 
[226] 
10μl-20μl Yes 50 10
6
-10
8 CD1, 
C57BL/6 
F N/M 
Death, Weight 
Loss 
 [238] 
10μl-20μl No 2,11,48 10
8 
CD1, BALB/c N/M 4-10 
Throat culture, 
Death 
 [143] 
15μl No 1,49 10
8 
BALB/c F 6-7 
BPI, 
 
NALT, Cervical Lymph node, 
spleen 
 
[170] 
15μl No 1 10
8 BALB/c 
background 
N/M N/M  NALT [228] 
15μl No 1 10
8
 C57BL/6 F 6-10  NALT [229] 
15μl No 1 N/M C57BL/6 N/M 7-8 Death NALT [242] 
20μl No 1, 49 10
8 
BALB/c F 8-11 BPI, NALT [216] 
20μl Yes 14 10
9 
CD1 F 9 Throat cultures  [156] 
20μl No 1 10
8 
CD1 F 8-10  Lungs, Anterior Nasal tract [144] 
20μl No 
24 
 
10
6 
BALB/c F 9 Death Lungs* [137] 
20μl No 24 10
7
 
C3H-HeN, 
BALB/c 
F 12-14 Death lungs, Blood [232] 
20μl No 89 10
8 
CD1 F 12-14  
Spleen, Blood, Thigh muscle, 
Anterior Nasal tract, NALT and 
Lungs 
[147] 
20μl No 5 ,24 10
7 
BALB/c N/M N/M Death  [154] 
20μl Yes 14 10
6 
CD1 F 10 
Throat culture, 
Death 
 [235] 
20μl No 106 10
6 
BALB/c F 9 -20 Death,  [138] 
20μl Yes 6, 50, 10
5 C3HeB/FeJ 
C57BL/10snJ 
M, F 4-5 
Throat culture, 
Death 
Blood, Trachea, Lung , 
Spleen, Nasal washings & 
meningeal swabs 
[220] 
20μl No 81 10
8 
CD1 F 6-8  Nasal Tract, NALT, Lung [46] 
20μl No 3, N/M CD1 N/M 3-5 
+ 
Death  [213] 
20μl No 1 10
7 
B10.BR F 8-10 
Throat culture, 
Death 
 [158] 
20μl Yes 50 10
6 
C57BL/6 F 4-6 Throat culture Pharynx* [246] 
20μl Yes 6  CD1 F 10-11 
Throat culture, 
death 
 [157] 
20μl No 6 10
4
-10
5 
BALB/c nu F 4-6 Death  [248] 
20μl nasally 
30μl orally 
No 14 10
7 
CD1 N/M 4-8 Throat cultures  [217] 
20μl-40μl Yes 1,23,106 N/M NMRI, CD1 F 11-13 Death  [145] 
25μl No 3 10
7 
BALB/c F 14 Death lungs, spleen and liver [231] 
25μl No 1, 3, 12 10
7 
BALB/c F 8 Death, lungs, spleen  liver & kidney [234] 
25μl No 1 10
7 
BALB/c F 8 Death Lung, Liver, Spleen, Kidney [239] 
30μl No 1 N/M Quackenbush N/M N/M 
Throat culture, 
Death 
 [162] 
30μl No 1 N/M Quackenbush N/M N/M 
Throat culture, 
Death 
 [161] 
30μl nasally 
30μl orally 
No 12 N/M BALB/c F 6 Throat cultures Head [227] 
40μl No 106 10
8 
BALB/c F 9-10 Death  [243] 
40μl No 106 10
8 
BALB/c F 9-10 Death  [244] 
40μl 
intranasally 
10μl orally 
Yes 6 
10
6
- 
10
7 CD1 N/M N/M 
Throat culture, 
Death 
 [155] 
50μl Yes 50 10
7 
NMRI F 14 Death  [236] 
50μl Yes 50 10
2
-10
8 
NMRI, CBA N/M 3-5 Death 
Pharynx, Brain, Heart, Lungs, 
Kidneys, Cervical Lymph 
Node & Blood 
[237] 
50μl No 23 10
6 
CD1 F 10 Death  [146] 
50μl No 1,6,12,23 10
8 
CD1 F 13 Death  [148] 
50μl No 3 10
7 
CD1 M 3-4
+ 
Death Blood [241] 
50μl Yes 50 10
7 
NMRI F 14 Death  [218] 
50μl No 1 10
6
-10
8 
CD1 M 3-4
+ Throat culture, 
Death 
 [247] 
100μl No 1,3, 49 N/M CD1 F 5 
+ 
Death  [171] 
N/M No 3 10
7 
BALB/c F 8 Death, lungs, spleen  liver, & kidney [233] 
N/M No 1 10
8 
C57BL/6 N/M 10-12  Nasal tract [240] 
N/M No 106 10
8 
BALB/c N/M N/M Death  [245] 
N/M No 106 10
8 
BALB/c N/M N/M Death  [245] 
N/M = Not Mentioned, * =Histological Analysis only, 
+
 = Only weight given in reference, Age estimated based on data from Charles 
River Laboratories 
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1.8. BIOPHOTONIC IMAGING  
Biophotonic imaging (BPI) is a technique based on the detection of light from 
biological sources, such as fluorescent proteins, or bioluminescence reactions [249]. 
The incorporation of these light sources into bacteria allows them to be tracked and 
quantified through the use of sensitive cameras. BPI provides a method to 
longitudinally monitor infection in a quantitative manner that limits the number of 
mice required during experiments, and allows mice to act as internal controls 
throughout a study. The technique therefore fulfils two of the ‘3Rs’ proposed by the 
National Centre for the Replacement, Refinement and Reduction of Animals in 
Scientific Research (NC3Rs), namely refinement and reduction [250].  
BPI is dependent on the transmission of light through tissue. As light passes through 
tissue, it is scattered and absorbed, which decreases the signal from any biophotonic 
source.  The wavelength of the light determines the degree to which it is scattered 
and absorbed within biological tissue. Light with shorter wavelengths, such as blue 
and green light, is absorbed more than light with longer wavelengths, such as red 
and infrared [251,252]. The greater the depth of the source, the greater the degree of 
scattering and absorption occurs. This imposes limits on the ability to detect sources 
within deep tissues. 
1.8.1. FLUORESCENCE  
Fluorescence is a physical process which occurs when light of a specific wavelength 
triggers the excitation of an electron within an atom, which then emits a photon of 
another wavelength as it returns from this excited state. The wavelength of light 
emitted from the atom is usually longer than the wavelength of light used to cause 
excitation. 
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The green fluorescent protein (GFP), which is produced by the jellyfish Aequorea 
victoria, has been utilised in research to tag proteins to aid visualisation of their 
expression. These have been useful for studying gene expression in cells through 
microscopy. The application of this technology to image bacteria within whole 
animals requires a number of challenges to be overcome. 
The absorption of light by biological tissues is one such challenge, as this limits the 
penetration of light to the fluorescent source, and the detection of light from the 
source. Biological tissues are inherently fluorescent, and can produce strong signals 
when the excitation wavelength is applied. This can impair the differentiation of the 
true source of fluorescence from the high background fluorescence [251].  
Most of the fluorescent proteins currently available have excitation wavelengths that 
are absorbed and scattered readily by human tissue. As discussed earlier, biological 
tissues transmit infrared light more readily than other wavelengths. Infrared dyes 
[253] and near infrared emitting fluorescent proteins are currently in development 
[254] for use in this form of imaging. 
1.8.2. BIOLUMINESCENCE 
Bioluminescence is a chemical reaction used by biological organisms to produce 
light. Bioluminescence occurs when a substrate (generically referred to as luciferin) 
is metabolised by an enzyme (generically referred to as luciferase) in a reaction 
which causes the emission of a photon.  
The gene which encodes the firefly luciferase was amongst the first to be used in 
research.  A number of red-shifted luciferases have also been created, which enable 
the better detection of light from within biological tissues [255]. Whilst the gene 
encoding the luciferase is known, the genes which synthesise the luciferin for this 
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reaction (known as D-luciferin) are not as well defined. Commercial luciferins are 
synthesised chemically rather than biologically [256].  D-luciferin therefore needs to 
be applied exogenously to allow for firefly based bioluminescence to occur. 
Another form of eukaryotic luminescence has also been characterised in the sea 
pansy Renilla reniformis. The Renilla luciferase requires the application of 
coelentarazine. The source of coelentarazine in nature has been harder to track 
down, as it is not produced endogenously by the Renilla, but from a food source, 
which is believed to be the copepod Metridia pacifica [257]. A number of other 
organisms produce luciferases which also metabolise coelentarazine, such as the 
copepod Gaussia princeps. The Renilla and Gaussia luciferases have both been 
applied to research, and the reactions are notable in that they do not require oxygen 
in order to occur, and produce brighter signals than the firefly luciferases. However, 
strong autoluminescent signals have also been observed [258]. 
Bacteria tagged with a eukaryotic luciferase will only luminesce in the presence of 
the exogenously applied luciferin. The signal obtained from these bacteria is 
dependent on the distribution and the concentration of luciferin within their immediate 
environment. Not knowing the concentration of luciferin at the site of infection makes 
the enumeration of bacteria using this technique more difficult, especially since 
different organs absorb the luciferin to different extents [259]. In addition, the 
reaction is short lived, and multiple applications of reagents are required to image 
mice over a time course. 
The bioluminescent reactions produced by prokaryotes such as the Gram negative 
bacterium Photorhabdus luminescens have also been studied for biophotonic 
applications. The luminescence trait is conferred by the luxCDABE operon, which 
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encodes the luciferase (luxAB) and the enzymes responsible for regenerating a long 
chain aldehyde (luxCDE) that is essential for the reaction to occur.  The luxAB genes 
encodes the α and β sub-units of the luciferase enzyme, which binds reduced flavin 
mononucleotide (FMNH2) to a long chain aldehyde using molecular oxygen [260] 
(Figure 1.2.). The long chain aldehyde is generated via a transferase, encoded by 
luxD, which transfers long chain fatty acid substrates produced by core metabolic 
pathways to a synthetase (luxE) that acts in concert with a reductase (LuxC) to 
reduce the long chain fatty acid to an aldehyde. 
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Figure 0- 2. The molecular basis of bioluminescence 
Figure 1.2. The molecular basis of bioluminescence.  LuxAB genes encode the α 
and β sub units of the luciferase which combines a fatty acid aldehyde, molecular 
oxygen and FMNH2 to form an unstable intermediate that decays to produce light, a 
carboxylic acid, water and reduced flavin mononucleotide [260]. The LuxCDE genes 
encode a reductase, a synthetase and a transferase respectively, which regenerates 
the long chain aldehyde required for this reaction. 
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This means that the reaction can only occur in the presence of aerobic respiration in 
living bacteria. All of the substrates for bacterial bioluminescence are present within 
the cell, and there is no need to provide exogenous compounds to enable 
luminescence. It is for this reason that the bacterial lux operon has been widely used 
for BPI studies of bacteria.  
The lux operon evolved in Gram negative organisms, and so produces very little light 
when expressed in Gram positive organisms. Rearrangement of the operon as 
luxABCDE, with Gram positive ribosomal binding sites between the genes [261] has 
allowed the monitoring of infection in a number of Gram positive pathogens, 
including Staphylococcus aureus [262], Listeria monocytogenes [263] and 
Streptococcus pneumoniae [264]. These models have enabled investigators to 
image the colonisation of organs and tumours by L. monocytogenes [263], 
colonisation of Staphlyococcus epidermidis in implanted catheters [265], antibiotic 
efficacy against S. pneumonia [266], and the in vivo germination of  Bacillus 
anthracis [267], to provide a few examples.  
The luxABCDE operon has previously been integrated onto the chromosome of an 
emm49 skin isolate [268] of S. pyogenes using a transposon, and the resulting 
bioluminescent strain has been used to examine systemic [160], and intranasal 
infection [216]. Following intranasal administration, bioluminescent streptococci were 
identified in the NALT of infected mice, leading to the proposal that the NALT was a 
major repository for S. pyogenes in mice. However, it is known that isolates derived 
from the skin have different tissue tropisms from those which infect the nasopharynx, 
therefore this may not be an appropriate isolate to model nasopharyngeal 
colonisation. Furthermore, emm49 strains have not been associated with disease in 
the west for several decades [71]. The emm49 bioluminescent isolate is 
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commercially available but has not been widely used, despite the increasing 
availability of facilities to image bioluminescence in vivo. There is a perceived need 
to derive newer, clinically relevant bioluminescent derivatives of S. pyogenes to 
model both pharyngeal and invasive infection using emm types that reflect those 
causing disease today. A major aim of this project was to derive such a strain, and 
determine if BPI could be used to improve or broaden the applications of this model 
of upper respiratory tract infection with S. pyogenes. 
1.9. PRELIMINARY WORK TO DEVELOP NEW METHODOLOGY 
In preliminary work, new methods to model infections were investigated with the long 
term aim of improving a model for S. pyogenes carriage in the upper respiratory 
tract.  
BPI was used to investigate how the dose volume of bioluminescent Citrobacter 
rodentium [269,270] determined its immediate distribution within the respiratory tract 
(Figure 1.3). The dose volume retained solely to the nasopharynx was determined to 
be 5μl, although a volume of 10μl was the highest volume that did not immediately 
distribute to the lung, confirming previous findings [214,215,225] and demonstrating 
unequivocally that volumes in excess of 20 μl would reach the lung. 
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Figure 0-3. Biophotonic imaging of bacterial distribution after intranasal inoculation with bioluminescent C. rodentium 
Figure 1.3 Biophotonic imaging of bacterial distribution after intranasal 
inoculation with bioluminescent C. rodentium. 10
8
 colony forming units (cfu) of 
bioluminescent C. rodentium were administered intranasally to CD1 outbred mice in 20 
µl (n=3), 10 µl (n=2), 5 µl (n=3) and 2.5 µl (n=2) of PBS. Images were acquired using 
an IVIS spectrum system, and are displayed as images of peak bioluminescence, with 
variations in colour representing light intensity at a given location. Red represents the 
most intense light emission, while blue corresponds to the weakest signal. The colour 
bar indicates relative signal intensity (as photons s
-1
 cm
-2
 sr
-1
). Two representative 
mice are shown for each group. 
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Using a fixed dose volume of 5μl, different pharyngeal and blood culture clinical 
isolates of S. pyogenes from major emm types were screened in vivo to determine 
which would result in successful nasopharyngeal infection.  In these preliminary 
studies, groups of 7 BALB/c mice were infected with emm1, emm2, emm75, or 
emm81 S. pyogenes strains. A new technique was used to detect and quantify the 
carriage of S. pyogenes within the nasopharynx. This involved the detection of S. 
pyogenes shed from the mouse nasopharynx via swabbing the anterior nares 
directly onto Columbia blood agar, a technique which is described in Chapter 2. 
Strains derived from cases of non-invasive pharyngitis tended to colonise mice more 
effectively than those derived from invasive diseases. An emm75 pharyngitis isolate 
(H347) colonised the upper respiratory tract better than all the others tested (Figure 
1.4). However, the overall poor susceptibility of BALB/c mice to infection in the 
nasopharynx provided an obstacle to further use.   
56 
 
 
Figure 0-4. Shedding intensity of different serotypes of S. pyogenes in BALB/c mice 
Figure 1.4. Shedding intensity of different serotypes of S. pyogenes in 
BALB/c mice. Emm1, emm2, emm81 and emm75 isolates of S. pyogenes were 
intranasally infected into BALB/c mice (n=7). Nasal shedding was recorded at 24h, 
48h, and 72h.  Rows indicate individual mice throughout the time course. The 
colours of each block indicate the numbers of S. pyogenes recovered from direct 
nasal samples with red indicating the highest recorded levels of carriage (≥5000 
cfu), green indicating the lowest levels of carriage (1 cfu) and blank blocks 
indicating no recovery of S. pyogenes. 
57 
 
 1.10. AIMS 
1.10.1. DEVELOPING A MOUSE MODEL OF NASOPHARYNGEAL INFECTION 
There is a need for more appropriate mouse models of S. pyogenes colonisation of 
the upper respiratory tract, as current models vary with respect to the bacterial and 
mouse strains used. Age and gender are also known to exert an effect on invasive S. 
pyogenes infection.  The optimisation and balancing of these factors may produce an 
improved mouse model that is more susceptible to nasopharyngeal colonisation than 
those currently available. The development of a robust model of murine 
nasopharyngeal infection will provide a platform from which other features of 
streptococcal infection can be explored in the future such as, for example, factors 
affecting transmission of S. pyogenes from infected to naive mice, and the 
aerosolisation of respiratory droplets. 
1.10.2. DEVELOPING A BIOLUMINESCENT STRAIN OF S. PYOGENES 
The currently available bioluminescent strain of S. pyogenes is derived from an 
uncommon skin isolate that may not effectively model pharyngitis. There is a need 
for a more clinically relevant strain of S. pyogenes to be made bioluminescent. It is 
also important that the bioluminescence expressed by this strain can produce a 
visible signal in vivo.  
1.10.3. APPLYING A BIOLUMINESCENT STRAIN OF S. PYOGENES TO A MODEL OF 
NASOPHARYNGEAL INFECTION 
The creation of a suitable bioluminescent strain of S. pyogenes will enable the study 
of nasopharyngeal infection. It will be necessary to determine whether BPI can be 
used to accurately quantify S. pyogenes within the nasopharynx. 
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1.10.4. DETERMINING THE EFFECT OF VIRULENCE REGULATOR DYSFUNCTION IN 
A MODEL OF NASOPHARYNGEAL INFECTION 
The switch from colonisation in the nasopharynx to invasive infection is believed to 
be mediated by mutations or altered phosphorylation status of virulence regulators 
such as covR/S. The use of BPI and direct nasal sampling techniques may provide 
new insights into the effects of covR/S mutation on infection in the nasopharynx. 
1.10.5. UTILISING A MODEL OF NASOPHARYNGEAL INFECTION TO ASSESS 
VACCINE CANDIDATES 
The primary benefit of creating a new model of infection is the potential to evaluate 
the effects of different vaccine candidates on pharyngeal infection by S. pyogenes. 
Evaluation of effect will be based upon monitoring the presence of bacteria in the 
nasopharynx, rather than on proxies for disease severity. BPI will allow the clearance 
of S. pyogenes to be quantitatively imaged, and used as a criterion for determining 
vaccine efficacy. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1. CHEMICALS 
Methanol (Fisher) 
Microsol (Anachem) 
Acetic acid (Fisher) 
Agarose (Sigma) 
EDTA (Sigma) 
Ethanol (Fisher) 
Glucose (VWR) 
IPTG (Sigma) 
Isopropanol (Fisher) 
Formalin (VWR) 
Pilocarpine (Sigma) 
MgCl2 (Sigma) 
NaCl (VWR) 
NaHCO3 (VWR) 
Na2CO3 (VWR) 
Tris (Sigma) 
Sodium Azide (Sigma) 
Sodium dodecyl sulphate (Sigma) 
SYBR-safe (Invitrogen) 
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Tween (Sigma) 
Dried Milk powder (Sigma) 
BSA (VWR) 
KH2PO4 (VWR) 
Mg SO4.7H2O (Sigma) 
Yeast extract (Oxoid) 
Glycine (VWR) 
DTT (Sigma) 
2.1.2. ANTIBODIES 
Biotin conjugated Goat Antimouse IgG (Sigma) 
Biotin conjugated Goat Antimouse IgA (Abcam) 
Streptavidin conjugated HRP (Amersham) 
Rabbit Anti SpeB (Abcam) 
HRP conjugated Goat anti rabbit (Sigma) 
2.1.3. ENZYMES 
Proteinase K (Sigma) 
Phusion DNA polymerase (Finnzymes) 
Mutanolysin (Sigma) 
Lysozyme (Sigma) 
2.1.3. PRIMERS 
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Table 0-1. Primers and oligonucleotides 
 
2.1.4. PLASMIDS 
Table 0-2. Plasmids used in this study 
Plasmid Antibiotic 
resistance 
Properties Source 
pUCMUT Kanamycin   
pET100-CEP Ampicillin  Expression of a 
recombinant fragment of 
SpyCEP 
 
pICL18 Kanamycin, 
Ampicillin 
Shown in Figure 2.1. Produced by James 
Peacock 
pICL18lux Kanamycin Shown in Figure 2.1. This study 
pICL18vlux Kanamycin Shown in Figure 2.1. This study 
pICL180 Kanamycin Shown in Figure 2.1. This study 
pTHLK Kanamycin, 
Erythromycin 
Shown in Figure 2.1. Produced by Dr Colin 
Bateman 
Table 2.2. Plasmids used in this study 
 
2.1.5.  BUFFERS AND STANDARDISED SOLUTIONS 
 Electroporation media 
90mls 1mM autoclaved MgCl2 
4.9g D- Glucose filter sterilised into 10mls sterile distilled water, and 
preserved at 4oC. 
 SET 
750μl of 5M NaCl 
Table 2.1. Primers and oligonuceotides 
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2.5ml 0.5M EDTA 
1ml of Tris pH 7.5 
This was made up to 50mls with sterile distilled H2O. 
 50 x TAE buffer stock 
121.0g Tris  
28.6ml acetic acid  
50ml 0.5M EDTA  
This was made up to 500mls with sterile distilled H2O.  
 Fixing Solution 
50mls methanol 
10mls Acetic acid  
40mls Sterile distilled water 
 Carbonate coating buffer 
0.53g Na2CO3 
0.42 NaHCO3 
0.1g Sodium Azide 
100 mls Sterile distilled water 
 Western Wash Buffer 
100mls 10×PBS  
500µl Tween 
This was made up to 1L of sterile distilled water. 
 ELISA Wash buffer 
5mls 10× PBS 
5μls Tween 
40mls Sterile distilled water 
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 Transblot buffer 
0.25M Tris 
1.92g Glycine 
 Milk blocking buffer 
50mls PBS 
50µl Tween 
2.5 g Dried milk powder 
 BSA Blocking buffer 
0.6g BSA 
60mls PBS 
2.1.6. BACTERIAL MEDIA 
 Todd Hewitt Yeast (THY) Broth 
7.28g Todd Hewitt broth 
0.4g Yeast extract 
200mls Sterile distilled H2O 
 Todd Hewitt (TH) Agar 
7.28 Todd Hewitt broth 
4.0g  Bacterial Agar 
200mls sterile distilled H2O 
 LB broth 
6.4g LB broth 
200mls sterile distilled H2O 
 LB Agar 
7g LB Agar 
200mls sterile distilled H2O 
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 C-media 
0.27g - KH2PO4 
0.02g -  Mg SO4.7H2O 
0.2g – NaCl 
3g yeast extract 
20mls sterile distilled H2O 
 SOC media (Invitrogen) 
 Columbia Blood Agar (Oxoid) 
2.1.7. KITS 
 PathoDX Streptococcal grouping Kit (Oxoid) 
 
 QIAgen Spin Miniprep Kit 
 
 QIAgen PCR purification Kit 
 
 Novagen His Bind  Bugbuster purification Kit 
 
 Fluka Gram staining Kit  (Sigma) 
 
 Oxidase Testing Kit (Fisher) 
 
 ECL developing kit (Amersham) 
 
 Invitrogen Colloidal Blue Staining Kit 
 
2.1.8. BACTERIAL STRAINS 
An emm75 S .pyogenes clinical strain, H347, from a pharyngitis case isolated in the 
Imperial College Healthcare NHS Trust Diagnostic Laboratory was used in all 
studies. An isogenic covR/S mutant of the emm75 strain, H494, has been previously 
described, and is known to have enhanced expression of SpyCEP due to insertional 
mutagenesis of both covR and covS  [45]. The streptococcal strains used during this 
work are listed in Table 2.3. All were clinical strains from pharyngitis cases and were 
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emm typed [67] using standard methods and criteria by Bonita Song (Gram positive 
pathogenesis group, Imperial College). All streptococcal strains were cultured either 
in Todd Hewitt Yeast broth (THY), C-media (CM) or on Colombia Blood Agar (CBA). 
Lactococcus lactis strain H826 was used as a negative control for initial vaccination 
studies. Bioluminescent Citrobacter rodentium strain ICC180 [271] was used for 
nasal dosing studies described in the introduction. Plasmids were propagated in 
Escherichia coli strain DH5α (Invitrogen), and protein production was performed in E. 
coli strain BL21 (Invitrogen), which were both grown in Luria-Bertani (LB) broth.  
Table 0-3. Strains of S. pyogenes used in this study 
Strain Designation Emm type Antibiotic resistance(s) Source 
H347 emm75  [45] 
H494 emm75 Erythromycin [45] 
H347pTHLK emm75 Erythromycin, Kanamycin This study 
H347vlux emm75 Kanamycin This study 
H347lux emm75 Kanamycin This study 
H3470 emm75 Kanamycin This study 
H494lux emm75 Erythromycin, Kanamycin This study 
H683 emm1  This study 
H768 emm2  This study 
H689 emm3  This study 
H679 emm4  This study 
H682 emm6  This study 
H675 emm12  This study 
H696 emm22  This study 
H704 emm28  This study 
H686 emm89  This study 
Table 2.3. Strains of S. pyogenes used in this study 
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2.2. METHODS 
2.2.1. PCR TO AMPLIFY THE KANAMYCIN RESISTANCE GENE APH-A3. 
Polymerase chain reactions were performed using Phusion DNA polymerase (0.5μl), 
×5 Phusion HF buffer (10μl), 10mM dNTP mix (1μl) and the Aph-a3 primers (1μl 
each) and 1μl of the template DNA (pUCmut), and 36.5μl of H2O to make the volume 
up to 50μl.  
Cycles Temperature Time 
1 cycle 98oC 30 sec 
30 cycles 
98oC 10 sec 
65oC 30 sec 
72oC 45 sec 
1 cycle 72oC 7 minutes 
1 cycle 4oC Hold 
 
2.2.2. PCR TO AMPLIFY THE SPY0535 LOCUS 
Polymerase chain reactions were performed using Phusion DNA polymerase (0.5 
μl), ×5 Phusion HF buffer  (10 μl), 10mM dNTP mix (1 μl) and the spy0535 primers (1 
μl each) and 1μl of the template DNA (S. pyogenes strain H347 DNA extract),  and 
36.5μl of H2O to make the volume up to 50μl.  
Cycles Temperature Time 
1 cycle 98oC 30 sec 
30 cycles 
98oC 10 sec 
67oC 30 sec 
72oC 30 sec 
1 cycle 72oC 7 minutes 
1 cycle 4oC Hold 
 
2.2.3. PCR TO CONFIRM CHROMOSOMAL INSERTION INTO THE SPY0535 LOCUS 
Polymerase chain reactions were performed using Phusion flash master mix (10 μl) 
and primers (1μl each) and 0.5 μl of the template DNA and 7.5 μl of H2O to make the 
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volume up to 20μl. Annealing temperatures were set at 10oC below the lowest Tmo 
of the primers for the first 15 cycles, and then at 3oC below the lowest Tmo of the 
primers for 30 cycles.  
Cycles Temperature Time 
1 cycle 98oC 10 sec 
15 cycles 
98oC 1 sec 
55oC 5 sec 
72oC 3 min 
30 cycles 
98oC 1 sec 
60oC 5 sec 
72oC 3 min 
1 cycle 4oC Hold 
 
2.2.4. PLASMID CONSTRUCTION OF PICL18LUX AND PICL18VLUX 
The pTHLK plasmid (Figure 2.1 A) was derived from pIB184, and constructed by Dr 
Colin Bateman, Imperial College. The pICL18 plasmid was derived from pUC18N 
during a previous Masters project by Mr James Peacock, Imperial College (shown in 
Fig 2.1 B). The Aph-A3 gene was amplified from pUCMUT  [272] using the Aph- A3 
F and Aph-A3 R amplification primers (Table 2.1) and ligated into this vector via a 
PacI/SacI fragment. 
The Spy0535 gene region was amplified from emm75 S. pyogenes target DNA using 
the Spy0535 L and Spy0535 R primers (Table 2.1) before being ligated into the 
vector as a SacI/KpnI fragment. The bla ampicillin resistance was removed via 
digestion with PvuI, and susceptibility to ampicillin was confirmed through successive 
streaking of transformed E.coli onto selective media to make the integrating vector 
pICL18lux (Figure 2.1 C). The Pveg
 promoter was exchanged for the Phelp to create 
pICL18vlux (Figure 2.1 D). 
2.2.5. EXCISING LUXABCDE FROM PICL18LUX 
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Linker primer F and Linker primer R (Table 2.1) were heated to 90oC, and then 
allowed to cool at room temperature to allow for the linker fragments to form. The lux 
operon was excised via an EcoRI/BglII digest and then the linker was used to ligate 
the incompatible ends of the vector to create pICL180. The genomic insertion of the 
above plasmids was confirmed using the PCR diagnostic primers shown in Table 
2.1.  
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Figure 0-1 Schematic diagrams of plasmids 
Figure 2.1. Schematic diagrams of plasmids. Arrows indicate locations and 
orientations of open reading frames. The replicating plasmid construct pTHLK (A), the 
original pICL18 plasmid (B) and the integrating plasmids  pICL18
vlux
 (C)  pICL18
lux
 (D) 
and the pICL18
0
 (E) are shown. 
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2.2.6. DNA EXTRACTION FROM S. PYOGENES 
Overnight cultures of S. pyogenes in THY broth were spun at 1864×g for 10 minutes 
at 4oC. The pellet was resuspended in 1 ml of 1×PBS with 20μl mutanolysin (10,000 
U ml-1) and 20μl of lysozyme (100 mg ml-1). This was incubated at 37oC for 10 
minutes. 
The cells were then centrifuged at 200×g for 10 minutes and resuspended in 500 μl 
SET medium. 50  μl of SDS and 5 μl of proteinase K was added to this mixture, and 
it was incubated at 55oC with occasional mixing for 2 hours. 175 μl of 5M NaCl and 
500 μl of chloroform were added, and incubated for 30 minutes before being 
centrifuged at 10,000×g for ten minutes. 500 μl of the aqueous phase was removed 
and added to 500 μl of isopropanol to precipitate the DNA.  This was centrifuged at 
10,000×g, and the pellet was re-suspended in ethanol and the centrifugation step 
was repeated. The ethanol was discarded, and the DNA pellet was dried for 30 
minutes. It was then dissolved in 200 μl of molecular grade H2O. 
2.2.7. PLASMID EXTRACTION FROM E.COLI 
The extraction of plasmid was performed using a QIAgen Spin Miniprep Kit utilising a 
modified protocol to account for the >10Kb sizes of the plasmids used in this work. 
40 mls of overnight LB cultures of DH5α were centrifuged at (1294×g), and the 
pellets were re-suspended in 400 μl buffer P1 and transferred to a 1.5 ml tube. 400 
μl of buffer P2 was added and mixed by inversion 4-6 times. 620 μl of buffer N3 was 
added and mixed in the tube; this was centrifuged for 10min at 15,000×g. 800 μl of 
the mixture was added to a QIAprep spin column nestled in a collection tube. This 
was centrifuged for 1 minute and the eluate was discarded after this and each 
subsequent centrifugation. The remaining 620 μl was then added to the filtration 
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column and spun once more for 1 minute. 0.5 ml of buffer PB was added to the 
microfiltration column and centrifuged for 1 minute.  750 μl of buffer PE was added, 
and centrifuged for 1 minute (15,000×g), and then again for 1 minute to remove 
excess wash buffer. 30 μl of molecular grade water heated to 70oC was added to the 
column, and left for 5 minutes. The eluate from this reaction was collected during a 1 
minute centrifugation step (15,000×g). 30 μls of 70oC molecular grade water was 
added again, incubated for 5 minutes and the eluate from the microfiltration columns 
was collected once more, to produce a 60 μl solution of plasmid DNA. 
2.2.8. TRANSFORMATION OF E.COLI 
DH5α heat competent cells were thawed on ice, and 50 μl was added to 5 μl of 
plasmid and incubated on ice for 30 minutes before being heat shocked at 42oC for 
30 seconds. The mixture was incubated for 5 minutes then 950 μl of SOC media was 
added prior to incubation at 37oC with shaking for 1 hour, then plating out onto LB 
agar containing kanamycin (50 μg ml-1), ampicillin (100 μg ml-1) or erythromycin (500 
μg ml-1) as appropriate. Plates were incubated overnight at 37oC and 4.5-5% CO2. 
2.2.9. ELECTROTRANSFORMATION OF S. PYOGENES 
An overnight culture of S. pyogenes was diluted 1:20 into THY broth and incubated 
to an OD600 of 0.15-0.17. The bacteria were washed twice in ice cold sterile 
electroporation medium with re-suspension and centrifuged at 3000×g (Beckman 
Centrifuge, JA-20 rotor) for 10 minutes at 4oC. After the final wash, the cells were 
suspended in 750 µl electroporation medium. 75 µl of this suspension were 
transferred to 1.5 ml tubes containing 5 µl plasmid preparations. This suspension 
was electroporated at 150 mΩ, 50 µF and 1 kV (Gene Pulser Xcell, Bio-Rad). The 
time constants which were obtained for this were 6.3-6.5 s-1. The suspension within 
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the cuvette was added to 10 ml THY broth and incubated for 2 hours at 37oC without 
antibiotic. This broth was then centrifuged at 1200×g (RTH 750 Rotor, Sorvall) and 
the supernatant discarded. The remaining pellet was re-suspended in 100 μl THY 
broth and spread onto selective media containing kanamycin (500 μg ml-1) or 
erythromycin (50 μg ml-1), as appropriate.  Plates were incubated overnight at 37oC 
and 4.5-5% CO2. 
2.2.10. CEP5 PRODUCTION FROM E.COLI 
E. coli BL21 were transformed with pET100-CEP, a plasmid expressing his-tagged 
recombinant CEP5 representing 35-587aa of the SpyCEP protein created in 
previous work [147]. The transformation mix was aliquoted into 10 ml LB broth, with 
100 µg ml-1 ampicillin and shaken overnight at 37oC. This was then added to 490 ml 
of LB with ampicillin and grown for 3 hours (OD600 =0.6-0.8) when 250 μl of IPTG 
was added to make a final concentration of 0.5 mM. 50 ml fractions were centrifuged 
(RTH-750, Sorvall) at 1294×g for 20 minutes.  
Purification of CEP5 protein was performed using the Novagen His Bind kit. The 
eluted protein was concentrated using Millipore Amicon Ultra-15 centrifuge tubes 
which were spun at 1294×g for 30 minutes. The solution was cleaned with sterile 
PBS via three 30 minute centrifugation steps at 1294×g.   
Samples taken before and after purification were run on Bis-tris gels as described 
previously. The gels were incubated with shaking in fixing solution for ten minutes. 
The fixing solution was discarded and staining solution A for 10 minutes with 
shaking, followed by the addition of staining solution B. This was incubated with 
shaking at room temperature for 3 hours. This gel was de-stained overnight in 
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distilled water. The gel was then imaged using a GelDoc-it imaging system to 
confirm the production of a 60kDa CEP5 (Figure 2.2). 
 
Figure 0-2. SDS PAGE demonstrating production and purification of recombinant CEP5 
2.2.11. AGAROSE GEL ELECTROPHORESIS 
To analyse DNA products from PCR or from restriction digests, 0.8-1% agarose gels 
made with 1×TAE were made with SYBR-safe (concentration 1μl SYBR-safe /10mls 
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Figure 2.2. SDS PAGE demonstrating production and purification of 
Recombinant CEP5. 10μl of transformed E.coli broth (pre-purification) was 
compared to 10μl of purified recombinant CEP5 protein. 
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agarose.). These were run at 100V for 30 minutes and imaged using a GelDoc-it 
imaging system (UVP). 
2.2.12. SDS GEL ELECTROPHORESIS 
Samples were incubated with DTT and LDS sample buffer at 72oC for 10 minutes 
and run on a 10% Bis-Tris sodium dodecyl sulphate–polyacrylamide gels (NuPAGE) 
at 200V for 35 minutes with 500 ml MES buffer (NuPAGE) and 500 μl of antioxidant 
(NuPAGE). 
2.2.13. WESTERN BLOT 
10μl supernatants obtained from isolates cultured to the early log, mid log, and late 
log phases of growth in TH were run on a 10% Bis-Tris sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels (Invitrogen) as described 
above. A Hybond P membrane (Amersham) was activated in methanol for 10 
seconds, soaked in water for 10 minutes. The gel was placed atop the membrane in 
transblot buffer and then placed in the transblot tank (Mini Trans-Blot Cell, Bio-Rad), 
and run at 60V for 1 hour at 4oC. On completion of transfer, the membrane was 
washed 3 times with PBS and milk blocking solution was added and left to incubate 
with shaking for 1 hour.  Rabbit anti-SpeB antibody was added and left to incubate at 
4oC overnight. The membrane was then washed with western wash buffer 4 times. 
Milk blocking solution was added with HRP conjugated- goat anti-rabbit and 
incubated for 1 hour. The membrane was washed 4 times with wash buffer before 
being developed using the ECL system (GE Healthcare). 
2.2.14. BIOFILM ASSAY 
Biofilm assays were performed as described previously [273].  Overnight cultures 
grown in THY broth were diluted 1:20 into C-media, and incubated at 37oC with 5% 
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CO2 for 24 hours. The supernatant was removed from each well and collected in a 
corresponding 10 ml tube. The wells were washed three times with PBS, and the 
discarded washes were added to the supernatants for each well, which were then 
centrifuged at 1864xg (Sorvall RTH-750) to ensure all non-adherent bacteria were 
collected. The biofilms and supernatants were re-suspended in 0.2% crystal violet 
(Fluka) for 15 minutes, and then shaken with 1% SDS at 180 rpm (IKA HS 260 
Shaker) for 10 minutes. The solutions were diluted 1:10 in PBS in optical cuvettes, 
and had their OD600 measured to assess the presence of bacteria in the biofilms. 
Serial dilutions of an inoculum containing 108 CFU of S. pyogenes were made in 
triplicate, spun down and exposed to the crystal violet staining protocol described 
previously. Samples from these dilutions were plated out onto CBA to assess the 
numbers of S. pyogenes present, to allow for a standard curve to be drawn. 
2.2.15 GROWTH KINETICS AND LIGHT PRODUCTION KINETICS 
Growth rates of each strain were assessed through preparing an inoculum as 
described above, and inoculating it into 50mls THY broth (n=3).  The OD600 of a 1 ml 
sample from each culture was taken at hourly intervals. At half hourly intervals, a 
50μl sample of culture was taken and was measured using a Modulus Single Tube 
Luminometer either neat, or diluted 1:10 into PBS. 
2.2.16. LIGHT PRODUCTION OF THE BIOLUMINESCENT STRAINS 
Pellets from overnight cultures of S. pyogenes transformed with either the pICL18lux 
or pTHLK were re-suspended in PBS, and then serial tenfold dilutions were made to 
determine flux from each well of a 96 well plate, prior to plating onto agar for 
quantification. These were imaged using the IVIS100 system, and analysed mice 
using the region of interest (ROI) tool in the Living Image software program. 
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2.2.17. STABILITY OF BIOLUMINESCENCE EXPRESSION 
The stabilities of the replicative and integrated plasmids in S. pyogenes were 
assessed. An inoculum prepared from overnight cultures containing 107 colony 
forming units (CFU) were inoculated into THY broth with and without selection (n=3). 
Every 24 hours, 1 ml of each culture was inoculated into 49 ml of fresh THY broth 
with the same growth conditions as the previous culture.  Samples were taken at 
specific time points, from which serial dilutions onto selective and non-selective 
media were made to assess numbers of bacteria with or without the constructs, 
which was repeated up to 7 days after the initial inoculation. 
2.2.18. ANIMAL HOUSING AND ENRICHMENT 
Male and female 5-10 week old CD1, C57BL/6, A/J, BALB/c, FVB/n specific-
pathogen free mice (sourced from Harlan or Charles River, UK) were maintained in 
individually HEPA filtered cages with sterile bedding and free access to sterilised 
food and water. GLP Mini Fun Tunnels (Lillico), or Des. Res. Mini Mouse Houses 
(Lillico) were provided in each cage for environmental enrichment. Experiments were 
performed in accordance with the Animals (Scientific Procedures) Act 1986 and were 
approved by the local Ethical Review Process.  Food and water were provided ad 
libitum, and the facility was maintained on a 12 hour light dark cycle. 
Mice were maintained at cage densities between 3-8 mice per cage. Mice older than 
10 weeks were not housed in cage numbers greater than 6. Where there was 
evidence of intraspecific aggression, the aggressors were determined through 
behavioural observation, and wound analysis, and split into a separate cage. Extra 
enrichment was added to help ameliorate aggressive behaviour. Mice were weighed 
77 
 
daily for welfare purposes during experiments, and an observed daily weight loss of 
greater than 20% was a defined humane end point. 
2.2.19. INTRANASAL INFECTION 
Bacterial inocula were prepared from overnight stationary phase 50 ml THY broth 
cultures of S. pyogenes, with or without antibiotic selection where appropriate. 
Cultures were spun at 1864×g  (Sorvall RT7 Centrifuge with RTH-750 rotor) and re-
suspended in PBS to wash twice. A final spin was used to concentrate the bacteria. 
The optical density at 600nm (OD600) of a 1 in 100 dilution was adjusted to 1, so that 
a 5 µl sample would contain approximately 108 colony forming units (CFU).   
To produce bacterial inocula from S. pyogenes growing in exponential phase, 3× 50 
ml cultures were grown per strain over a 5 hour period. After 5 hours of growth, 
these were centrifuged, and the pellets were pooled together before being washed 
twice in PBS. The OD600 was adjusted to 1 of a 1 in 100 dilution, so that a 5μl sample 
would contain approximately 108 CFU. 
Intranasal inoculation: For streptococcal infection of the nasopharynx, 108 CFU of S. 
pyogenes was administered intranasally using a pipette to mice in a volume of 2.5 μl 
per nostril under 2-5% isoflurane anaesthesia. Mice were weighed daily; reduction by 
20% of the original weight was a defined humane end point. Numbers of viable 
bacteria within the inoculum were retrospectively assessed by plating of the 
inoculum onto Columbia blood agar. 
Intrapulmonary inoculation: An inoculum of approximately 107-108 CFU in a 5 µl 
volume prepared as described previously was diluted in sterile PBS to make a 20 µl 
inoculum suspension. This was then administered to mice under isoflurane 
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anaesthesia via the intranasal route using a pipette. Numbers of viable bacteria 
within the inoculum were assessed by retrospective plating onto CBA. 
2.2.20 INTRAMUSCULAR INFECTION 
108 CFU in a volume of 50μl S. pyogenes were administered to mice under 
isoflurane anaesthesia via injection with a 27 gauge needle into the right lateral 
gastrocnemius muscle within the thigh. Numbers of viable bacteria within the 
inoculum were assessed by retrospective plating onto CBA. 
2.2.21 IN VIVO COMPETITION ASSAY 
H347, H347lux or H3470 cultured overnight were centrifuged (1864×g for 10 min) and 
washed twice in PBS. The OD600 for each strain was adjusted to 100, and 
suspensions of different isolates were mixed 1:1 pairwise then infected into groups of 
8 mice. Bacterial colonies from the nasopharynx were replica plated onto selective 
media on day 1 (4 mice per group) or day 3 (4 mice per group).  Individual colonies 
were inoculated into THY and bioluminescence quantified after 5 hours of growth 
(Modulus Single Tube Luminometer). S. pyogenes that were either bioluminescent or 
kanamycin resistant were quantified to determine the proportion of each strain 
surviving in vivo. Competitive Indices (CI) were calculated as follows: CI=(mutant 
output/WT output)/(mutant input/WT input). 
 
2.2.22 MOUSE IMMUNISATION 
Mice were immunised with 50 μl of vaccine comprising either S. pyogenes strain 
H347 heat inactivated at 80oC, or SpyCEP protein (CEP5) intramuscularly 4, 2 and 1 
weeks prior to challenge.  To make a heat-killed vaccine, a suspension of S. 
pyogenes in sterile PBS was heated for 1 hour at 80ºC and concentrated to a final 
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density of 2 ×109 CFU/ml, yielding a dose of 108 CFU per mouse; an aliquot of 
suspension was plated out prior to heating to quantify CFU. Sterility of this vaccine 
was verified by plating out onto CBA after heating. 
CEP5 (2 mg ml-1) was mixed 1:1 with adjuvant to create the SpyCEP based vaccine. 
Each mouse therefore received 50μg CEP5 per immunisation. As controls, groups of 
mice were immunised either with PBS alone, or with PBS mixed 1:1 with adjuvant. 
For priming vaccinations, Complete Freunds Adjuvant was used, and subsequent 
boosters used Incomplete Freunds Adjuvant. 
2.2.23. SALIVA COLLECTION 
Mice were intraperitoneally injected with 100 μl 0.2% pilocarpine. Mice were then 
anaesthetised with isoflurane at an initial rate of 5%, and then maintained at a rate of 
2%. Mice were placed on an angled surface, and saliva was collected. Samples 
were frozen at 80oC after collection.  
2.2.24. IN VIVO BIOPHOTONIC IMAGING 
Bioluminescence (presented as photons s-1 cm-2 steridian [sr]-1) from infected 
animals was assessed after isoflurane anaesthesia using the IVIS 100 camera 
system (Caliper Life Sciences). The sample shelf was set to a field of view of 10-21.2 
cm. A reference image was taken under low illumination prior to quantification of 
photons emitted from S. pyogenes at a binning of 4 over 20-300 seconds using the 
software program Living Image 2.0 (Xenogen). For anatomical localisation, a 
pseudocolour image representing light intensity (blue, least intense to red, most 
intense) was generated using the Living Image software and superimposed over the 
grayscale reference image. Light intensity on reference image is presented as 
photons s-1 cm-2 sr-1, a standardised measure of luminescence. 
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Bioluminescent signals within specific regions of individual mice were quantified 
using the region of interest (ROI) tool in the Living Image software program. ROI’s to 
detect light emanating from the nasopharynx were drawn as shown in Figure 2.3. 
Data collected using ROI is displayed as total flux (p s-1) 
 
Figure 0-3. ROI for analysing luminescence from the mouse nasopharynx 
2.2.25 DISSECTION 
At the end of each experiment, mice were culled by cervical dislocation.  To remove 
the spleen, the peritoneum was exposed and an incision was made to the left side of 
the mouse halfway between the last rib and the hip joint.  To extract the liver, an 
incision was made to the right side under the last rib, and the liver was pulled away 
from the diaphragm and dissected out. The extraction of the lung was performed via 
an incision of the peritoneum underneath the ribcage. The diaphragm was cut away 
and the ribcage pushed upwards to allow for the dissection of the lung. The inguinal 
Click # FMA20100327145424
27 Mar 2010 14:54:24
Bin:M (4), FOV10, f8, 0.2s
Filter: Open
Camera: 13195, EEV
User: FA
Group: 
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ROI 1=27455
Figure 2.3. ROI for analysing luminescence from the mouse 
nasopharynx.  
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lymph node was dissected out via peeling back the flank and locating the lymph 
node adjacent to the deep circumflex iliac artery on the inner surface of the skin. 
To ensure complete extraction of the nasopharynx, the skin and mandibles were 
removed to expose the cranium. This was then sectioned along the coronal plane at 
the bregma. The brain tissue within the cranium anterior to this incision was 
removed, exposing the posterior aspect of the nasal cavity, known as the cribriform 
plate (dissection line shown in Figure 2.4). The orbits were removed from this tissue 
via sagittal incisions lateral to the pre-maxilla. The remaining tissue comprised the 
entire nasal cavity, and NALT. This was homogenised into PBS and serial dilutions 
plated onto CBA to quantify S. pyogenes from the whole nasopharynx. Dissection 
equipment was washed in microsol followed by ethanol before and after the 
dissection of each organ. 
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Figure 0-4. Dissection of the mouse nasopharynx 
 
2.2.26. BRONCHO-ALVEOLAR LAVAGE  
An incision was made into the neck of the mouse to expose the trachea. A small 
incision was made to the trachea, into which a lavage tube was inserted and surgical 
suture thread was looped around the trachea and tightened to secure the lavage 
tube in place. 1 ml of PBS was injected into the lung, and then aspirated out. 
Broncho-alveolar lavage fluid was collected in a 1.5ml tube and frozen at -80oC for 
later use. 
Dissection line 
Ethmoturbinates 
Brain case 
Superior maxillary 
Turbinelles 
Figure 2.4. Dissection of the mouse nasopharynx. Diagram 
depicts mouse cranium bisected along the midline, and displaying 
internal structure of the nasopharynx. Dotted line indicates the plane 
of the initial cut to separate the nasopharynx. Not shown are the cuts 
utilised to remove the eye and the maxilla. Anatomy based on [205] 
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2.2.27. COLONY IDENTIFICATION 
Colonies plated out onto CBA were checked for the presence of α and β-haemolysis. 
For further identification, Gram staining, catalase and oxidase testing were used, 
coupled with Lancefield grouping to confirm Group A S. pyogenes 
2.2.27.1. GRAM STAINING 
Individual colonies were emulsified onto the surface of a glass slide in PBS and air 
dried before being flooded with crystal violet for 30 seconds. Gram’s iodine was 
added for 30 seconds. The slide was flooded with ethanol/acetone decolouriser for 5 
seconds before counterstaining with safranin for 30 seconds. The section was 
washed under a running tap. Gram-positive bacteria appear purple and Gram-
negative bacteria appear pink under microscopic analysis. S. pyogenes was used as 
a positive control and E.coli was used as a negative control on each slide. 
2.2.27.2. CATALASE TESTING 
A bacterial colony was added to 0.1 % hydrogen peroxide on the surface of a glass 
slide, and the observation of gas bubble formation confirmed the presence of 
catalase. 
2.2.27.3. STREPTOCOCCAL GROUPING 
The grouping of streptococci obtained from samples was determined using a 
PathoDX grouping kit (Oxoid). For conventional testing, the instructions were 
followed as directed. For confirmation that a β-haemolytic colony is S. pyogenes, 
Individual colonies were emulsified in 20 μl of the extraction enzyme preparation 
(Oxoid), and incubated at 37oC for 10 minutes. 10 μl samples of this preparation 
were mixed with 10 μl samples of the latex reagent, and the agglutination reaction 
was observed as for the initial studies. These modifications allowed for a higher 
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throughput for testing possible S. pyogenes colonies by confirming the presence of 
the group A carbohydrate. 
2.2.27.3. OXIDASE TESTING 
A bacterial colony was placed onto filter paper, to which an oxidase reagent (BD 
biosciences) was added. The rapid production of purple colour after the addition of 
reagent indicated the presence of oxidase. This was used to differentiate Gram 
negative bacterial species residing within the nasopharynx. 
2.2.28. ENZYME LINKED IMMUNOSORBENT ASSAY FOR IMMUNOGLOBULIN 
To assay for immunoglobulin G or A specific for bacteria, 108 CFU of heat-killed 
bacteria (either L.lactis or S.pyogenes) in 10 ml of carbonate coating buffer was 
added at 100μl per well of a 96 well plate, and incubated overnight at 4oC. To assay 
for immunoglobin specific for CEP5, 400 μl of a solution of 2 mg ml-1 of SpyCEP was 
added to 9.6 ml of carbonate coating buffer and aliquoted at 100 μl per well of a 96 
well plate which was incubated overnight at 4oC. 
Plates were then washed (ELx50 Strip Microplate Washer, BioTek) and incubated for 
two hours with BSA blocking solution before being washed again. Dilutions of 
samples from serum were incubated in volumes of 100 μl on the plates for two 
hours. After another wash step, anti-mouse IgG (Sigma) or anti-mouse IgA (AbCam) 
were added in PBS and incubated for 90 minutes. The plate was washed again, and 
incubated with a 1:200 dilution of streptavidin conjugated to HRP (R&D systems) in 
the dark for 20 minutes. The plates were washed, and incubated with 50 μl of TMB 
for ten minutes, after which 50 μl of a 1M solution of H2SO4 was added to stop the 
reaction. The optical density at 450 nm (OD450) was measured for each well using an 
ELISA plate reader (μQuant Universal Microplate Spectrophotometer, BioTek). 
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For analysis of saliva and BAL samples, ELISA was performed as above, except 
with Milk blocking solution used instead of BSA blocking solution. 
2.2.29. HISTOPATHOLOGY 
The head of each mouse was removed at the atlanto-occipital joint and sagittally 
hemi-sected. One half was fixed in formalin and processed routinely to paraffin wax, 
while the other was homogenised and plated to assess S. pyogenes numbers in the 
nasopharynx. The brain was sectioned coronally at the optic chiasm to image a 
lesion within it. Paraffin sections were cut at 6 µm and stained with Haematoxylin 
and Eosin and Gram stains, then reviewed by an experienced histopathologist 
(Professor Ken Smith, Royal Veterinary College, London). 
2.2.30. STATISTICS 
Statistics were performed using Prism Graphpad version 5.02. Data are presented 
as median, ± interquartile range. PS  Power and Sample Size calculator was used to 
prospectively determine the numbers of mice to be used in experiments using >10 
mice based on data from preliminary experiments. 
 
2.2.30.1. REGRESSION ANALYSIS 
Regression analysis was used to fit data to the appropriate linear, logistic and 
exponential decay models to determine rate constants and to allow curve 
comparison. An r2>0.95 was determined to be a good fit for the data. For curve 
comparison, P values less than 0.05 were defined as significant. 
2.2.30.2 MANTEL-COX LOGRANK 
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For statistical analysis of Kaplan-Meier survival curves, the Mantel-Cox Logrank test 
was applied. P values less than 0.05 were defined as significant. 
2.2.30.3 KRUSKAL WALLIS ANALYSIS 
 For statistical analysis of colony count comparisons, a non-parametric Kruskal-
Wallis test and Dunn’s post-test were used.  To analyse transmission data, P values 
less than 0.05 were defined as significant.  
2.2.30.4 MANN WHITNEY 
 For statistical analysis of colony count comparisons, a non-parametric Mann-
Whitney test was used.  To analyse transmission data, P values less than 0.05 were 
defined as significant.  
2.2.30.5 AREA UNDER THE CURVE ANALYSIS 
To compare colony counts taken over a time course, the area under the curve 
statistics for each individual mouse were calculated. These statistics were compared 
using either Kruskal-Wallis analysis, or Mann-Whitney tests outlined above. P values 
less than 0.05 were defined as significant.  
 
 
2.2.30.6. TWO WAY ANOVA 
 To analyse bioluminescence data over a time course, Two-way ANOVA was 
performed with Bonferroni correction. P values less than 0.05 were defined as 
significant.  
2.3. NEW TECHNIQUES 
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2.3.1. DIRECT NASAL SAMPLING 
The level of shedding of S. pyogenes from the nasopharynx was assessed 
longitudinally using direct nasal sampling. The nares of each mouse were gently 
pressed onto the surface of a CBA plate ten times.  The bacterial colonies were 
exhaled onto the surface of the plates were spread out using a plastic sterile loop, 
and the plates were then incubated overnight at 37ºC with 5% CO2 for bacterial 
enumeration. Viridans streptococci, staphylococci, pseudomonads and 
corynebacteria were recovered in preliminary experiments from uninfected mice, but 
no β haemolytic Group A streptococci were found to naturally colonise the mouse 
nasopharyngeal tract.   
For mice infected with S. pyogenes, β-haemolytic colonies were counted for each 
mouse and confirmed as S. pyogenes through Gram staining, catalase testing, 
oxidase testing, and Lancefield grouping. No other β-haemolytic bacteria were 
recovered from the mouse nasopharynx. Kaplan-Meier plots were created to analyse 
the duration of S. pyogenes shedding. Mice were determined to have stopped 
shedding upon the first instance of a nasal sample turning up negative. 
2.3.2. SETTLE PLATES IN INDIVIDUALLY VENTILATED CAGES 
Airborne bacteria produced by infected mice were detected via the inclusion of CBA 
plates were placed on the grids of the IVC’s in which the mice were housed (n=4 per 
cage).  These were exposed for variable lengths of time of between 8-24 hours for 
the duration of the experiment. Plates were incubated overnight at 37ºC and the 
numbers of S. pyogenes colonies (identified by Gram staining, catalase testing, and 
Lancefield grouping) were enumerated.   
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CHAPTER 3: CHARACTERISING A MODEL OF INFECTION IN 
THE MURINE NASOPHARYNX 
3.1. INTRODUCTION 
There is a need for a reproducible mouse model for the infection of the upper 
respiratory tract by S. pyogenes to study the factors underlying infection in this 
region. Mice are generally less susceptible to streptococcal infection, with the 
exception of the emm50 S. pyogenes strain (B514), which was attenuated at a key 
virulence regulator locus (mga), making it unsuitable for studying human clinical 
infection [222,226]. 
The resistance of mice to S. pyogenes infection has proven to be a formidable 
obstacle to investigating transmission. Some early studies utilised a nebuliser 
system to infuse the air of a mouse cage with droplets of S. pyogenes [211]  to 
model airborne transmission. However, the specialised nature of the equipment 
required for this model, and the variability of the results obtained using it prevented it 
from being developed further [212]. There are currently no models that can reliably 
induce mouse to mouse transmission of S. pyogenes. 
Previous work established that mouse strains differ in their susceptibility to 
streptococcal infection [192,193], and that age [196] and gender [194,195] can play a 
role in this susceptibility. As noted earlier (Chapter 1, Table 1.3) a variety of different 
mouse strains of different ages have been used in previous work to model infection 
in the respiratory tract.  The goal of this work is to assess the effects of these factors 
and use them to devise a reproducible model of non-invasive nasopharyngeal 
infection. 
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To study the progression of nasopharyngeal infection, longitudinal techniques are 
required that enable non-lethal sampling of the nasopharynx.  In previous work, a 
method for directly sampling bacteria shed from the nasopharynx during an infection 
was pioneered by quantifying colonies of S. pyogenes shed from the nasopharynx 
directly onto blood agar. It is not known whether the numbers of S. pyogenes 
recovered using this technique accurately represent the abundance of streptococci in 
the nasopharynx. In this chapter, data will be presented that addresses these 
questions and lead to the development of a more robust murine model of upper 
respiratory tract infection. 
3.2. RESULTS 
3.2.1. COLONY COUNTS OF S. PYOGENES SHED BY MICE CORRELATE WITH S. 
PYOGENES COLONY COUNTS FROM DISSECTED NASAL TISSUE.  
To longitudinally track bacterial colonisation in the nasopharynx, direct nasal 
sampling was used to detect the numbers of S. pyogenes shed from the 
nasopharynx during an infection. This utilised the ‘direct nasal sampling’ technique 
outlined in Chapter 2.3.1. In previous work (Chapter 1.9.) , an emm75 strain (H347) 
had been found to cause nasopharyngeal infection more effectively than other 
streptococcal strains and hence was used in subsequent experiments.  Mice 
experienced a decrease in weight immediately after nasal inoculation, and 
occasional conjunctivitis. The numbers of emm75 S. pyogenes colonies recovered 
from the nasal samples at different time points following infection was directly 
proportional to the numbers of bacteria present in nasal tissues upon dissection at 
the same time points (Figure 3.1.  r2<0.95, n=36).  
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Figure 
3.1. Quantitative correlation of S. pyogenes (H347) recovered from nasal 
shedding with S. pyogenes recovered from dissection of the nasopharynx.  
Direct nasal samples taken on days 3, 7, and 14 during intranasal infection were 
compared to bacterial numbers obtained from dissected samples on the same days. 
(r²> 0.95, n=36). Data shown from individual mice. 
 
3.2.2 FVB/N STRAIN MICE CARRY S. PYOGENES IN THEIR NASOPHARYNX 
BETTER THAN OTHER MOUSE STRAINS. 
To determine the background nasopharyngeal flora of mice from different strain 
backgrounds, BALB/c (n=14), CD1 (n=14), FVB/n (n=8), A/J (n=6) and C57BL/6 
(n=12) mice were sampled, 5 days before intranasal inoculation with S. pyogenes 
H347, and for the 3 days during infection.  The bacteria detected from the 
nasopharynx by nasal sampling onto CBA were identified through the presence of 
Figure 0-1. Quantitative correlation of S. pyogenes H347recovered from nasal shedding with S. 
pyogenes recovered from dissection of the nasopharynx 
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haemolysis, Gram staining, catalase testing, oxidase testing and Lancefield 
grouping. The emm75 S. pyogenes isolate was administered intranasally to all mice 
in a in a 5 µl dose containing 108 CFU (as 2.5 µl per nostril). 
At 5 days prior to inoculation, no S. pyogenes was detected in any of the murine 
strains tested. Viridans streptococci and staphylococci were the species most 
frequently observed in uninfected mice. Corynebacter spp. were also seen 
infrequently in some of the mouse strains. During the course of intranasal S. 
pyogenes infection, Pseudomonas spp. and Haemophilus spp. also appeared. 
(Figure 3.2) 
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Figure 0- 2. C omparison of  commensal bact eria in  different mouse strains 
Figure 3.2. Comparison of commensal bacteria in different mouse strains. 
FVB/n (n=8) CD1 (n=14), BALB/c (n=14), C57BL/6 (n=12) and A/J (n=6) mice were 
nasally sampled before and during infection with S. pyogenes (H347). Colony 
identification, Gram staining, Catalase Testing, Lancefield Grouping and Oxidase 
testing were used to identify the bacteria shed by the mice throughout the time 
course. Bars indicate proportions of mice shedding bacteria. 
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Of all the mouse strain backgrounds tested, the FVB/n strain was the only group in 
which all mice had detectable S. pyogenes at all time points tested after inoculation 
(Figure 3.2).  FVB/n mice shed significantly more S. pyogenes H347 on the final day 
of the time course than all other strains tested (Figure 3.3 Kruskal-Wallis with Dunns 
post-test).  Thus, the FVB/n mice were used in all further studies. 
 
Figure 0-3. Comparison of nasopharyngeal shedding of S. pyogenes H347 between different mouse 
strains 
 
 
 
Figure 3.3. Comparison of nasopharyngeal shedding of S. pyogenes 
(H347) between different mouse strains. Bacterial counts shed by FVB/n 
(n=8) CD1 (n=14), BALB/c (n=14), C57BL/6 (n=12) and A/J (n=6) at 72 hours. 
Individual points represent individual mice.  (Kruskal Wallis with Dunns Post 
Test p<0.05).  Bars indicate the median, ND= no detectable bacteria 
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3.2.3. GENDER HAS AN EFFECT ON THE NASOPHARYNGEAL CARRIAGE OF S. 
PYOGENES THAT IS DEPENDENT ON THE AGE OF THE MICE. 
To evaluate the effect gender may have on the duration of shedding of S. pyogenes 
in the nasopharynx, pre pubertal (n= 10 per group, 5 weeks of age) and post 
pubertal (n= 10 per group, 10 weeks of age) male and female FVB/n mice were 
challenged intranasally with 108 CFU S. pyogenes H347.  
The duration of shedding from the nasopharynx was measured through direct nasal 
sampling. A period of continuous shedding persisted immediately after infection, in 
which no negative nasal samples were recovered, the end of which was defined by 
the first negative nasal sample, which in most mice correlated to a loss of carriage. 
However, some mice were observed to become re-infected after this initial period, 
and resumed shedding S. pyogenes. There was no significant difference between 
the 5 week old males and females over a 21 day period based on the duration of 
continuous carriage (Figure 3.4 A, Logrank p>0.05).  The intermittent transmission 
events which occur after the cessation of continuous shedding were taken into 
account via a measure of total shedding duration. The total duration of shedding also 
did not differ significantly between the two groups.  
 However, the 10 week old male mice were found to shed S. pyogenes for 
significantly longer than 10 week old female mice based on continuous shedding 
duration (Figure 3.4 C, Logrank test p<0.05) and on total shedding (Figure 3.4. D, 
Logrank test p<0.05). The abundance of S. pyogenes (H347) present in the 
nasopharynx of mice tended to “plateau” in the majority of mice at the second or third 
day after infection, but could last up to the fourth day after infection (Shedding 
Intensity plot, Appendix  3.2.). Whilst the 10 week old males were better carriers, 
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they had to be housed separately to ameliorate the effects of aggression. For 
practical and humane reasons, male mice were not used in further long term 
carriage experiments. 
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Figure 0-4. Comparison of duration of shedding for S. pyogenes H347 between genders in two different age groups 
Figure 3.4. Comparison of duration of shedding for S. pyogenes H347 between 
genders in two different age groups. Male and female mice either 5 weeks or 10 weeks 
of age were infected intranasally and sampled non-invasively through direct nasal 
sampling over 21 days. The duration that 5 week old mice continuously shed S. pyogenes  
was not significantly different between the genders (A, p>0.05 Mantel–Cox Logrank test, 
n=10). After this period of continuous carriage, mice became re-infected. Thus, the total 
duration of shedding was determined based on the last positive nasal sample. The 
difference the total duration of shedding was also not significantly different between the 
genders in this age group (B, p>0.05 Mantel–Cox Logrank test).  At 10 weeks of age, 
Male mice carried S. pyogenes H347 significantly longer than female mice based on both 
the duration of continuous shedding (C, p<0.05 Mantel–Cox Logrank test, n=10) and total 
shedding (D, p<0.05 Mantel-cox Logrank test). 
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3.2.4. INTRANASAL ADMINISTRATION OF S. PYOGENES RESULTS IN A 
SUPPURATIVE UPPER RESPIRATORY TRACT INFECTION THAT RESOLVES OVER 
21 DAYS.  
5 week old female FVB/n mice infected with emm75 S. pyogenes H347 
demonstrated inflammatory changes affecting the nasal cavity over the first week of 
infection, particularly in the caudal (ethmoturbinate) region.  A moderate to marked 
suppurative rhinitis with complete erosion or ulceration of the nasal mucosa and 
neutrophilic exudate on the mucosal surface (Figure 3.5 A-C) was observed by 72h 
in all mice, confirming that the infection resulted in an inflammatory process.  On 
days 3 and 7, mice occasionally demonstrated necrosis of underlying turbinate bone 
and extension of inflammation and infection across the cribriform plate, resulting in a 
localised meningoencephalitis affecting the olfactory bulbs, although this was limited 
to single mice. However, by Day 21, the inflammatory damage to the nasal mucosa 
had resolved (Figure 3.5 D). Semi-quantitative assessment revealed that the 
observed inflammation decreased throughout the time course consistent with the 
lowering of the bacterial load (Figure 3.5. E). S. pyogenes could still be cultured from 
the nasopharynx even after the resolution of inflammation had begun. 
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Table 0-1. Histopatho logical analysis of upper resp iratory tract tissue f rom mice infected with emm75 S. pyogenes H 347 
Table 3.1. Histopathological analysis of upper respiratory tract tissue from 
mice infected with emm75 S. pyogenes (H347). At each of four time points, 3 
mice per group were analysed to determine the severity of infection and 
assigned a numerical designation. - = No significant abnormality, + =Mild, ++= 
Moderate, +++ = Marked, ++++ = Severe and ND= Non diagnostic sections. 
This data was collected concurrently with the histopathological data shown in 
Table 6.1. Each row represents the findings for one mouse at each of the time 
points shown. 
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Figure 3.5. Histopathological analysis of upper respiratory tract tissue from 
mice infected intranasally with emm75 S. pyogenes (H347). Photomicrographs 
demonstrating mice infected with emm75 S. pyogenes (H347) (n=3 per group) were 
taken at days 3, 7, 14 and 21 after infection (Haemotoxylin & Eosin staining).  N = 
Neutrophilic exudate, M= Nasal mucosa, S= Nasal stroma. Scale bar as shown.  
Damage to the nasal mucosa with surface neutrophilic exudate was apparent at day 3 
post inoculation (A). The nasal epithelium of mice infected with S. pyogenes (H347) 
was widely eroded or ulcerated by Day 7 (B). At day 14, the inflammation had begun 
to resolve (C). By day 21, only mild inflammation was observed (D).   Representative 
sections from single mice are shown. This experiment was performed concurrently 
with histopathological data shown in Figure 6.5. 
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Figure 0- 5. H istopatholog ical analysis of upper respiratory tract tissue from mice infected  intranasally with emm75 S.pyogenes (H 347)  
Figure 0- 6 
3.2.5. TRANSMISSION OF S. PYOGENES WITHIN A MOUSE CAGE IS 
DEPENDENT ON THE PROPORTION OF DONOR MICE PRESENT.   
When monitoring FVB/n mice infected with S. pyogenes over time, infection was 
occasionally observed to recur in mice after they had cleared the initial infection (see 
Appendix 3.2.).  This raised the possibility that S. pyogenes was either present in the 
nasal tract at concentrations too low to be detected, or that it was being transmitted 
from infected mice within the cage. 
The transmissibility of S. pyogenes (H347) in the nasopharynx was investigated 
through introducing infected “donor” mice into cages of uninfected “recipient” mice 
(n=8 per cage). Varying the Donor: Recipient (D:R) ratio in a cage was used as a 
way of altering the exposure of recipients to S. pyogenes.  
The first direct nasal samples taken at 4 hours post infection revealed transmission 
had already occurred to all of the recipient mice.  Recipient mice in cages with a 
higher proportion of donor mice acquired higher numbers of S. pyogenes (H347) 
than those with lower densities of donor mice. The recipient mice in the cage with 
four donors had significantly more bacteria in their nasopharynx compared to the 
cage with only 2 donors (Figure 3.6. p<0.05). 
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Figure 0-7. Transmission of S. pyogenes H347 occurs more frequently as the density of infected carriers 
within a cage is increased 
Figure 3.6.  Transmission of S. pyogenes (H347) occurs more frequently as the 
density of infected carriers within a cage is increased.  Donor mice infected 
intranasally with S. pyogenes H347 were introduced into a cage of naïve recipient 
mice. The Donor: Recipient (D:R) ratio was varied between 4:4, 3:5 and 2:6 between 
cages.  Recipient mice were sampled at 4, 24, 48, 72 and 96 hours after the 
introduction of infected donor mice to a cage. Data show counts from direct nasal 
sampling from recipient mice only. Donor mice had >10,000 cfu recovered at all time 
points (not shown).  The burden of transmitted infection was significantly higher in 
cages with a D:R ratio of 4:4 compared with cages with a 2:6 ratio. (AUC analysis, 
followed by Kruskal Wallis with Dunns Post test p<0.05). Bars indicate median. 
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3.2.6. TRANSMISSION BETWEEN MICE AND TO THE AIR IS NOT DEPENDANT ON 
PASSIVE TRANSFER OF S. PYOGENES DIRECTLY AFTER INOCULATION. 
The early detection of S. pyogenes H347 transmitted between mice in the previous 
experiment may have been due to droplets of bacterial suspension being transferred 
between mice directly after inoculation. To rule this out, a transmission experiment 
involving cages with a D:R ratio of 3:5 where Donors were segregated from the 
Recipients for 4, 24 and 48 hours post inoculation was conducted. 
Transmission was observed within all groups of mice, in spite of any delays in 
introduction (Figure 3.7 A), which suggests that the mice were actively transmitting 
S. pyogenes H347 throughout their infection.  
To determine if S. pyogenes H347 was aerosolised from infected mice, settle plates 
were placed in each cage, at a height that precluded direct contact between mice 
and blood agar. Settle plates included in each cage revealed that airborne S. 
pyogenes H347 were present after the introduction of the donor mice into each cage 
(Figure 3.7 B).  The time points where the highest levels of S. pyogenes were 
detected in the air coincided with the time points where the highest numbers of 
bacteria were detected in the recipient mice. The greatest burden of transmission 
was observed in the cages where the donor mice were introduced at 24 hours after 
infection.  However, it should be noted that transmission was greatest in all of the 
mice at 24 hours.  The differences in transmission to recipients between groups were 
reflected in the detection of airborne bacteria on settle plates, and are likely due to 
variation in the behaviours and activity of the mice. 
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Figure 0- 8. Transmission of S. pyogenes H347 bet ween mice and to the air is not dependant on passive inoculum transfer  
Figure 3.7. Transmission of S. pyogenes H347 between mice and to the air is 
not dependant on passive inoculum transfer. Naïve recipients co-mingled at a 
D:R ratio of 3:5 with mice infected with S. pyogenes H347 and sampled after the 
introduction of the donor mice (A,C,E, n=5 recipients per group) at 4, 24 and 48 
hours post inoculation. Donor mice had >10,000 CFU recovered from direct nasal 
sampling throughout the experiment. Data shown from individual recipient mice. 
Settle plates retrieved from each cage (B,D,F, n=4 per cage) revealed the presence 
of airborne bacteria after the introduction of the donor mice. Data shown for each 
settle plate. 
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3.2.7. INFECTION OF DIFFERENT EMM TYPES IN THE NASOPHARYNX 
The FVB/N model was developed using an emm75 S. pyogenes strain based on 
demonstrably superior longevity of carriage in BALB/c mice in preliminary work. To 
determine if the FVB/n model could support infection with a wider range of emm 
types, clinical pharyngitis isolates of the emm types 1, 2, 3, 4, 6, 12, 22, 28, 75 and 
89 were inoculated intranasally into FVB/n mice and sampled daily for seven days 
after (Table 3.2, n=3 per group). The data showed that the model could support 
infection with all emm types up to 48h, however over one week, different emm types 
were cleared or resulted in death. After one week only emm2, emm75, and emm89 
S. pyogenes were carried by at least 2/3 mice in each group. 
The mice carrying the emm1 and the emm12 strains had to be culled early due to 
the severity of the disease in these mice. Lungs, livers and spleens were dissected, 
and the highest levels bacterial counts were observed within the spleen in mice 
infected with these isolates (Figure 3.8 A). In one mouse carrying an emm12 strain, 
the right hemisphere of the brain demonstrated a macroscopic lesion. This was 
analysed using histopathology (Figure 3.8 B) and showed a focal meningeal 
haemorrhage with large numbers of cocci.  These data suggest that the emm1 and 
emm12 genotypes can cause a systemic infection in FVB/n mice in spite of being 
given a dose that is initially confined to the upper respiratory tract. 
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Table 0-2. The carriage of different S. pyogenes emm types in the nasopharynx of a mouse over time 
Table 3.2. The carriage of different S. pyogenes emm types in the 
nasopharynx of a mouse over time. Mice (n=3) were inoculated with 10
8 
cfu of 
different emm types of S. pyogenes, and sampled every day over a week long 
period. The numbers of carriers present within a cage on a specific day was 
determined through the use of direct nasal sampling.  The fractions show the 
numbers of carriers per cage (numerator) and the total numbers of mice in the 
cage (denominator). The colour coded key indicates the numbers of carriers per 
cage, and the numbers of deaths occurring in each cage.  
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Figure 0-9. Invasive infection in the nasopharynx caused by emm1 and emm12 types 
 
Figure 3.8. Invasive infection in the nasopharynx caused by emm1 and 
emm12 types.  Mice (n=3) were inoculated with 10
8 
cfu of different emm types of 
S. pyogenes, and sampled every day over a week long period (A) Mice infected 
with the emm12 and emm1 S. pyogenes reached humane endpoints before the 
end of the experiment. Multiple organs were dissected out, and cultured; as 
shown. (B) Photomicrograph demonstrating meningeal haemorrhage 
(Haemotoxylin & Eosin staining) in a mouse infected with emm12 S. pyogenes. 
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3.3. DISCUSSION 
To facilitate the investigation of bacterial and host factors that influence S. pyogenes 
in nasopharyngeal infection, a new model of nasopharyngeal colonisation was 
devised. A mouse host strain sensitive to nasopharyngeal infection was identified 
using a refined technique for nasal sampling. 
The FVB/n mouse strain carried a greater number of bacteria for a longer period of 
time than other mouse strains tested. The FVB/n mouse is an inbred strain derived 
from the Swiss mouse based on the presence of the  fv-1b  gene, which confers 
susceptibility to Friend Virus B through the absence of an interfering gag variant  
[274,275] and the susceptibility to Citrobacter rodentium through the cri-1 locus 
[276,277]. 
Crucially, the direct nasal sampling technique employed during this study provided 
quantitative data that correlated with bacterial burden in the nasopharynx, 
demonstrating that the method is a valid method for monitoring bacterial burden. The 
direct nasal sampling technique also provided information regarding other bacteria 
which colonise the mouse upper respiratory tract. It was important to develop a 
system to distinguish the infecting S. pyogenes from these resident organisms. The 
dominant species in most of the mouse strains tended to be α-haemolytic viridans 
streptococci and staphylococci, which have also been shown to be present in the 
healthy human nasopharynx [278]. However, it should be noted that Haemophilus 
spp. only grew in regions of the blood agar plates that had been subject to β-
haemolysis by S. pyogenes, and this may be the reason for its increased detection 
after infection. A similar sampling issue cannot be discounted as the reason for the 
increase in Pseudomonas spp. after S. pyogenes infection. The direct nasal 
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sampling method used in this work was optimised for the recovery of S. pyogenes, 
and whilst trends in commensal bacteria recovered using this method were 
interesting, and important to distinguish from S. pyogenes, a full investigation of the 
normal mouse nasopharyngeal flora was beyond the scope of the project and would 
ideally require molecular techniques such as 16S RNA sequencing. Importantly it 
was easy to distinguish S. pyogenes as this was a distinctive β-haemolytic bacterium 
whose presence could be confirmed by standard microbiological techniques.  
It has been suggested in previous work that gender plays a role in the susceptibility 
of mice to invasive streptococcal disease [58,194]. It was found that gender had an 
impact on susceptibility to carriage in post pubertal mice only. Data were consistent 
with other published work demonstrating an increase in susceptibility to infection in 
male mice [194]. However, the levels of aggression shown by males of the FVB/n 
strain made them difficult to house in groups, and it is possible that the differences 
seen here could be due to housing these older mice individually. These welfare 
issues made male mice of this strain impractical for use in further experiments.  
These early characterisation experiments demonstrated that S. pyogenes can be 
shed from the nasopharyngeal tract of mice in great numbers. The numbers of S. 
pyogenes were highest during a “plateau” during the first four days of infection. 
However, this “plateau” was due to the numbers of S. pyogenes retrieved from direct 
nasal sampling becoming so large that S. pyogenes formed a lawn on the surface of 
the blood agar plates, making accurate counts impossible. As a result, it is likely that 
this “plateau” defines the upper limit of quantification for this nasal sampling 
technique, and may be masking a peak of infection that occurs during the first four 
days of infection. 
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Multiple apparent re-infection events were observed after the first observed loss of 
carriage, suggesting transmission was occurring. To determine whether this was 
indeed the case, co-mingling experiments were conducted. 
Co-mingling studies demonstrated that transmission occurred as early as 4 hours 
post introduction, and the numbers of bacteria recovered from the nares of the 
recipients increased as the number of infected donor mice in the cage was 
increased. However, in this initial experiment the donor mice were co-mingled 
immediately after inoculation, and so it is possible that the actual inoculum may have 
transferred to the other mice through passive means. 
To address this issue, donor mice were segregated from the recipient mice for 
different lengths of time after inoculation before being re-introduced to the recipient 
mice. Transmission was still observed between mice after these delays, suggesting 
that it occurs as a result of an active infection in the donor mice. Settle plates placed 
in each cage detected airborne S. pyogenes in all cages after the introduction of the 
donor mice.  
Importantly, these transmission events may not necessarily result in a productive 
infection in recipients, as S. pyogenes did not reach the same abundance in recipient 
mice as observed in donor mice, although persistent carriage was detectable for 
several days in recipients. Further histopathological studies are required to clarify 
this.   
Having demonstrated that transmission to naive mice did occur, the possibility that 
apparent re-infections during longer term studies were artefacts resulting from the 
insensitivity of the nasal sampling technique was not formally discounted. However, 
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this could be addressed in future studies by infecting mice with strains carrying 
different genetic tags. 
The model was initially developed using an emm75 S. pyogenes strain shown to be 
superior in BALB/c mice. An important consideration for the application of this model 
is whether it could be used to analyse different emm types of S. pyogenes. All strains 
(with the exception of the emm28) infected the FVB/n mouse strain for at least 2 
days. Furthermore, systemic infections were observed in all the mice infected with 
the emm1 and emm12 genotypes, which are two of the most common causes of S. 
pyogenes infection in Europe, North America, Australia, New Zealand, Japan and 
Hong Kong [72].  
The model described in these experiments allowed the study and quantification of 
emm75 S. pyogenes longitudinally during infection of the FVB/n murine 
nasopharynx; the model could be extended to alternative emm types and could be 
used to study transmission, something that has not been previously possible. 
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3.4. APPENDIX  
 
112 
 
 
 
 
113 
 
CHAPTER 4: CHARACTERISATION OF A BIOLUMINESCENT 
STRAIN OF S. PYOGENES 
4.1. INTRODUCTION 
In the preceding chapter, the carriage of S. pyogenes in the nasopharynx was 
assessed through a direct sampling technique to assess the numbers of bacteria 
shed from the nasopharynx. This technique, whilst sensitive and quantitative, has an 
upper limit of quantification preventing detailed analysis during the most severe 
stages of infection. 
Bioluminescent reporter genes such as the lux operon have been used to tag 
bacteria, allowing them to be imaged in vivo via the use of sensitive cameras. BPI 
has been used to study a variety of Gram negative  [279,280] and Gram positive 
bacteria [262,281]  
BPI has been previously used to observe severe infection using a bioluminescent 
derivative of an emm49 S. pyogenes strain from a skin isolate via an insertion into 
the Spy0535 locus with no reported fitness cost [170,216,268]. However this strain 
has not been broadly taken up by investigators studying S. pyogenes infection. As 
described earlier, different strains of S. pyogenes exhibit specific tissue tropisms 
[64,70], with skin isolates rarely being the cause of pharyngitis.  For this work, the 
emm75 pharyngitis isolate (H347) was chosen to be bioluminescently tagged, as it 
was not only clinically relevant, but demonstrably produced nasopharyngeal infection 
in mice. 
There are a number of considerations that need to be taken into account when 
creating a bioluminescent strain for use in vivo, the first of which is that it must 
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express enough light to be detected. The strength of the bioluminescent signal can 
be boosted by varying the copy number of the genes (for example by expressing 
from a multi-copy plasmid), the promoter driving expression, or even by codon 
optimising the luciferase gene, as has been described for Mycobacterium spp [258].  
For in vivo experiments, the expression of bioluminescence must also be stable 
within S. pyogenes, as in the previous characterisation experiments, nasopharyngeal 
shedding persisted for a median survival time of seven days in the FVB/n mouse 
strain. As the use of multi-copy plasmids for luciferase expression can require the 
use of selective media throughout an experiment to ensure a bioluminescence 
phenotype is maintained, and this can be difficult to deliver in vivo, a plasmid 
conferring bioluminescence was constructed to target and integrate into a 
pseudogene, spy0535. Spy0535 is present in the chromosome of all sequenced S. 
pyogenes strains and encodes a hypothetical protein of unknown function. 
There has been considerable prior research to analyse how light penetrates different 
tissues [252] but much of this work relies on the wavelengths of light that are more 
commonly used for fluorescence excitation, rather than the wavelengths of light seen 
in the production of bioluminescence. The differential light absorption properties of 
biological tissue have been recognised [282] but their effects on light produced by 
the bioluminescent reaction have not been quantified. Furthermore, in previous work 
a background bioluminescent signal has been observed from the mouse 
nasopharynx [251] and it is likely that this would exert an effect on the sensitivity of 
bioluminescence imaging. The aim of this chapter was therefore to develop 
bioluminescent derivatives of emm75 S. pyogenes by transforming the parent strain 
with luxABCDE on either a replicating plasmid or through integration into the 
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bacterial chromosome. The resulting strains were then characterised both in vitro 
and in vivo with regard to application in future studies of nasopharyngeal infection. 
4.2. RESULTS 
4.2.1. EXPRESSION OF BIOLUMINESCENCE IN S. PYOGENES WITH A PLASMID 
BORNE CONSTRUCT  
The replicating plasmid pTHLK was constructed with the highly expressed 
constitutive Listeria monocytogenes promoter Phelp [283] to express luxABCDE, 
kanamycin and erythromycin resistance as described in Chapter 2. The emm75 
isolate, H347, was electroporated with pTHLK, to create the H347pTHLK strain, 
selected on erythromycin. This strain was grown alongside the H347 parental strain 
over a ten hour time period, with optical density measured hourly, and luminescence 
measured at half hourly intervals. Growth data from both strains were fitted to a 
logistic curve through regression (Figure 4.1 A, r2>0.95). No significant differences 
between the growth rates and the carrying capacities for these bacteria were 
detected.  Luminescence was measured in 50 μl samples of the broth culture, either 
neat, or diluted 1:10 into PBS. The diluted samples produced the highest 
luminescence readings, and demonstrated that the peak of luminescence occurred 
after 7 hours of growth (Figure 4.1. B). 
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Figure 0-1. Growth kinetics and luminescence and production of H347
pTHLK
 
A 
B 
Figure 4.1. Growth kinetics and luminescence production of H347
pTHLK
 
The growth of H347pTHLK was compared with the wild type parental strain (A, n=3 
separate cultures per group) and a logistic regression line was fitted to the data 
(r
2
>0.95). Luminescence was quantified during growth either from a neat 50 µl sample, 
or a 50 µl sample with the same number of bacteria diluted 1:10 into PBS to produce a 
500μl sample (B)
  
Error Bars indicate median and interquartile range. 
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4.2.2. INTEGRATION OF A BIOLUMINESCENT CONSTRUCT INTO S. PYOGENES. 
A set of plasmids containing the luxABCDE operon were created with a region of 
homology targeting a single crossover with the spy0535 region of the S. pyogenes 
chromosome (Figure 4.2 A). The pICL18lux plasmid utilised the Listeria promoter Phelp 
to promote bioluminescence, whereas the pICL18vlux plasmid utilised the Bacillus 
promoter Pveg instead [284]. These constructs were used to transform the parent 
emm75 S. pyogenes strain H347, and transformants were selected on kanamycin. A 
control plasmid which did not contain luxABCDE but which did contain the Spy0535 
region of homology was used to derive a control transformant that had an ‘empty’ 
plasmid integrated at the same site.  
As pICL derivatives have a Gram negative origin of replication and no Gram positive 
origin, transformants would only have arisen following chromosomal integration. To 
confirm integration into Spy0535, primers targeting regions within the pICL based 
plasmid sequence adjacent to the spy0535, and the genes adjacent to spy0535 on 
the bacterial chromosome were used to confirm target insertion (Chapter 2, Table 
2.1).  Three primer pairs were used; LF-LR and RF-RR would amplify products of 
similar size based on the presence of the construct between the flanking genes 
spy0534 and spy0536, while the LF-RR pair would only produce a product if 
spy0535 alone was present, as would be expected in the parent H347 strain (Figure 
4.2 A). PCR products revealed successful integrations for the pICL18lux, and pICL180 
plasmids (Figure 4.2 B).  It should be noted that the pICL18vlux integrated strain did 
not produce an LF-LR product, although the presence of the RF-RR fragment 
suggests that the integration was successful. The strains containing the pICL18lux, 
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pICL18vlux and pICL180 plasmids were designated as the H347lux, H347vlux and 
H3470 strains respectively. The wild-type H347 only produced an LF-RR product. 
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Figure 0-2. Confirmation of integration into the S. pyogenes H347 chromosome 
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4.2.3. THE GROWTH AND LUMINESCENCE OF THE INTEGRATED CONSTRUCTS IN 
S. PYOGENES . 
 Two bioluminescent derivatives of strain H347 were derived with different promoters 
driving the expression of the luxABCDE operon. The H347lux and H347vlux strains 
expressed bioluminescence using the Phelp and Pveg promoters respectively. The 
growth of these two strains was measured over ten hours, with luminescence 
readings taken at every half hour (Figure 4.3.). Similar to the strains transformed with 
replicating plasmids, the peak of luminescence was again observed approximately 7 
hours from the start of the experiment. The luminescent signals observed for H347vlux 
were lower than those observed for H347lux, but the difference was not significant. 
The growth rate data were fitted to logistic curves through regression (Figure 4.3. 
r2>0.95) There were no significant differences in the growth rates between the 
H347lux and H347vlux bioluminescent strains. However, the H347 parental strain had 
a significantly higher carrying capacity. The carrying capacity is a statistic that 
defines the maximum population capacity of S. pyogenes that can be sustained 
within a culture. This suggests that the bioluminescent strains had a growth deficit. 
To determine whether these growth defects were due to the expression of 
bioluminescence, or the integration into the spy0535 section of the streptococcal 
chromosome, the non-bioluminescent plasmid pICL180  was used to transform H347 
to create H3470 which had the same plasmid integration into spy0535 (Figure 4.2 B). 
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Figure 0-3. Growth kinetics and lumnescence production of H347
vlux
 and H347
lux
 
 
The H347lux, H3470 and H347 parental strains were grown over 10 hours. The data 
were fitted to a logistic curve (r2>0.95), which demonstrated that there was no 
significant difference in growth rate, but there was a significant difference in the 
µmax between the wild-type and control strains and the bioluminescent strains 
(Figure 4.4). This suggests that any growth defect is conferred by the expression of 
bioluminescence, rather than the potential disruption of the spy0535 locus. 
Figure 4.3. Growth kinetics and luminescence production of H347
vlux
 and H347
lux
. 
The growth of H347
vlux
, H347
lux
 and the H347 wild type parental strain were compared 
over a time course (n=3 separate cultures per group). A logistic curve was fitted to the 
growth data through regression (r
2
>0.95).   The luminescent signal from H347
vlux
 and 
H347
lux
 is also displayed. Error bars indicate median and interquartile range 
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Figure 0-4. Bioluminescence confers in vitro growth defects 
 
Figure 4.4. Bioluminescence expression confers in vitro growth defects.  
The growth of H347
lux
, H347
0
, and H347 wild type strain were compared over a 
time course (n=6 separate cultures per group). Logistic curves were fitted to the 
data through regression (r
2
>0.95). Error bars indicate median and interquartile 
range. 
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4.2.4. COMPARISON OF BIOLUMINESCENCE EXPRESSION BETWEEN S. PYOGENES 
STRAINS TRANSFORMED WITH REPLICATING PLASMID OR INTEGRATED 
CONSTRUCTS 
S. pyogenes carrying pTHLK (H347pTHLK) and S. pyogenes with integrated pICL18lux 
(H347lux) were grown to logarithmic phase and imaged using BPI. There was a 
significant difference in light production by the two bioluminescent strains (Linear 
regression p<0.05.) H347pTHLK produced on average 26.19 photons ± 0.06 SE per 
CFU (Figure 4.5), whereas H347lux produced on average 1.062 photons ± 0.012 SE 
per CFU (Figure 4.5).  
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Figure 0-5. Characterisation of bioluminescent strains 
Figure 4.5. Characterisation of Bioluminescent strains.  Serial dilutions of 
the bioluminescent strains with either the bioluminescent plasmid (H347
pTHLK
) 
or the integrated construct (H347lux) were imaged on a 96 well plate (n= 3 
separate cultures) using an IVIS 100 system. Colony counts were obtained 
through serial plating. Error bars indicate median and interquartile range. 
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4.2.5. THE STABILITY OF THE BIOLUMINESCENT CONSTRUCTS IN S. PYOGENES 
The H347pTHLK and H347lux strains were passaged daily with and without antibiotics, 
and plated onto selective and non-selective media daily to assess whether S. 
pyogenes carrying LuxABCDE and the Aph-A3 kanamycin resistance gene 
constructs were still present.   
The number of bacteria retaining the replicating plasmid based constructs declined a 
thousand-fold after each passage, when grown without selection (Figure 4.6 A). In 
contrast, there was no loss of the bioluminescence constructs when integrated into 
the chromosome over a seven day period even in the absence of antibiotics (Figure 
4.6 B). These data showed that the luxABCDE construct integration was stable in the 
streptococcal chromosome, but the plasmid based construct was unstable. The 
integrated luxABCDE strain was therefore determined to be more suitable for in vivo 
models of infection. 
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Figure 0-6. Stability of bioluminescent plasmids 
A B 
Figure 4.6. Stability of Bioluminescent plasmids. H347
pTHLK
 and H347
lux
 were 
passaged in vitro with or without antibiotic to determine the stability of 
bioluminescence expression.  After 24 hours, the numbers of H347
pTHLK
 containing 
the plasmid based construct pTHLK declined without antibiotic, whilst bacteria 
cultured in the presence of antibiotic retained the plasmid (A, n=3 separate 
cultures). In contrast, H347
lux
 carrying the integrated pICL18
lux
 was maintained in 
similar numbers whether or not antibiotic was present (B, n=3 separate cultures). 
Colony counts were obtained through serial plating. Error Bars indicate median and 
range. 
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4.2.6. THE EFFECT OF BIOLUMINESCENCE EXPRESSION ON STREPTOCOCCAL 
BIOFILM FORMATION  
As biofilm formation is purported to underlie the successful colonisation of the 
pharynx, the H347lux, H3470 and H347 strains were assessed for their ability to form 
biofilms through the crystal violet staining method [273]. A standard curve was 
constructed to ensure that the optical density measured by the previous method 
correlated to the numbers of bacteria (Figure 4.7 A). H347lux were significantly less 
abundant in biofilms compared to the H347 parental strain and the H3470 (Figure 4.7 
B, p <0.05 Kruskal-Wallis with Dunns post test).  
Total numbers of bacteria within the entire well were calculated based on 
measurements taken from non-adherent as well as adherent bacteria (Figure 4.7 C). 
When bacterial CFU in biofilm were adjusted to take into account the total number of 
bacteria, it transpired that the lower abundance of H347lux in biofilm resulted from a 
generalised lower abundance in cultures. This suggests that the expression of 
bioluminescence impairs S. pyogenes growth, but not its ability to form biofilms. 
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Figure 0-7. Biofilm forming capacity of bioluminescent strains 
129 
 
4.3. DISCUSSION 
A suite of plasmids carrying bioluminescence reporter genes were constructed with 
the purpose of creating a bioluminescent derivative of the emm75 strain of S. 
pyogenes H347 used in the preceding chapter to characterise a model of intranasal 
infection. 
The replicating plasmid pTHLK showed initial promise, as the strain H347pTHLK did 
not show any specific growth defects, and produced a 25-fold stronger luminescent 
signal than the H347lux. The pTHLK plasmid was however shown to be unstable 
when passaged in the absence of antibiotic, making it unsuitable for use in an in vivo 
model. Luminescent signals needed to be diluted 1:10 in order to prevent the effects 
of quenching and obtain accurate readings. A reduction in the bioluminescent signal 
was observed as the S. pyogenes cultures entered stationary phase. This effect has 
been observed for S. pneumoniae [285] and S. aureus [281], and is suspected to be 
due to a lack of available FMNH2 in Gram positive bacteria during this phase of 
growth. 
The luminescent strains H347lux and H347vlux, in which the bioluminescence operon 
was integrated alongside spy0535 in the chromosome, had lower carrying capacities  
compared to the wild type strain. The reduction in carrying capacity observed in the 
bioluminescent strains could conceivably be due to the changes to the spy0535 
locus of the chromosome incurred by the integration of a plasmid into the region. To 
determine whether this was the case, a control plasmid pICL180 that did not confer 
bioluminescence was integrated into this region. H3470 did not demonstrate any 
growth defect in vitro confirming that the site of integration per se was not harmful. 
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Despite using different promoters to drive luxABCDE expression, there was no 
significant difference found in bioluminescence between these strains. The H347lux 
strain with the Phelp promoter was used for further studies as this allowed for a better 
comparison with the H347pTHLK strain, and because its bioluminescence appeared to 
be stronger than the H347vlux which used the Pveg promoter. 
The integrated strains were assessed for defects in growth and biofilm formation. 
Although raw numbers of H347lux in biofilm were lower than the non-bioluminescent 
strains, analysis of the non-adherent bacteria revealed that this was a manifestation 
of the defect in carrying capacity seen during growth. Importantly, the lack of any 
biofilm formation, or growth defect in the H3470 strain suggest that the fitness cost is 
incurred by the expression of bioluminescence itself. This may explain why the 
replicative plasmid pTHLK was so rapidly lost, as S. pyogenes that stop expressing 
bioluminescence would have a fitness advantage.   
However, this fitness deficit appears to only affect the maximum numbers of S. 
pyogenes present within culture, and it is possible that this may not manifest during 
infection in the nasopharynx. 
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CHAPTER 5: IN VIVO CHARACTERISATION OF 
BIOLUMINESCENT S. PYOGENES   
5.1 INTRODUCTION 
Isogenic bioluminescent derivatives of the emm75 clinical pharyngitis isolate H347 
could enable the quantification of S. pyogenes in vivo using biophotonic imaging. 
However, a number of considerations must be addressed before such strains can be 
used in vivo.  
Previous studies have found that many living organisms can themselves produce 
weak bioluminescent signals [286,287]. In mice, the main source of signal has been 
identified as the gastrointestinal tract, due to the presence of chlorophyll in alfalfa 
diets contributing to a chemiluminescent signal [251]. 
In the previous chapter, a S. pyogenes strain carrying a non-integrating plasmid 
pTHLK (H347pTHLK) produced a higher bioluminescent signal in vitro compared with 
the signal from S. pyogenes transformed with integrated pICL18lux (H347lux).  The 
use of this brighter bioluminescent strain could allow for the more sensitive detection 
of S. pyogenes. However the bioluminescent construct of this strain was unstable 
without antibiotics, in contrast to H347lux, and required regular antibiotic application in 
order for it to be maintained.  
The expression of bioluminescence attenuated the in vitro growth of S. pyogenes 
H347lux (Chapter 4.2.3 and 4.2.6), hence the degree to which growth attenuation 
exerts an effect in vivo required determination. 
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5.2. RESULTS 
5.2.1. CHARACTERISATION OF THE BACKGROUND LUMINESCENT SIGNAL FROM 
THE MURINE NASOPHARYNX 
 Uninfected FVB/n mice were imaged using an IVIS camera. The background 
bioluminescent signal was not homogenously distributed throughout the anatomy of 
the mouse. The background luminescence from the nose and the lungs were 
determined through imaging FVB/n mice from both dorsal and ventral viewpoints, 
with an integration time of 300 seconds (Figure 5.1 A & B). The luminescent signals 
from the nasopharynx did not exceed 104  photons s
-1
 cm
-2
 sr
-1
. 
The luminescent signals taken from the nose (Figure 5.1 C, ROI as described in 
Chapter 2) and the lung (Figure 5.1 D, ROI as described in Chapter 2) were 
quantified from both the dorsal and ventral viewpoints. The background 
luminescence from the dorsal viewpoints in the lung and the nose were found to be 
significantly higher than that detected from the ventral viewpoints. The nasal tracts of 
the mice were dissected out, and a background signal was observed in the anterior 
portion of the nasopharynx (Figure 5.1 E). The mean background luminescence was 
found to be 15952 photons s-1 (± 2571 SE).  
To account for this background, any signal obtained from the nasopharynx of around 
2 ×104 p/s was treated as background, and images are displayed with a set 
luminescence threshold of at least 4000 p s-1cm -2 sr-1. 
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Figure 0- 1. B ackground luminescence from mice 
Figure 5.1. Background luminescence from mice. FVB/n strain mice (n=10) were 
imaged using the IVIS 100 system with an integration time of 300 seconds both 
dorsally (A) and ventrally (B). The background luminescent signals from the nasal 
tract (C, Mann-Whitney U p<0.05) and the lung (D, Mann Whitney U, p<0.05) were 
quantified both dorsally and ventrally. Images from the dissected nasopharynx of 
controls revealed the origin of the background bioluminescent signal (E). Data shown 
for individual mice, bar indicates median.  
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5.2.2. IN VIVO INSTABILITY OF THE MULTI-COPY PLASMID IN S. PYOGENES 
ANTIBIOTIC APPLICATION 
Whilst the in vitro work suggested that the H347pTHLK was unstable without 
antibiotics, the possibility remained that it could be maintained in vivo with the 
application of antibiotics. H347pTHLK was inoculated intranasally into FVB/n mice 
(n=4) that were exposed to antibiotics (2.5mg/kg, intraperitoneal erythromycin) 6 
hours before the inoculations, and at 12 hour intervals afterwards.  
Mice were imaged on the day of inoculation and every day after inoculation for 72 
hours (Fig. 5.2 A). The luminescence from the dorsal view of the nose was assessed 
(Fig 5.2 B), direct nasal samples taken daily onto CBA to assess S. pyogenes 
shedding, and then onto selective medium to determine the numbers of bacteria still 
carrying the pTHLK plasmid (Fig 5.2. C). H347pTHLK rapidly lost the plasmid pTHLK in 
vivo, despite repeated antibiotic application. Only one mouse had erythromycin 
resistant bacteria 24 hours post inoculation, and this was the only mouse that 
showed any bioluminescent signal. This same mouse had high numbers of S. 
pyogenes the day afterwards, but none of the bacteria retained the plasmid. The 
poor stability of this plasmid in vivo precluded its use in further in vivo experiments.  
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Figure 0-2. Instability of the pTHLK replicating plasmid in vivo 
A B 
Figure 5.2.  Instability of the pTHLK replicating plasmid in vivo. Mice 
inoculated with H347
pTHLK
 were imaged over 72 hours post inoculation (A, n=4). 
Luminescent signal was assessed from the dorsal view (B). An autoluminescent 
signal was obtained from the red dye used to mark the tail of one mouse. Direct 
nasal samples were taken daily onto CBA to determine total S. pyogenes 
numbers, and onto THA with erythromycin to determine the numbers of S. 
pyogenes still carrying pTHLK (C).   Data shown for individual mice. 
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5.2.3. INTRANASAL INFECTION WITH STABLY BIOLUMINESCENT S. PYOGENES 
OVER A LONGITUDINAL TIME COURSE 
S. pyogenes strain H347lux that was transformed with a chromosomally-integrated 
luxABCDE operon, was inoculated intranasally into FVB/n mice and imaged over a 
five day time course (Figure 5.3 A, n=6). In contrast to bacteria transformed with a 
replicating plasmid, H347lux retained visible bioluminescent properties in vivo without 
antibiotic treatment. The bioluminescent signal obtained from the dorsal viewpoint 
was found to be much higher than that obtained from the ventral viewpoint. In the 
majority of mice, the signal declined to background levels by day four post 
inoculation (Figure 5.3 B), a decline that was matched by direct nasal samples that 
were taken daily (Figure 5.3 C). Throughout the experiment, 100% of the colonies 
tested remained bioluminescent and antibiotic resistant, demonstrating that the 
construct was stable even without antibiotic treatment. 
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Figure 0-3. Imaging of S. pyogenes H347 with a stably integrated lux operon over a time course 
 
 
 
 
 
 
Figure 5.3. Imaging of S. pyogenes H347 with a stably integrated lux 
operon over a time course. Mice intranasally inoculated with S. pyogenes 
(H347
lux
) were imaged over five days (A, three representative mice shown), and 
had luminescence from the nasal tract quantified from the dorsal and ventral 
viewpoints (B, n=6), alongside direct nasal samples that were taken daily (C, 
n=6).  Data shown for individual mice. 
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5.2.4. CORRELATION OF BIOLUMINESCENT S. PYOGENES WITH THE 
BIOLUMINESCENT SIGNAL DETECTED FROM THE NASOPHARYNX 
 The bioluminescent signal from H347lux in the nasopharynx was quantified from the 
dorsal and ventral viewpoints. Nasal tracts were dissected out and total S. pyogenes 
numbers were quantified.   
Bioluminescence data, mapped to lines determined by linear regression, 
demonstrating that the signal from the dorsal viewpoint was significantly higher than 
that obtained from the ventral viewpoint (Figure 5.4 A, n= 18, r2>0.95, p<0.05).  The 
surface luminescence from the dorsal viewpoint was 0.022 photons per CFU (± 
2.864×10-4 SE), compared with 0.006 photons per CFU (±7.547× 10-5 SE) obtained 
from the ventral viewpoint. Dissection revealed that the primary anatomical location 
of S. pyogenes during the first 3 days of nasal infection was within the 
ethmoturbinates (Figure 5.4 B). The luminescent signal was from a different location 
from the background luminescence, and much brighter. 
The nasal associated lymphoid tissues (NALT) from each mouse, previously 
reported to be a major site for S. pyogenes infection, were imaged ex vivo. No 
correlation was found between the signal obtained from this organ and streptococcal 
numbers within it (Figure 5.4. C, Spearman correlation, p>0.05). In contrast, the 
bioluminescent signal from the ex vivo nasal tract correlated linearly to streptococcal 
numbers within it (Figure 5.4.D, r2 >0.95).  
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Figure 0-4. Correlation of bioluminescent signal to S. pyogenes numbers within the nasopharynx 
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Figure 5.4. Correlation of bioluminescent signal to S. pyogenes numbers 
within the nasopharynx.  Bioluminescence measurements  from the dorsal and 
ventral viewpoints taken during an intranasal infection were compared to bacterial 
numbers obtained on dissection on the same day and a linear trend was fitted to the 
data using regression (A, r
2
 >0.95, n=18). The nasal tract was extracted and imaged 
(B) NALT was extracted upon dissection and imaged, and the signal from this tissue 
was plotted against S. pyogenes obtained from this tissue (C). The nasal tract was 
also dissected out and imaged, and the bioluminescent signal from this tissue was 
plotted against the numbers of bacteria obtained from it (D). 
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5.2.5. THE EXPRESSION OF BIOLUMINESCENCE IN VIVO CONFERS A COMPETITIVE 
DISADVANTAGE IN THE NASOPHARYNX. 
To determine if the site of integration of the lux construct (spy0535) was in itself 
harmful, a control strain was constructed that had an integrated plasmid at spy0535 
but no bioluminescent operon (H3470). A growth defect that was ascribed to 
bioluminescence expression had already been detected in vitro (Chapter 4).  
Inocula containing pairwise mixes of H347, H347lux and H3470 were administered 
intranasally to determine competitive survival in vivo (Figure 5.5 A). Mice were culled 
on days 1 and 3 post inoculation (n=4 per group per time point) and the nasal tracts 
were extracted for bacteriology. S. pyogenes recovered from these mice were tested 
for antibiotic resistance (Kanamycin, 500μg/ml) and luminescence production. The 
competitive indices were calculated for H347lux and H3470 (Figure 5.5 B) and 
showed that H347lux was significantly attenuated over the time course compared to 
H3470 (Two way ANOVA p<0.05). There was however no significant difference 
between H347 and H3470, confirming that the chromosomal site of integration was 
not in itself harmful.  
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Figure 0-5. Bioluminescence confers in vivo growth defects 
Figure 5.5.  Bioluminescence confers in vivo growth defects. Mice were 
intranasally administered with mixed inoculation combinations of the bioluminescent 
strain (H347
lux
), the wild type control (H347), and the spy0535 integrated control 
(H347
0
).  Mice were culled at day 1 post inoculation, and at day 3 and the relative 
abundance of each strain was assessed through replica plating onto selective media 
(A, n=8 per group). Based on these, the relative abundance of the bioluminescent 
strain and the spy0535 integrant were calculated relative to the wild type. (B) The 
bioluminescent strain was less competitive compared to the non-bioluminescent 
integrant. 
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5.2.6. BIOLUMINESCENT S. PYOGENES OCCASIONALLY CAUSES A 
SUPPURATIVE UPPER RESPIRATORY TRACT INFECTION   
Mice intranasally infected with H347 lux were euthanised at days 3, 7, and 15 (n=3 
per group per time point) and sagittal sections of the head, including the nasal cavity, 
nasopharynx and the brain were examined.  At day 3 post inoculation, only one 
mouse out of three exhibited marked rhinitis, while on day 15, one mouse had mild 
rhinitis (Table 5.1.). S. pyogenes counts taken from each mouse nasopharynx 
revealed that S. pyogenes were present, even when no significant abnormality was 
detected. The inflammation caused by H347lux was less than had been observed 
with the wildtype H347 (see Chapter 3.2.3).  
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Table 0-1. Histopatho logical analysis o f upper resp iratory tract tissue f rom mice infected with bio luminescent S. pyogenes 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1.  Histopathological analysis of upper respiratory tract tissue 
from mice infected with bioluminescent S. pyogenes. At each of three time 
points, 3 mice per group, infected with H347
lux
 , were analysed 
histopathologically to determine the severity of infection and assigned a 
numerical designation. - = No significant abnormality, + =Mild , ++= Moderate, 
+++ = Marked, ++++ = Severe and ND= Non diagnostic sections. Bacterial 
counts from the same nasopharynx are also shown. This data was collected 
concurrently with the histopathological data shown in Table 6.2. Individual mice 
are shown on each row, for each time point. 
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5.2.7. THE EFFECT OF INTRANASAL INFECTION WITH STATIONARY VS 
EXPONENTIAL PHASE S. PYOGENES  
S. pyogenes (H347lux) grown to either stationary or exponential phases were 
concentrated into inocula.  108 CFU were dosed intranasally into FVB/n mice, which 
were then imaged over a 48 hour time course (Figure 5.6 A & B, n=6 per group, per 
time point).  The bioluminescent signal obtained from the nasopharynx was 
compared to the bacterial numbers obtained on dissection using linear regression. 
The exponential phase S. pyogenes produced a significantly lower signal in vivo than 
bacteria used for infection whilst in stationary phase (Figure 5.6 C, r2 > 0.95, 
p<0.05). Streptococcal counts from nasal tracts extracted over the 48 hour time 
course revealed that mice infected with S. pyogenes carried the bacterium less well 
where exponential phase inocula were used, than where stationary phase  inocula 
were used (Figure 5.6. D). 
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Figure 0-1 Biophotonic imaging of mice inoculated with either exponential or stationary phase grown S. pyogenes 
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Figure 5.6.  Biophotonic imaging of mice inoculated with either exponential or 
stationary phase grown S. pyogenes.  Mice inoculated with bioluminescent S. 
pyogenes (H347
lux
) in either the exponential (A) or the stationary phase (B) were 
imaged over 48 hr. The in vivo bioluminescence was compared to cfu present within 
the nasopharynx in both groups at all time points (C, r
2
>0.95). The bacterial numbers 
obtained on dissection from each group over the time course were enumerated for 
each day (D). Data shown for individual mice.  
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5.3. DISCUSSION 
A number of different factors need to be considered when examining streptococcal 
infection using bioluminescence in an in vivo situation. The first consideration for this 
model is the natural background luminescence exhibited by living organisms. A 
previous study discovered a signal emanating from the nasopharynx [251]. The control 
mice imaged in this study also exhibited luminescence from the nasopharynx, and this 
luminescence was stronger from the dorsal viewpoint compared to the ventral 
viewpoint, suggesting the source of the luminescence was closer to the dorsal surface 
of the mouse. Dissection of the mouse heads confirmed that the source of this 
background bioluminescent signal was towards the anterior portion of the nasopharynx. 
The actual tissue causing this bioluminescent signal could not be determined within this 
study, but was important to take into consideration given the likely reduction in 
sensitivity of bioluminescence imaging for the detection of bioluminescent S. pyogenes 
in the nasopharynx.   
In the preceding chapter, two bioluminescent derivatives of the S. pyogenes clinical 
throat isolate H347 were characterised. The H347pTHLK isolate carrying a replicating 
plasmid was more bioluminescent in vitro, but the plasmid was unstable. The regular 
application of antibiotics failed to maintain the plasmid, and the expression of 
bioluminescence, in vivo. S. pyogenes expressing luxABCDE from the integrated 
construct, H347lux, was found to express bioluminescence for up to five days post 
inoculation, and paradoxically produced a higher signal in vivo. Therefore, the H347lux 
strain was used for further characterisation studies. 
The luminescent signal expressed by H347lux in vitro was found to be around 1 photon 
per CFU (see Chapter 4.2.4). The surface bioluminescence measured in vivo however 
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was lower, due to the attenuation of the signal as it travels through the tissue. The 
signal detected in vivo was found to be approximately 0.022 photons per CFU when 
taken from the dorsal viewpoint, and 0.006 from the ventral view. This equates to 
approximately a 50-fold reduction in signal when collected from the dorsal viewpoint, 
and an approximate hundred fold reduction when collected from the ventral viewpoint. 
The presence of the jaw obscures the pathway of light from the nasopharynx when 
images are taken from the ventral viewpoint, causing a greater degree of absorption 
and scattering than from the dorsal viewpoint, in which only the skull skin and fur 
obstruct the passage of light. 
Previous reports using bioluminescence to study S. pyogenes  suggested that the 
primary site of S. pyogenes colonisation in mice was within the NALT [216]. However 
for H347, a clinical isolate, the primary point of infection was within the caudal nasal 
tract, in the ethmoturbinates (Chapter 3.2.4). Bioluminescence imaging of the 
nasopharynx revealed that this was the primary point of colonisation for the 
bioluminescent H347lux strain as well. Although earlier studies identified the NALT as 
harbouring S. pyogenes, the reports did not described any consistent attempt to identify 
S. pyogenes in other tissues of the upper respiratory tract. 
NALT did not produce any bioluminescent signal that correlated with the presence of S. 
pyogenes. However, the bioluminescent signal from dissected nasal tissue produced a 
much higher bioluminescent signal that did correlate to the presence of S. pyogenes, 
providing further evidence that this was the primary site of colonisation. 
Previous work (see Chapter 4.2.3 & 4.2.6) demonstrated that the expression of 
bioluminescence confers a growth cost in vitro. These growth costs contributed to a 
lack of competitiveness of the H347lux strain in the nasopharynx with respect to the wild 
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type (H347) and its isotypic control (H3470). Furthermore, the disease caused by the 
bioluminescent strain was less severe than that of the wild type (Chapter 3.2.4) with the 
majority of infected mice not showing inflammation over a long term time course. 
The metabolic state of S. pyogenes influenced its bioluminescence expression in vitro, 
with the brightest signal being obtained whilst it was in its exponential phase of growth. 
However, infecting mice with S. pyogenes in exponential phase did not result in an 
increased luminescent signal immediately after infection. Furthermore, mice infected 
with S. pyogenes in the exponential phase tended to clear it more quickly than mice 
infected with S. pyogenes in stationary phase.  
The primary focus of this chapter was to define the limits of bioluminescence imaging in 
vivo. The background bioluminescent signal exhibited by the FVB/n mice impacted on 
the sensitivity of this technique. The expression of bioluminescence by S. pyogenes 
exerted fitness costs in vivo. This contributed to the instability of the pTHLK plasmid in 
vivo, decreased competitiveness in the H347lux strain and its reduced invasiveness 
relative to the wildtype.  These factors are essential to consider in all studies utilising 
recombinant bacteria that express bioluminescence. Taken together, the data suggest 
that H347lux could be used for shorter (<5 day) BPI studies involving nasopharyngeal 
infection to address therapeutic or vaccination studies where bacterial clearance is 
being measured 
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CHAPTER 6: IMPACT OF COVR/S MUTATION ON 
NASOPHARYNGEAL S. PYOGENES INFECTION AND 
TRANSMISSION 
 
6.1 INTRODUCTION 
The survival of S. pyogenes during invasive infection is dependent on the expression of 
virulence factors. The two component regulator CovR/S represses a variety of virulence 
factors concerned with resistance to neutrophil mediated killing such as hyaluronic acid 
capsule, DNase and SpyCEP [45,49,78,91,96]. Mutations in covR/S  de-repress these 
virulence genes, which can confer a selective advantage to S. pyogenes in mouse 
models of  invasive infection, leading to greater mortality [96,288].   
Although naturally occurring mutations in covR/S have been described among invasive 
clinical S. pyogenes strains, in particular of the emm1 type, the impact of such 
mutations on nasopharyngeal infection, and hence transmission in the community and 
the clinical setting, is unclear. 
The role of covR/S mutations in the nasopharynx have not been well characterised 
experimentally, in part due to a paucity of available animal models. In chapter 3, one 
such model was devised using a clinical emm75 pharyngitis isolate H347. In previous 
work, an isogenic derivative of H347 was constructed that had undergone inactivation 
of covR/S by insertion mutagenesis [45]. This covR/S mutant (designated strain H494) 
produced markedly higher levels of SpyCEP compared to wild type H347 [45]. In this 
chapter the effects of changing covR/S expression were investigated with regard to S. 
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pyogenes persistence in the nasopharynx and transmission using the tools devised in 
the preceding chapters. 
6.2. RESULTS 
6.2.1 THE IN VITRO CHARACTERISATION OF A COVR/S MUTANT 
The CovR/S regulatory system promotes the repression of up to 15% of the S. 
pyogenes genome, but paradoxically promotes the expression of cysteine protease 
SpeB [289]. Therefore, the SpeB production by the covR/S mutant (H494) should be 
impaired compared to the parental strain if covR/S has been fully inactivated. To 
determine if H494 demonstrated the predicted phenotype, supernatants taken from S. 
pyogenes cultures grown to early log, mid log, late log and stationary phase were 
analysed for SpeB production (Figure 6.1).  The wild type S. pyogenes (H347) 
produced higher levels of SpeB at all time points compared to the covR/S mutant 
(H494). This did not reflect a general loss of fitness in H494, since this strain produced 
far more SpyCEP than the wildtype [45]. 
Strains of S. pyogenes with mutations in covR/S have, in previous studies, shown 
defects in biofilm formation [97]. To confirm this finding for the emm75 S. pyogenes 
isolate used, crystal violet biofilm binding assays were performed as described 
previously (Chapter 4.3.4) to determine the presence of adherent bacteria within 
biofilms (Figure 6.2 A). To ensure that the difference observed was not due to a growth 
defect (as was observed in Chapter 4.2.), the supernatants were also collected to 
assess the percentage of adherent bacteria within each well (Figure 6.2. B). The 
covR/S mutant not only produced less biofilm, but also produced less as a percentage 
of the bacteria present, suggesting that the biofilm forming capacity is specifically 
impaired. 
151 
 
 
 
Figure 0-1. Inactivation of CovR/S results in loss of cysteine protease SpeB expression 
Figure 6.1 Inactivation of CovR/S results in loss of cysteine protease SpeB 
expression. Western blot analysis for SpeB in the culture supernatant from the wild 
type emm75 S. pyogenes isolate H347 and ΔcovR/S (H494) grown to early-log, mid-
log, late log and stationary phase cultures revealed a difference in SpeB expression. 
ΔcovR/S consistently produced less SpeB than the wild-type strain. Purified 
recombinant SpeB (28kDa domain) standards are shown for reference. 
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Figure 0-2. Biofilm formation is affected by the loss of CovR/S regulation 
 Figure 6.2. Biofilm formation is affected by the loss of CovR/S regulation. 
Bacteria grown in stationary cultures were incubated for 24 hrs in C-media. There were 
significantly less ΔcovR/S S. pyogenes (H494) present in biofilms compared to the wild 
type (H347) (A). The percentage of S. pyogenes adhered in biofilms as a percentage of 
total bacteria present was also reduced, demonstrating that this difference was not due 
to any specific growth defect caused by the mutation (B). Data shown for individual 
wells with median indicated.  
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6.2.2 COVR/S MUTATION CONFERS ENHANCEMENT OF VIRULENCE IN AN 
INVASIVE MODEL OF S. PYOGENES INFECTION.  
To ensure that the covR/S mutation conferred an invasive phenotype during invasive 
streptococcal infection, groups of mice were infected either with the wild type H347 
strain or the covR/S mutant (H494) intramuscularly into the gastrocnemius muscle 
(n=12 per group). There was no quantitative difference between isogenic S. 
pyogenes strains cultured from the muscle after 72h (Figure 6.3.A). Whilst fewer wild 
type H347 disseminated to the Liver (Figure 6.3 C) and the Spleen (Figure 6.3 D) 
compared to the ΔcovR/S strain, the difference was not significant. However the 
ΔcovR/S strain did disseminate to the ipsilateral inguinal lymph node in greater 
numbers than its wild type counterpart (Figure 6.3.B, p<0.05 Mann-Whitney).  This 
confirmed that ΔcovR/S strain was, as expected, more invasive than the wild type 
strain, due to increased expression of invasive virulence factors.  
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Figure 0-3. The loss of virulence factor regulation aids bacterial dissemination in invasive infection 
Figure 6.3.  The loss of virulence factor regulation aids bacterial dissemination 
in invasive infection. FVB/n mice (n=12) were inoculated intramuscularly into the 
right thigh with either wildtype S. pyogenes strain (H347) or the covR/S mutant 
(H494).  After three days there was no significant difference in growth within the thigh 
(A), but there was a significant difference in bacterial numbers in the ipsilateral 
inguinal lymph node (Mann Whitney U p<0.05) (B). No significant difference was 
found in the numbers of bacteria disseminating to the Liver (C) and the Spleen (D) 
Data shown for individuals with median indicated. 
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6.2.3. MUTATION OF COVR/S IS DETRIMENTAL TO LONG TERM S. PYOGENES 
COLONISATION IN THE NASOPHARYNX.  
To determine whether the phenotype conferred by covR/S mutation is beneficial 
during in vivo infection in the nasopharynx, two groups of mice (n=20) were infected 
intranasally with 108 CFU of either H347 or H494 in 5 µl and observed over 21 days.  
Survival curves based on daily nasal samples demonstrated that the covR/S mutant 
H494 was shed from the nasopharynx for a shorter length of time compared to its 
wild type counterpart. (Figure 6.4 A, Mantel Cox Logrank p<0.05). The duration of 
continuous shedding was determined to have terminated upon the first negative 
sample. However, as was seen previously (Chapter 3.2.2) this was followed by a 
period of intermediate shedding, where S. pyogenes numbers were either too low to 
be detected, or mice became re-infected. When the end point of this stage was used 
to define the end point of infection, a significant difference was still observed 
between the two groups (Figure 6.4 B Mantel Cox Logrank, p<0.05). The raw data 
from the nasal samples is represented by heat maps (See Appendix 6.1.). Taken 
together, data confirmed that the covR/S mutant strain H494 was carried less well in 
the nasopharynx than an isogenic wild type parental strain H347. 
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Figure 0-4. Nasopharyngeal infection is adversely affected by covR/S mutation 
Figure 6.4. Nasopharyngeal infection is adversely affected by covR/S 
mutation.  FVB/n mice were inoculated intranasally with either the wild 
type, or the ΔcovR/S strain (n=20 per group). To determine the duration of 
shedding, direct nasal samples were taken over a 21 day period. The 
duration of continuous shedding was plotted based on the first negative 
nasal sample (A) and the total duration of shedding was determined based 
on the last positive nasal sample (B).   The wild type strain was shed over a 
significantly longer time period than the ΔcovR/S strain based on both 
criteria. (Logrank Mantel Cox p<0.05).  
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6.2.4. S. PYOGENES WITH A COVR/S MUTATION CAN CAUSE AN ATTENUATED 
SUPPURATIVE UPPER RESPIRATORY TRACT INFECTION.  
To better understand any differences between nasopharyngeal infection caused by 
the wild type and ΔcovR/S  strains, mice were intranasally infected with the covR/S 
mutant (Figure 6.5) and then euthanised at days 3, 7, 14 and 21 (n=3 per group per 
time point);sagittal sections of the head, including the nasal cavity, nasopharynx and 
brain were examined. 
These mice demonstrated inflammatory changes affecting the nasal cavity over the 
first week of infection, particularly in the ethmoturbinate region, which had been 
demonstrated previously as the primary site of S. pyogenes infection within the 
nasopharynx.  
Mice infected with the S. pyogenes covR/S mutant H494 demonstrated mild to 
marked suppurative rhinitis at days 3 and 7 post inoculation. However by day 14 the 
majority of mice had normal nasal mucosa, and at day 21, the mice infected with 
H494 had normal nasal mucosa or showed only mild inflammation (Table 6.1) 
despite still carrying S. pyogenes. The inflammation seen in mice infected with H494 
was however less severe and less protracted than the inflammation caused by the 
wild type strain H347 alone (See Chapter 3.2.3). The differences seen between 
these two strains with regard to pathology were consistent with what was observed 
with regard to the bacterial load. 
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Figure 0-5. Histopathological analysis of the ethmoturbinates during nasal infection 
Figure 6.5. Histopathological analysis of the ethmoturbinates during nasal 
infection. Nasal tissues from mice infected with a covR/S mutant of S. pyogenes 
(H494) (n=3 per group) were taken at days 3, 7, 14 and 21 after inoculation 
(Haemotoxylin & Eosin staining).  N = Neutrophilic Exudate, M= Nasal mucosa, S= 
Nasal stroma. Scale bar as shown.  Damage to the nasal mucosa with surface 
neutrophilic exudate was apparent at day 3 post inoculation (A) This exudate was still 
present at day 7 (B) At day 14 the inflammation had begun to resolve (C). By day 21, 
the no abnormality was observed in the nasal mucosa (D). Representative sections 
from single mice are shown. Semi quantitative results are shown in Table 6.1. This 
experiment was performed concurrently with the histopathological data shown in 
Figure 3.3. 
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Table 0-1. Histopathological analysis of upper respiratory tract tissue from mice infected with the covR/S 
mutant H494 
 
Time 
   
Day 3 Day 7 Day 15 Day 21 
Strain Histology 
grade 
Bacterial 
counts 
Histology 
grade 
Bacterial 
counts 
Histology 
grade 
Bacterial 
counts 
Histology 
grade 
Bacterial 
counts 
H494 
+ 45,000 +++ 1,000 - 2 ND 0 
+ 31,000 ++ 12,000 - 242 + 0 
+++ 25,000 ++ 2,000 ++ 84 - 0 
 
Table 6.1. Histopathological analysis of upper respiratory tract tissue from 
mice infected with the covR/S mutant H494. At each of four time points, 3 mice 
per group, infected with the ΔcovR/S strain, were analysed histopathologically to 
determine the severity of infection and assigned a numerical designation. - = No 
significant abnormality, + =Mild , ++= Moderate, +++ = Marked, ++++ = Severe and 
ND= Non diagnostic sections. This experiment was performed concurrently with the 
histopathological data shown in Table 3.1. 
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6.2.5. INVESTIGATION OF COVR/S MUTATION USING BIOLUMINESCENCE: 
INTENSITY OF INFECTION IN NASOPHARYNX AND LUNGS 
A bioluminescent derivative of the ΔcovR/S strain was developed through the 
integration of the pICL18lux plasmid into the spy0535 region of the H494 
chromosome to create H494lux.  Mice were infected intranasally with either H347lux or 
H494lux, to determine whether any differences conferred by the covR/S mutation 
could be observed using bioluminescence imaging (Figure 6.6 A & B). Mice were 
infected with either 5 μl to deposit bacteria within the nasopharynx (n=3 per group, 
per time point), or 20 μl to trigger a pulmonary infection (n=3 per group, per time 
point).  It should be noted that one of the mice infected with 20 μl of the covR/S 
mutant H494lux reached a humane end point and had to be culled before it could be 
imaged. No significant difference was found between bioluminescent signals for 
each strain within in the nasopharynx (Figure 6.6. C, r2 >0.95). This finding was 
confirmed using traditional quantitative bacteriology. Indeed, no significant difference 
was observed between the carriage of H347lux and H494lux in the nasopharynx in 
mice infected with 5 µl (Figure 6.6. D), or in the lung, in groups infected with 20 µl 
(Figure 6.6. E) These results contrasted with those obtained when comparing non-
bioluminescent S. pyogenes wild type and covR/S mutant strains. 
Mice that were administered 20 µl inocula were imaged from the ventral viewpoint to 
examine the lung (Figure 6.7 A). However, a signal was only visible from the lungs of 
one mouse in the group infected with the wild-type derived strain, H347lux. One of the 
mice infected with the bioluminescent ΔcovR/S strain, H494lux demonstrated multiple 
regions to which bacteria had disseminated on imaging (Figure 6.7. B). Dissection 
revealed that the inguinal lymph nodes were amongst the regions affected, and 
bacteriology revealed the presence of S. pyogenes.  However, such events were 
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sporadic and not statistically significant. Interestingly, one of the mice infected with 
H347lux showed colonisation originating from the genital tract.  
Overall, there was no quantitative difference in S. pyogenes infection of the 
nasopharynx or the lung between the bioluminescent derivatives H347 lux and H494
lux 
despite differences in functional covR/S, in contrast to findings for the non-
bioluminescent strains H347 and H494.  
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Figure 0-6. Imaging of a bioluminescent covR/S mutant during nasopharyngeal infection 
Figure 6.6. Imaging of a bioluminescent covR/S mutant during nasopharyngeal infection. 
Mice were infected with 5 µl or 20 µl of either the H347
lux
 or the H494
lux
 then were imaged for 
three days post inoculation (A & B, n=3 mice per treatment group, per time point). The 
bioluminescent signal obtained from the dorsal view was correlated to the numbers of S. 
pyogenes present on direct culture of nasal tissues for both strains at all time points (C, r
2
> 0.95). 
The colony counts from the nasopharynx of mice infected with 5µl (D) and 20µl (E) showed no 
significant difference in bacterial numbers between strains. Data shown for individual mice. 
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Figure 0-7. Imaging of a bioluminescent covR/S mutant during intrapulmonary infection 
 
Figure 6.7. Imaging of a bioluminescent covR/S mutant during intrapulmonary 
infection. Mice were infected with 20 µl of either the H347
lux
 or the H494
lux
 were 
imaged for three days post inoculation (A, n=3 mice, per group, per time point). One 
mouse infected with H494
lux
 showed dissemination to a variety of areas, including the 
inguinal lymph nodes, which were positive for S. pyogenes upon dissection on day 1 
post inoculation (B). The colony counts from the lungs of mice infected with 20µl 
showed no significant difference in S. pyogenes carriage between strains (C). Data 
shown for individual mice. 
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6.2.6. COVR/S MUTATION MAY PARTIALLY COMPENSATE FOR GROWTH 
DEFECTS CONFERRED BY BIOLUMINESCENCE DURING LONG TERM S. 
PYOGENES COLONISATION IN THE NASOPHARYNX.  
The bioluminescent derivatives of the wild type and covR/S mutant (H347lux and 
H494lux, respectively) were infected intranasally and compared with regard to 
streptococcal shedding over a 15 day time course.  
In contrast to results obtained when comparing non-bioluminescent strains, the 
duration of continuous shedding for the ΔcovR/S H494lux strain was significantly 
longer than that for the H347lux strain (Figure 6.8 A, Mantel Cox Logrank p<0.05). 
However, when looking at the total duration of shedding (Figure 6.8 B) there was no 
significant difference between the groups. Mice from each group had the 
nasopharynx dissected at Days 3, 7 and 15 post-inoculation, and demonstrated no 
significant difference in bacterial counts between these groups (Figure 6.8.C). 
165 
 
Figure 0- 8. Expr essi on of biol uminescence alters  the impac t of covR/S mutation
Figure 6.8. Expression of bioluminescence alters the impact of covR/S mutation.  
FVB/n mice were inoculated intranasally with either H347
lux
 or H494
lux
 (n=18 per 
group). To determine the duration of shedding, direct nasal samples were taken over a 
15 day period. The period of continuous shedding for the H494
lux
 strain was 
significantly longer than for H347
lux
 (A, Mantel Cox Logrank p<0.05). However, for the 
total period of shedding, there was no significant difference between the strains (B). S. 
pyogenes in the nasopharynx were enumerated from mice dissected on Day 3, Day 7 
and Day 15 (C).  
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6.2.7. BIOLUMINESCENT ΔCOVR/S S. PYOGENES CAUSES A SUPPURATIVE 
UPPER RESPIRATORY TRACT INFECTION 
Mice intranasally infected with H494lux were euthanized at days 3, 7, and 15 (n=3 per 
group per time point) and sagittal sections of the head, including the nasal cavity, 
nasopharynx and the brain were examined (Table 6.2). Bacterial counts taken from 
each mouse nasopharynx revealed that bacteria were present, even when no 
significant abnormality was detected. Interestingly even when bacteria had cleared, 
the inflammation did not fully resolve. The inflammation observed in this strain was 
less severe than the non-bioluminescent H494 isolate (Table 6.1), but paradoxically 
was greater than the H347lux strain (Table 5.1). As bioluminescence expression 
appeared to confound the impact of covR/S mutation, further experiments that 
examined virulence traits and CovR/S excluded the use of bioluminescent strains. 
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Table 0-2. Histopathological analysis of upper respiratory tract tissue from mice infected with a 
bioluminescent ΔcovR/S S. pyogenes strain (H494
lux
) 
 
 
 
 
 
 
 
 
 
Table 6.2. Histopathological analysis of upper respiratory tract tissue from 
mice infected with a bioluminescent ΔcovR/S S. pyogenes strain (H494lux). 
At each of four time points, 3 mice per group, infected with the emm75 ΔcovR/S 
strain H494lux, were analysed histopathologically to determine the severity of 
infection and assigned a numerical designation. - = No significant abnormality, 
+ =Mild , ++= Moderate and +++ = Marked. This experiment was performed 
concurrently with the histopathological data shown in Figure 5.1. 
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6.2.8. COVR/S MUTATION IS DETRIMENTAL TO THE TRANSMISSION OF S. 
PYOGENES IN A MOUSE MODEL.  
Mice infected with either the wildtype (H347) or the covR/S mutant (H494) strains 
were introduced into cages at a D:R ratio of 3:5 to determine whether the expression 
of virulence factors has an effect on transmission. To eliminate the effects of passive 
inoculum transfer, mice were separated for six hours after inoculation. Direct nasal 
samples taken from recipient mice revealed that transmission occurred more 
frequently from donors carrying the wild-type strain than from the covR/S mutant 
(Figure 6.9. A, AUC analysis with Mann Whitney U p<0.05). Settle plates incubated 
in each cage detected no significant difference in airborne S. pyogenes (Figure 6.9 
B). However, in previous studies the differences in burden of colonisation between 
mice infected with the covR/S mutant and the wild type manifested after three days, 
and may have accounted for the observed difference in transmission.   
To eliminate this potential confounding factor, mice were observed over a shorter 
time course of three days. A power calculation was used to determine the correct 
experimental numbers to allow for the detection of differences in transmission, and 
aerosolisation at this stage of infection. The transmission of the wild type strain to 
recipient mice was significantly higher than the transmission of the ΔcovR/S strain 
(n=24 at a D;R ratio of 3:5, Figure 6.10.A, AUC analysis, with Mann Whitney U 
p<0.05). However, the settle plates revealed no significant difference between the 
levels of airborne wildtype S. pyogenes H347, or the ΔcovR/S strain H494 (Figure 
6.10 B). 
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Figure 0-1. Transmission of S. pyogenes is hampered by the loss of CovR/S regulation
170 
 
Figure 0-2. Transmission of S. pyogenes is hampered by the loss of CovR/S regulation 
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Figure 6.10. Transmission of S. pyogenes is hampered by the loss of CovR/S 
regulation. Naïve recipients co-mingled at a D:R ratio of 3:5 with mice infected with 
either the wild type strain H347 or the ΔcovR/S strain H494 and sampled after the 
introduction of the donor mice. (n=15 recipients per group from 3 identical studies). 
Donor mice had >5000 cfu recovered from direct nasal sampling throughout the 
experiment.  Donor mice infected with H494 transmitted significantly less well to 
recipients compared to H347 (AUC analysis, followed by Mann-Whitney U test). Data 
shown from settle plates through the time course revealed that there were no 
significant differences in the bacteria deposited on the surface of the plates by mice 
infected with H347 or H494 (B) Error Bars indicate median and interquartile range. 
 
* 
A 
B 
0 24 48 72
101
102
103
104
H494
H347
hours post inoculation
C
o
lo
n
y
 C
o
u
n
ts
 f
ro
m
 S
e
tt
le
 P
la
te
s
(c
fu
/m
2
/h
r)
171 
 
6.3. DISCUSSION 
An isogenic derivative of the emm75 strain with a covR/S mutation was created in 
previous work and was shown to have increased SpyCEP production [45]. Here, it 
has been demonstrated to have impaired SpeB production  and biofilm formation, 
similar to emm1 strains with covS mutations reported recently [97,289]. The covR/S 
mutation in the strain studied here (H494) was derived by a single crossover 
homologous recombination event [45]. Such a mutation can have polar effects on 
bacterial gene function that are distinct from the specific inactivation events intended. 
A global polar effect in fitness was considered highly unlikely since the strain was 
known to have no growth defect in vitro [45] and is known to have an almost 
complete block in transcription of covR and covS, resulting in a 100 fold increase in 
the transcription of the IL-8 cleaving enzyme SpyCEP.  
The covR/S mutant was demonstrably more invasive as it disseminated to the 
inguinal lymph nodes in greater numbers than its wild type counterpart during 
intramuscular infection. This again corroborated the effects of the mutation of the 
covR/S gene as described in other work [96] as it is known to de-repress a large 
number of genes essential for defence against neutrophil mediated killing. 
However, whilst the covR/S mutation confers advantages during invasive infection, 
the converse was observed during infection in the nasopharynx. The duration of both 
continuous shedding and total shedding was shorter in mice infected with the 
ΔcovR/S strain (H494) compared to those infected with wild type (H347).  The 
inflammation caused by infection with the ΔcovR/S strain (H494) was less severe 
and resolved faster than observed for the wild type in Chapter 3, which could be due 
to the lower numbers of S. pyogenes present. 
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To determine whether bioluminescent imaging could offer greater insight into the 
impact of covR/S mutation, a bioluminescent derivative of the covR/S mutant was 
created through the integration of the pICL18lux plasmid into the spy0535 region of 
the chromosome to create H494lux. Mice infected with the ΔcovR/S bioluminescent 
derivative (H494lux) showed no significant difference in bioluminescence in vivo 
compared to mice infected with the parent bioluminescent strain, H347lux in the 
nasopharynx. When infected at a volume in which the bacteria would be delivered to 
the lungs, no significant difference in carriage could be found in this region, or the 
nasopharynx. However, one mouse infected with H494lux had to be culled early due 
to the severity of its illness, and multiple dissemination events were observed after 
infection with the H494lux strain in another mouse.  
Importantly, the expression of bioluminescence in S. pyogenes led to different 
outcomes in the nasopharynx when observed over a longer time course. In the 
preceding chapter, the expression of bioluminescence conferred growth defects in 
vitro, and within the nasopharynx. In light of this, the reduced duration of continuous 
and total shedding of the H347lux strain when compared to its wild-type non-
bioluminescent counterpart was to be expected.  The finding that this H347lux strain 
had a reduced duration of continuous shedding when compared to its isogenic 
bioluminescent ΔcovR/S counterpart, H494lux was surprising.  
Earlier work in this chapter showed that the non-bioluminescent strain H347 led to 
protracted carriage and transmission. The duration of total shedding was not 
significantly different to the wild type, which is reflected in the data from dissection. 
The inflammation caused by this strain in the nasopharynx was also lower, but 
greater than that seen following infection with the H347lux strain. This highlights an 
important and broadly relevant consideration when exploiting bioluminescent strains 
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to determine the importance of single gene differences. The fitness burden conferred 
by bioluminescence may outweigh the impact of any additional genetic changes. 
The removal of covR/S regulation, in conjunction with the metabolic cost conferred 
by bioluminescence may modulate the expression of virulence factors to a level that 
allows for H494lux to be carried longer than H347lux. It should be noted that the 
differences between continuous carriage duration and total carriage duration are 
defined by the probability of re-infection, and that these differences could be 
explained by a general impairment in transmissibility caused by a covR/S mutation. 
In either event, the differences in the behaviour of H494lux when compared to its non-
bioluminescent counterpart suggest that it would not be appropriate to use this strain 
for further study of the effects of covR/S mutation.  
Co-mingling was then used to examine the impact of covR/S on transmission using 
the non-bioluminescent strains. Over time courses of five and three days, the 
ΔcovR/S strain was less transmissible than wild-type S. pyogenes, despite the fact 
that the infection burden (as measured by direct nasal sampling) was similar 
between the two donor groups in the first 72h. Furthermore, settle plates placed in 
each cage revealed no significant difference in aerosolisation between the two 
strains. This suggests that either the bacteria are primarily transmitted via close 
contact between recipients and donors, or that the covR/S mutant is impaired when 
infecting mice from a droplet borne state. 
There is thus a fitness cost conferred by covR/S mutation specific to the 
nasopharynx that may explain why such bacteria have not become prevalent in 
community S. pyogenes infections despite being advantageous in invasive infection. 
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covR/S mutation impacts the longevity of infection pathology in the nasopharynx and 
transmissibility from it. Biophotonic imaging failed to detect a phenotype imparted by 
covR/S mutation, and this is likely related to the global fitness burden conferred by 
expression of bioluminescence, a drawback that is important to underline in 
molecular microbiology since it is of relevance to both fluorescently and 
bioluminescently-labelled bacteria.  
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6.4. APPENDIX  
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CHAPTER 7: THE UTILITY OF BIOPHOTONIC IMAGING IN 
ASSESSING VACCINE EFFICACY 
7.1. INTRODUCTION 
The models of nasopharyngeal infection utilised in many studies tend to cause 
invasive infection, and often studies use death as the outcome to evaluate the 
protection conferred by a vaccine [137,138,231]. However an effective vaccine 
against S. pyogenes must also curb the onset of non-invasive diseases such as 
pharyngitis, particularly if the aim of vaccination is to reduce the incidence of acute 
rheumatic fever.  
The application of bioluminescence to study S. pyogenes infection in the 
nasopharynx allows for the progression of infection to be studied non-invasively.    
Although conferring a fitness burden on the infecting bacterium, BPI provides a 
longitudinal method that can be used to evaluate the efficacy of new vaccine 
candidates through direct measurements of S. pyogenes in the nasopharynx. 
Subunits of SpyCEP, a cell wall-associated IL-8 protease, have demonstrated 
efficacy as vaccines against S. pyogenes during intravenous, intramuscular and 
lower respiratory tract infections [145–148]. The model of non-invasive infection, and 
the bioluminescent S. pyogenes developed and utilised in the preceding chapters 
provide an opportunity to assess the protective efficacy of this vaccine candidate 
during non-invasive upper respiratory infection. 
Whilst the preceding chapters have revealed a few disadvantages to the use of BPI 
in certain situations, this chapter sets out to illustrate the application of BPI to 
vaccine development. 
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7.2. RESULTS 
7.2.1 INTRAMUSCULAR BUT NOT INTRANASAL IMMUNISATION CONFERS 
PROTECTION AGAINST INTRANASAL CHALLENGE AGAINST S. PYOGENES 
The efficacy of intranasal and intramuscular vaccination in protection against S. 
pyogenes nasopharyngeal infection was assessed, using heat-killed L. lactis as a 
control for non-specific responses, and heat-killed S. pyogenes as the protective 
vaccine. A vaccine comprising heat-killed S. pyogenes can act as a positive control 
for any vaccine study, since the vaccine should provide protection against infection 
with live bacteria of the same strain. 
Mice were intranasally immunised with either heat-killed emm75 S. pyogenes or 
heat-killed L. lactis at 4, 2 and 1 weeks prior to intranasal challenge with live emm75 
S. pyogenes. Serum IgG taken after the final immunisation revealed no specific 
immune response to either S. pyogenes or L. lactis (Figure 7.1. A). Broncho-alveolar 
lavage (BAL) samples taken at the time of dissection did not show the presence S. 
pyogenes-specific IgG (Figure 7.1. B) or IgA (Figure 7.1.C). 
Mice were challenged intranasally with bioluminescent S. pyogenes (H347lux), and 
imaged for two days post infection (Figure 7.1 D).  Intranasal immunisation with 
either heat killed S. pyogenes or L. lactis followed by S. pyogenes challenge resulted 
in similar levels of bacterial infection in both groups (Figure 7.1. E) Hence, intranasal 
immunisation with heat killed bacteria did not result in systemic or mucosal immune 
responses, nor did it confer any specific protection in vivo against intranasal 
infection. 
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Figure 0- 1. Intranasal immunisation  with  heat kil led  S. pyogenes or  L. lactis and the resultant  immune response 
 
Figure 7.1. Intranasal immunisation with heat killed S. pyogenes or L. lactis and the 
resultant immune response.  (A) Serum IgG response to either heat killed S. pyogenes of 
heat-killed L.lactis following immunisations. Samples were taken prior to challenge. (B) IgG  and 
(C) IgA response in BAL fluid following vaccination with heat killed S. pyogenes or heat killed L. 
lactis ; Lavages taken at the time of dissection at 48 hours following challenge with live S. 
pyogenes. (D) Bioluminescent signal following live S. pyogenes (H347
lux
) challenge in mice 
vaccinated with either heat killed S. pyogenes or heat killed L. lactis. (E) Quantitative S. 
pyogenes numbers obtained from dissected nasal tissues at the end of the previous 
experiment. Data shown for individual mice (n=6), lines and error bars indicated median and 
interquartile range. 
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Mice were then immunised intramuscularly with either heat killed S. pyogenes or L. 
lactis. Serum taken after the final vaccination revealed the presence of specific 
immune responses against S. pyogenes and L. lactis in mice immunised with each 
preparation (Figure 7.2. A). BAL fluid taken on dissection showed an S.pyogenes-
specific IgG response (Figure 7.2. B), but no specific IgA response in S. pyogenes 
vaccinated mice (Figure 7.2. C). 
Following intramuscular vaccination, mice were then challenged intranasally with 
bioluminescent S. pyogenes (H347lux) and imaged for two days post inoculation 
(Figure 7.2. D). Whilst streptococcal numbers were lower in the mice immunised with 
S. pyogenes, this difference was not significant (Figure 7.2 C). Taken together, it 
appeared that intramuscular immunisation resulted in a specific and detectable 
immune response that could not be reproduced using intranasal vaccination. 
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Figure 0- 2. Intramuscu lar immunisation with heat killed S. pyogenes or L.lact is and  the result ant immune response 
 
Figure 7.2. Intramuscular immunisation with heat killed S. pyogenes or L. lactis and the 
resultant immune response.  (A) Serum IgG response to either heat killed S. pyogenes of heat-
killed L.lactis following immunisations. Samples were taken prior to challenge. (B) IgG  and (C) IgA 
response in BAL fluid following vaccination with heat killed S. pyogenes or heat killed L. lactis ; 
Lavages taken at the time of dissection at 48 hours following challenge with live S. pyogenes. (D) 
Bioluminescent signal following live S. pyogenes (H347lux) challenge in mice vaccinated with either 
heat killed S. pyogenes or heat killed L.lactis. (E) Quantitative S. pyogenes numbers obtained from 
dissected nasal tissues at the end of the previous experiment. Data shown for individual mice (n=6), 
lines and error bars indicated median and interquartile range.
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To determine whether a nasopharyngeal mucosal response could be elicited by 
immunisation, mice were immunised either intranasally or intramuscularly with heat-
killed S. pyogenes (n=8 per group). Saliva samples were taken from these mice 
before immunisation, and after the final vaccination. These revealed no differences 
in the presence of IgA in all groups, but mice immunised intramuscularly had IgG 
specific for S. pyogenes (Figure 7.3.). These findings indicated that intramuscular 
immunisation with heat killed S. pyogenes produced an IgG response in both serum, 
BAL fluid, and saliva.  
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Figure 0- 3. Saliv ary IgA and  IgM responses following vaccination with heat killed S. pyogenes admin ist ered intramuscularly o r intranasally 
 
A B 
C D 
Figure 7.3. Salivary IgA and IgM responses following vaccination with heat 
killed S. pyogenes administered intramuscularly or intranasally. (A) Anti S. 
pyogenes IgG in saliva prior of following intramuscular vaccination with heat killed S. 
pyogenes. (B) Anti S. pyogenes IgG in saliva prior of following intranasal vaccination 
with heat killed S. pyogenes. (C) Anti S. pyogenes IgA in saliva prior of following 
intramuscular vaccination with heat killed S. pyogenes. (D) Anti S. pyogenes IgA in 
saliva prior of following intranasal vaccination with heat killed S. pyogenes. Lines 
indicate median, error bars indicate interquartile range. 
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7.2.2 USE OF BPI TO DETERMINE THE PROTECTIVE EFFICACY OF A HEAT KILLED 
S. PYOGENES BASED VACCINE. 
The previous experiments demonstrated that intramuscular vaccination with heat 
killed S. pyogenes produced a detectable IgG immune response and may be 
protective. Data from this study were used to power a more substantive study 
evaluating protection. 
Intramuscular vaccination with either heat-killed S. pyogenes or a PBS control was 
performed at 4, 2, and 1 week prior to intranasal challenge with bioluminescent S. 
pyogenes.  Serum samples taken a week before challenge revealed the presence of 
specific IgG reactive against heat killed S. pyogenes in vaccinated mice compared 
with controls (Figure 7.4 A). 
Mice were imaged for four days after intranasal challenge (Figure 7.4 B).  Mice 
immunised with heat-killed S. pyogenes emitted significantly less bioluminescence 
compared to the controls immunised with PBS (Figure 7.4 C, Two-Way ANOVA 
p<0.05).  On the final day, mice were culled and nasal tissue was extracted for 
quantitative bacteriology (Figure 7.4. D). There were significantly fewer S. pyogenes 
in the nasopharynx of the mice immunised with heat killed S. pyogenes compared 
with controls. (Mann-Whitney Test p<0.05). The experiment provided proof that heat 
killed S. pyogenes can protect against nasopharyngeal carriage, and that BPI was a 
robust tool for evaluating vaccine efficacy. 
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Figure 0- 4. B PI revealed  the protective efficacy of a v accine based  on heat- kil led  bacteria 
 
Figure 7.4. BPI revealed the protective efficacy of a vaccine based on heat-killed 
bacteria. Mice were immunised with either PBS or with heat-killed S. pyogenes strain 
H347. A serum IgG response against heat-killed S. pyogenes was detected in the 
vaccinated group (A). Mice challenged with bioluminescent S. pyogenes were imaged 
for four days post infection using an IVIS 100 system (B). The luminescent signal 
recovered from the mice immunised with PBS was significantly higher than that 
recovered from mice immunised with heat-killed bacteria (C, Two way ANOVA  p<0.05). 
Colony counts obtained from dissections performed on the final day confirmed that 
mice immunised with heat-killed S. pyogenes had significantly less bacteria than mice 
immunised with PBS alone (D, Mann-Whitney p<0.05). Data is shown for individual 
animals, bars indicate median. 
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7.2.3. THE USE OF BPI TO DETERMINE THE PROTECTIVE EFFICACY OF A VACCINE 
BASED ON SPYCEP 
The same immunisation protocol was then used to determine the protective efficacy 
of a vaccine candidate based on SpyCEP. A mix of recombinant CEP5 (a sub-unit of 
SpyCEP) with complete Freunds adjuvant was intramuscularly injected 4 weeks prior 
to infection, followed by boosters at 2 and 1 weeks prior to intranasal challenge using 
Freunds incomplete adjuvant. Controls received vaccination with Freunds mixed with 
PBS. Serum samples taken a week before challenge revealed the presence of 
specific IgG reactive against SpyCEP (CEP5) in vaccinated mice compared with 
controls (Figure 7.5 A).  
Mice were imaged over a four day period post infection (Figure 7.5. B). The 
luminescent signal retrieved from the nasopharynx revealed that the mice immunised 
with SpyCEP carried significantly fewer bacteria than the controls (Figure 7.5. C. 
Two-way ANOVA p<0.05). This was confirmed at the end of the experiment, when 
mice were culled and nasal tissue cultured to determine S. pyogenes burden (Figure 
7.5. D, Mann-Whitney test p<0.05). The data demonstrated that inclusion of SpyCEP 
as a vaccine confers additional protection compared to the vehicle alone. However, it 
must be noted that the protection conferred was less dramatic than that conferred by 
heat killed bacteria.  
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Figure 0- 5. B PI revealed  the protective efficacy of a v accine based  on SpyC EP  
 
Figure 7.5. BPI revealed the protective efficacy of a vaccine based on SpyCEP. 
Mice were immunised with either Freunds adjuvant or CEP5 + Freunds adjuvant. A 
serum IgG response against CEP5 was detected in the vaccinated group (A). Mice 
challenged with bioluminescent S. pyogenes were imaged for four days post infection 
using an IVIS 100 system (B). The luminescent signal recovered from the mice 
immunised with Freunds adjuvant was significantly higher than that recovered from 
mice immunised with CEP5 (C, Two way ANOVA p<0.05 ). Colony counts obtained 
from dissections performed on the final day confirmed that mice immunised with CEP5 
had significantly less bacteria than mice immunised with Freunds adjuvant alone (D, 
Mann-Whitney p<0.05). Data is shown for individual animals, bars indicate median. 
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7.3. DISCUSSION 
The unique benefit of BPI is that it allows quantitation of bacterial load at the site of 
infection non-invasively. This capability provided an opportunity to study the efficacy 
of vaccination in a way that was not possible before.  
BPI was used to study the effects of immunisation with heat killed bacteria 
administered either via intramuscular inoculation or intranasal application. Whilst 
heat-killed S. pyogenes are unsuitable for use in human vaccines due to issues of 
safety and poor coverage, they can be used as a proof of principle to test how well 
BPI can gauge vaccine efficacy. 
Vaccination with heat-killed L. lactis was used as a control to allow for a more 
specific analysis of the immune response against S. pyogenes. L. lactis has a similar 
cell wall to S. pyogenes comprising peptidoglycan and teichoic acid, yet does not 
have the repertoire of immunogenic proteins that S. pyogenes possesses.  
Intriguingly, there may even be some cross species protection, for example through 
conserved antigens expressed by different Gram positive species. A recent report 
suggested that the conserved DLDH and P5CDH proteins may be protective against 
both Staphylococcus aureus and Streptococcus pneumoniae [290]. Live L. lactis has 
been investigated as a method for vaccine delivery [235], and may also produce a 
cross protective immune response. 
In this study it was not possible to elicit any protection following intranasal 
vaccination with S. pyogenes and this was associated with a failure to elicit any 
specific immune response. This contrasts with previous studies using S. pyogenes in 
intranasal vaccines [157,243], and although it could be related to strain differences, 
or differences in end-points, the lack of any response was surprising.  Adjuvants are 
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often required for intranasal vaccination with proteins, however this was considered 
unnecessary when administering heat killed whole bacteria. 
Whilst some antigens expressed by S. pyogenes do not appear to require the 
presence of adjuvants to confer protection [138], adjuvants such as alum [148,160], 
or the cholera toxin B sub-unit [156,159] are used in the majority of vaccines 
targeted to the nasopharynx [170]. It is possible that an adjuvant is necessary for a 
vaccine to be effective in the nasopharynx, although it was expected that a whole 
cell vaccine would provide such an adjuvant stimulus. It is also possible that the 
strain of S. pyogenes used in this study may not be amenable for use as an 
intranasal vaccine candidate, since other studies have demonstrated protection 
when emm24 S. pyogenes was used as a vaccine [224]. However, the previous 
study used PBS as a control, and it is possible that there is a non-specific immune 
reaction caused by both L. lactis and S. pyogenes, which would make a comparison 
between the two invalid. It should also be noted that in that study, bacteria were heat 
killed at a temperature of 56oC, whereas a temperature in excess of 80oC was used 
in these studies due to safety regulations to ensure all the bacteria are reliably killed. 
For mice immunised via the intramuscular route, IgG responses were seen in the 
serum, saliva and BAL fluid. A specific anti-streptococcal IgA response, which tends 
to be associated with mucosal immunity [224], was not observed in this study. The 
production of IgA is thought to derive from the induction of immunity at mucosal 
sites, and so the lack of this response after intramuscular immunisation may not be 
surprising [291]. The lack of IgA response after intranasal immunisation suggests 
that mucosal specific adjuvants are necessary, and the heat killed vaccination 
preparation used in this study is not sufficiently immunogenic on its own. 
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These initial studies were not powered to detect a protective effect against S. 
pyogenes in the respiratory tract. A larger study was performed, with mouse 
numbers determined by a power calculation based on the previous data, to 
demonstrate protection by a heat-killed S. pyogenes vaccine. The mice were also 
followed over a longer period of infection, and PBS was used as a control instead of 
L. lactis. These data demonstrated that heat-killed S. pyogenes applied in an 
immunisation protocol can confer in vivo protection against nasal challenge over a 
four day observation period. In previous studies bioluminescent S. pyogenes was 
used to investigate the efficacy of a C5a peptidase vaccine during intranasal 
infection [170], and the efficacy of passive immunisation with anti-serum raised 
against a conserved C-terminal sub-unit of M-protein [160]. In the latter study, 
bioluminescence could only be assessed post mortem on dissected organs, which 
provides no better insight than simply performing quantitative bacteriology on the 
dissected organs.  In both of these studies, the strain utilised was derived from an 
emm49 skin isolate, and none of these studies directly looked at the presence of 
bacteria in the whole nasal tract. 
SpyCEP is but one of a number of different conserved proteins found via genomic 
[145,148] and proteomic [146] approaches which may become the basis for a 
combination vaccine. Such candidates have been shown to improve survival after 
intrapulmonary, intravenous and intraperitoneal infection [145,146,148] . The 
application of BPI allows for the measurement of bacterial clearance, as opposed to 
death, making it both a more humane and more relevant method for assessing the 
protectiveness of a vaccine. 
BPI was successfully used in this study to demonstrate that vaccination against 
SpyCEP can reduce S. pyogenes numbers in the nasopharynx. This method could 
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just as effectively be applied to measure the efficacy of other vaccine candidates in a 
similar way.   
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CHAPTER 8: GENERAL DISCUSSION 
The work described in this thesis was performed to fulfil the need for a reproducible 
model of nasopharyngeal infection that can be analysed longitudinally, and that can 
be used to determine the factors that influence carriage, infection, and 
transmissibility in future studies. The model was used to demonstrate the effects of 
global virulence factor de-repression on S. pyogenes survival and transmission 
within this niche.  A new bioluminescent strain of S. pyogenes was developed from 
an isolate known to cause nasopharyngeal infection in humans and mice; the 
resultant model was used to demonstrate its potential as a model to screen vaccine 
candidates. In this work, the efficacy of a vaccine candidate based on SpyCEP was 
evaluated.   
Whilst working towards these aims, a fitness cost conferred by the expression of 
bioluminescence in S. pyogenes was uncovered, new methods for non-invasively 
measuring bacterial carriage without the need for expensive equipment and 
genetically modified bacteria were tested, and a model for mouse to mouse 
transmission was devised.  In the following section these results will be discussed 
with respect to their broader applicability to previously published work, and possible 
future avenues of investigation. 
8.1. THE SUSCEPTIBILITY OF MICE TO S. PYOGENES INFECTION IN THE 
NASOPHARYNX IS BASED ON THE HOST STRAIN, GENDER AND AGE 
It was noted earlier that a variety of different methods have been utilised to 
investigate S. pyogenes in the nasopharynx using mouse models (Chapter 1, Table 
1.1).  A major issue for these models was the resistance of mice to streptococcal 
infection, and thus followed the requirement for high doses of inocula.  A number of 
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studies have established that the host background of mice can determine outcome of 
invasive infection induced by intraperitoneal, or intravenous injection [192,193], 
along with a gender difference. Mouse background and gender also impacted upon 
the model of intranasal infection devised in the current work, and the FVB/n mouse 
strain was found to be most susceptible to S. pyogenes infection.  This strain is not 
known to suffer from any immune deficiencies, save for the presence of the cri-1 
locus conferring susceptibility to C. rodentium infection [276,277], and  the genetic 
susceptibility to the strain B Friend mouse leukaemia virus that was used to 
differentiate this strain from its progenitors [274]. Conversely, other studies have 
found that this strain is more resistant to infection in the lungs based on the numbers 
of bacteria recovered from this region [292]. The experiments performed in the 
current work were specifically designed to avoid lung involvement, and thus do not 
contradict these findings. However, the findings raise the possibility that susceptibility 
to infection arose after the derivation of this strain, and certain populations of this 
mouse strain may not possess the susceptibility observed in this thesis. Importantly, 
the FVB/n mice used in these studies were sourced from two separate breeding 
colonies, Harlan and Charles-River, and no discernible difference in susceptibility 
was observed. 
Other studies have also determined that male mice tend to be more susceptible to 
invasive infection with S. pyogenes compared to female mice [192–194].  The 
reasons for this difference have been suggested to be due to the presence of a locus 
for susceptibility carried on the X-chromosome [192] or the presence of testosterone 
causing some inhibition to the immune response of male mice [194]. This latter 
evidence is supported by the finding that female mice tend to be more reactive to 
superantigen mediated toxic shock than male mice [195]. As observed in humans, 
193 
 
enhanced susceptibility to autoimmune disease is observed in female mice. 
Conversely, generally enhanced protection from sepsis is observed in females 
compared with males [293,294]. This ties in with globally enhanced immune 
responses, whether cytokine, immunoglobulin, or T cell –derived, to immune 
stimulus in females [295,296] 
The findings reported in this thesis support the findings from previous research 
studies, although the difference observed herein in susceptibility was detectable only 
after the mice had reached ten weeks of age, compared with pre-pubertal mice. 
Other work has similarly indicated that the susceptibility of  female mice to intranasal 
infection decreases after they age past 11-12 weeks [156] which supports the 
findings described here.  Earlier work examining the effects of age tended to 
examine much later time points of the mouse life cycle, and is not directly 
comparable to the work performed here [193,196]. 
The critical difference between mice aged 5 weeks and mice aged 10 weeks is the 
onset of puberty. This could support the hypothesis that sex hormones to some 
degree define mouse susceptibility to S. pyogenes infection. However, the male mice 
in the older age group had to be separated due to aggression. These mice tended to 
carry S. pyogenes for longer in spite of the lack of potential for re-infection caused by 
this situation. Previous studies have shown that individually housed mice show 
greater humoral immunity, and thus greater resistance to infections, which would 
suggest that separation is not responsible for enhanced susceptibility to infection 
[297]. 
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The documentation of sex specific determinants of S. pyogenes susceptibility 
supports the proposition that puberty may be a significant factor in the development 
of resistance to infection in female mice. 
It should be noted that the emm75 S. pyogenes strain utilised in these studies was 
chosen based on its ability to survive in the nasopharynx of BALB/c mice in initial 
studies. Importantly, pharyngitis strains of different emm types were found to cause 
infection in the FVB/n nasopharynx to an equivalent, if not greater, degree than the 
emm75 strain used to characterise the model.  
Whilst there are a number of studies in humans which support the findings that 
males are more susceptible to infection than females [294,298–301], and are more 
susceptible to toxic shock [195,302], there are some differences that need to be 
acknowledged. In humans, susceptibility to infection decreases after the onset of 
puberty, a finding that only appears to be corroborated by female mice in this model, 
as the male mice appeared to become more susceptible to experimentally induced 
pharyngitis after this period. This has not been observed in human adults, but the 
sheer prevalence of S. pyogenes infection in early life may be a confounding factor. 
These general issues stem from the differences in biology between the mouse and 
the human, and apply to the discussion of any findings from a mouse model. The 
questions that these models are used to investigate must be framed with these 
issues in mind. 
8.2 THE CHARACTERISATION OF S. PYOGENES INFECTION IN THE MOUSE 
The emm75 S. pyogenes was found to cause a suppurative infection in the 
nasopharynx of the FVB/n mice. The numbers of bacteria recovered from the 
nasopharynx tended to be highest in most mice during the first four days of infection 
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(Appendix 3.1).  This finding was corroborated through BPI; high numbers of bacteria 
were detectable by imaging during the first four days after infection, but thereafter 
were only detectable by conventional microbiological techniques.  After an initial 
phase of suppurative infection, mice remained colonised with S. pyogenes at much 
lower levels but with no visible symptoms or distress for up to 21 days post 
inoculation (Figure 3.5.). 
In artificial S. pyogenes infections induced in humans, the presence of bacteria on 
the tonsils was found to peak between 2-4 days post infection [109,124], although it 
should be noted that the period of observation in these studies was limited,  and the 
cessation of infection was caused by penicillin prescription rather than the natural 
induction of immunity, for obvious ethical reasons. However, in clinical cases of S. 
pyogenes pharyngitis, an asymptomatic carrier state is recognised to follow, after the 
cessation of suppurative infection  [114,116,298].  The similarities between the 
infection described in humans and the infection observed in mice during this study 
are striking.   
Whilst similarities exist between clinical and experimental infection, the fundamental 
differences in the anatomy between human and the inbred mouse must be taken into 
account when extrapolating the findings from this model to the human condition. The 
primary focus of infection in humans is within the tonsils. However, the rodent 
equivalent of the tonsils, the NALT, is situated above the hard palate, within the 
nasopharynx [209]. The suppuration induced by S. pyogenes occurred primarily 
within this tissue, and the highest numbers of S. pyogenes were found within the 
ethmoturbinates within the posterior nasopharynx. Whether this is due a specific 
preference, or simply because the high surface area of the ethmoids allowed for 
more S. pyogenes to colonise than the other portions of the nasopharynx was not 
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discovered in this study. This heavy colonisation of the posterior nasopharynx was 
documented to lead to damage to the cribriform plate, the bone which separates the 
brain from the nasopharynx, and the entry of S. pyogenes into the olfactory bulb. 
Although recognised to occur in invasive sinus infections associated with the S. 
milleri group and S. pneumoniae, this form of invasion has not been observed in S. 
pyogenes human infection, and may only occur due to anatomical differences in the 
distribution of S. pyogenes colonisation in mice compared with humans.   
8.3. THE TRANSMISSION OF S. PYOGENES BETWEEN MICE  
In the initial studies of S. pyogenes nasopharyngeal infection, direct nasal sampling 
allowed for the decline of S. pyogenes carriage to be examined. There was a curious 
trend that occurred during the latter stages of infection, whereby mice would appear 
to clear infection, only to later demonstrate apparent relapse or re-infection with S. 
pyogenes. Although it is possible that low level carriage of S. pyogenes fell below the 
limit of detection for the direct nasal sampling technique for a short period, there was 
the possibility that these were transmission events. This provided two potentially 
different end points when judging the time at which S. pyogenes infection ended.  
The most rigorous end point was the time point when the first negative sample was 
obtained from each mouse, eliminating any potential effects of re-infection events on 
nasal carriage, and ignoring any further positive cultures occurring after the level of 
carriage fell below the level of detection. This represented the period of continuous 
shedding.  
The period of intermittent shedding was, however, of biological interest, as the 
impact of transmission events had possible relevance to the human populations. 
This was evaluated by measuring the total duration of shedding, in which the last 
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positive sample of S. pyogenes was used to define the cessation of carriage.  The 
fact that the duration of continuous shedding often differed from the total duration of 
shedding suggests that transmission may play a role in the maintenance of 
nasopharyngeal infection in this mouse model. 
S. pyogenes is thought to be transmitted in airborne respiratory droplets, although 
direct contact may also contribute. The transmission of S. pyogenes between mice 
would provide an opportunity to study transmission in a way not previously possible, 
The resistance of mice to S. pyogenes infection described in previous works have 
necessitated the administration of inocula containing large numbers of S. pyogenes 
to individual mice by direct intranasal inoculation rather than by aerosolised droplets 
[303] . The exception to this is a set of work produced during the 1950’s, in which a 
nebuliser system was utilised to infect Swiss mice [211,212,304,305]. In one study, 
the spread of S. pyogenes between mice in separate cages was observed [304]. 
Later studies indicated that there were differences in the susceptibility of mice to 
infection by the nebuliser technique, and it was later abandoned [212]. The outbred 
nature of the strains used and the inconsistent environmental conditions likely played 
roles in this inconsistency. The use of inbred strains of mice in the current work, and 
the standardised environmental controls implemented in the housing and care of the 
mice in these studies mean that the current study is not subject to those particular 
sources of variability. 
A co-mingling model was implemented to study transmission, as it has been long 
recognised that transmission via the airborne route may not the primary mode of 
transmission. 
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Transmission was observed to occur rapidly, with recipient mice acquiring S. 
pyogenes in the nasopharynx within 4 hours of the introduction of donor mice. The 
numbers of S. pyogenes were observed to increase in the recipients when more 
donor mice were present. Furthermore, the deferred introduction of infected donor 
mice revealed that transmission was not simply an artefact of inoculum transfer.  
The acquisition of S. pyogenes in the nasopharynx of the recipient mice did not 
result in bacterial loads of the levels reached in mice that were inoculated directly. 
Importantly histopathological studies on recipient mice were not undertaken and it  
cannot be said whether the acquisition resulted in a productive inflammatory 
infection. In the human situation, asymptomatic carriers of S. pyogenes have been 
observed during outbreaks of infection [306,307]. The persistence of S. pyogenes in 
this state may aid its persistence in a cage of infected mice in a similar manner to 
which it enables persistence within a community. However, there is a strong 
behavioural component to transmission in mice via this co-mingling model which 
cannot be ignored. Mice tend to maintain a social hierarchy that is reinforced by 
grooming and subtle demonstrations of aggression. In the studies described, donor 
mice had to be separated from their cage mates for specific periods of time, which 
had the potential to upset this hierarchy, causing increased subtle aggression in 
some cages upon the reintroduction of the donor mice and introducing a source of 
variability when investigating transmission. 
The transmission events demonstrated did not differentiate between transmission 
due to direct contacts and transmission due to aerosolised droplets. Nonetheless, 
the potential for airborne transmission was ably demonstrated by the transmission of 
beta haemolytic streptococci to the settle plates in the upper levels of cages, at a 
height of 10cm above the cage floor. Future studies will necessarily involve 
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segregation of infected donor and naïve recipient mice by panels that prevent direct 
contact and grooming, but allow passage of air.  
8.4. EFFICACY OF DIFFERENT METHODS FOR DETERMINING THE PRESENCE OF 
S. PYOGENES IN THE NASOPHARYNX LONGITUDINALLY 
The primary focus in this work was the development of non-invasive techniques for 
assessing long term S. pyogenes colonisation in mice. During a previous Master’s 
project, a technique was developed utilising direct nasal sampling from the 
nasopharynx onto agar plates. In the current study, the numbers of exhaled S. 
pyogenes recovered using this technique were found to correlate with the actual 
numbers of bacteria within the nasopharynx of the mice. This technique allowed for 
the course of an infection to be tracked, and for the infection to be assessed on the 
basis of the survival of S. pyogenes within the nasopharynx, rather than the survival 
of the infected hosts after infection. However, whilst this technique was sensitive, the 
upper limit of accurate quantification was sometimes restricted during the first three 
days of infection. During the point of greatest carriage, S. pyogenes colonies from 
direct nasal sampling could reach 100% confluence on the surface of the sampling 
plates, making the precise assessment of S. pyogenes numbers impossible. This 
prevented the study demonstrating how the S. pyogenes numbers exhaled from the 
nasopharynx change quantitatively over this period. Thus, although the technique 
provided quantitatively useful information at certain levels of carriage, the main value 
of the technique was to longitudinally monitor the presence or absence of group A 
streptococci, rather than quantities. 
There was no such upper limit of quantification when biophotonic imaging was used 
to study S. pyogenes infection. Bioluminescent derivatives of an emm75 isolate were 
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created for use in this study. Whilst a strain bearing a non-integrating plasmid, 
H347pTHLK, was found to be brighter in vitro, the instability of this plasmid made this 
strain unsuitable for use in vivo. A strain of S. pyogenes with the luxABCDE operon 
integrated into the spy0535 locus, H347lux, was found to stably produce 
bioluminescence both in vitro and in vivo.   
During the course of intranasal infection, the bioluminescent signal was detectable 
within the first four days of infection, the period of infection where direct nasal 
sampling could not be used to reliably assess bacterial numbers.  However, BPI 
could not be used when there were less than 103 bacteria present in the 
nasopharynx, as the attenuation caused by the tissues of the mouse and the 
presence of a background signal limited the sensitivity of detection.   
In addition to this, it was found that the bioluminescent isolate utilised in this study, 
H347lux, was attenuated in growth relative to the wild type parental strain. The 
creation of an isogenic strain with a plasmid insertion in the same spy0535 locus 
confirmed that this attenuation was not due to the disruption of this gene region. The 
expression of bioluminescence itself was the reason for the fitness cost. 
The basis for the bioluminescence conferred by the luxABCDE operon comes from 
two reactions, of which the luxAB genes are the only ones which are essential for 
bioluminescence expression, as the products of the luxCDE reaction can be supplied 
exogenously. This could reduce the energy cost of bioluminescence by up to 67%, 
but the luxAB reaction still demands energy from intracellular stores of FMNH2 [308].  
While the long chain fatty acid aldehyde decanal can be supplied to enable luxAB to 
function, administration of this compound in vivo is complicated by its toxicity to 
animals. 
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In spite of this fitness deficit, bioluminescent S. pyogenes still maintained the ability 
to grow within the nasopharynx, and thus provide some useful information about 
infection. 
8.5. THE UTILITY OF BIOLUMINESCENCE IMAGING FOR EVALUATING VACCINES 
AND IMAGING INFECTION 
Non-invasive pharyngitis accounts for a large portion of S. pyogenes disease that is 
estimated to afflict 616 million people worldwide per year [1] and incurs an estimated 
cost of 224-539 million dollars per year to the USA [309]. To effectively prevent these 
diseases, vaccine candidates must ensure bacterial clearance during S. pyogenes 
pharyngitis [145,146,148]. 
In a number of previous studies, vaccines based on SpyCEP have shown some 
degree of efficacy in preventing death after the onset of pneumonia, and 
dissemination from an invasive disease. Few studies have demonstrated that 
immunisation against SpyCEP can facilitate bacterial clearance from the 
nasopharynx [147].  
BPI enables real time assessment of bacterial numbers in the nasopharynx, and was 
used to show that an immunisation strategy utilising SpyCEP could facilitate bacterial 
clearance from the nasopharynx using the previously described model of infection. 
The data suggest that this vaccine candidate may not only ensure protection against 
invasive disease, but may also prevent less invasive infections, making it an ideal 
component of any future developmental vaccine. Indeed, this antigen is included in a 
vaccine being developed by the company Novartis[310]. 
The real advantage of BPI is in the discovery of new niches and foci of infection that 
would not have been revealed in other situations. During the course of this work, it 
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was discovered that colonisation of the female urogenital tract regularly occurred 
following intranasal infection. It appeared likely that S. pyogenes was deposited 
genitally during the course of grooming. The mice which became infected in this 
region did not demonstrate any outward indication of infection such as inflammation 
or distress. Preliminary studies which involved administration of β-estradiol to control 
the oestrus cycle suggest that there may be a hormonal component to susceptibility. 
Further investigations are required in order to fully characterise how genital infection 
develops, and the underlying factors that govern it, and these will be discussed with 
regards to further work. It is known that S. pyogenes can cause vaginitis in pre 
pubertal children [106,311] and to a lesser extent in adults [312,313]. However, there 
are very few mouse models available to study this form of infection. The infection of 
the urogenital tract was only discovered in mice through the use of BPI, and 
demonstrates how readily S. pyogenes can spread between mucosal epithelial sites.  
8.6. COVR/S MUTATIONS IMPAIR S. PYOGENES COLONISATION OF THE 
NASOPHARYNX 
Mutations in the CovR/S gene regulator are known to facilitate a change to a 
phenotype that is considered to be more virulent [78,91,95,96,288]. Mutations in 
CovR/S have been shown to promote survival of S. pyogenes in mouse models of 
invasive infection [49,314]. Increased invasiveness was confirmed in a murine model 
of intramuscular infection in the current study using the emm75 pharyngitis isolate 
(H347) and an isogenic covR/S mutant (H494). As expected, the covR/S mutant was 
found to disseminate more readily to other organs than the wild type counterpart. In 
the context of infection in the nasopharynx however, the deletion of covR/S and the 
expression of a “hypervirulent” phenotype led to a different outcome. 
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In terms of both continuous carriage and the total duration of carriage, the covR/S 
mutant survived significantly less well than the wild type counterpart. The 
inflammation caused by the covR/S mutant was also diminished compared to the 
wild type when analysed histopathologically.  The utilisation of the previously 
described co-mingling model of transmission repeatedly showed that recipients 
housed with mice carrying covR/S mutant S. pyogenes did not acquire it as readily 
as those housed with mice carrying the wild type strain. This suggests a general 
deficit in the ability of the covR/S mutant to survive within, and transmit from the 
nasopharynx.  Settle plates were used to evaluate the presence of airborne S. 
pyogenes within these cages, and demonstrated no difference in the presence of 
either the wild type or the covR/S mutant in the air. This suggests that during the 
early stages of nasopharyngeal infection both the covR/S mutant and the wild type 
strains are aerosolised equally from the nasopharynx, but that, nonetheless, 
transmission occurs more readily from mice infected with the wild type strain. The 
numbers of S. pyogenes shed from the nasopharynx during the earlier phases of 
infection were above the upper limit of quantification by direct nasal sampling, and 
thus made it very difficult to determine whether contact-related shedding differed 
between the groups. Given that airborne transmission was similar in these early 
stages, it seemed likely that shedding would be similar. Taken together, the data 
suggest that transmission of wild-type bacteria was greatest because the wild type 
bacterium is better able to productively infect recipient mice.  
Whilst the covR/S mutant survived less well than its wild type counterpart within the 
nasopharynx, the question of whether it could disseminate systemically from this 
region remained open. A bioluminescent derivative of the covR/S mutant was 
generated to answer this. In initial intranasal infection studies, dissemination to 
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various lymph nodes was observed in one mouse. However, further characterisation 
of this bioluminescent covR/S mutant revealed a worrying discrepancy.  With regard 
to the total duration of shedding, there was no significant difference between the 
bioluminescent covR/S mutant and the isogenic bioluminescent counterpart 
expressing a functional covR/S locus. Indeed, in contrast to findings with non-
bioluminescent strains, the bioluminescent covR/S mutant survived longer in the 
nasopharynx than the bioluminescent strain expressing wild type covR/S. It 
appeared likely that any fitness cost or advantage imparted by the deletion in covR/S 
was compensated for by the overwhelming fitness cost of expression of the 
bioluminescence operon. The energy cost incurred by bioluminescence could be 
implicated, as it would consume resources that would otherwise be used to produce 
virulence factors and ensure bacterial survival. The loss of covR/S could conceivably 
upregulate the production of these factors to levels that match the wild type. Whilst 
the duration of continuous carriage was longer, the total duration of carriage was not 
different to the wild type. This may suggest that in this situation the covR/S mutant is 
impaired in its capacity to transmit and re-infect after the initial cessation of 
shedding.  This is speculation, and further work will be required to fully elucidate the 
interfering effects of bioluminescence expression on S. pyogenes pathogenesis. 
In spite of these issues, it was clear that covR/S mutation in non-bioluminescent S. 
pyogenes impaired bacterial survival within the nasopharynx. Previous studies have 
revealed that the inactivation of covR/S impairs biofilm formation and adhesion to 
cells derived from the nasopharynx and the skin [97]. The covR/S mutant utilised in 
this study was also attenuated with respect to biofilm formation. This impairment with 
respect to biofilm formation may explain why the covR/S mutant survives less well 
within the nasopharynx. The failure to produce biofilm may allow bacteria to be 
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cleared by the host in spite of their increased virulence factor production. covR/S 
mutant S. pyogenes strains produce an abundance of virulence proteins related to 
resistance to phagocytosis such as SpyCEP and the hyaluronic acid capsule 
biosynthesis enzymes. It is conceivable that capsule may impede colonisation of the 
nasopharynx by concealing important adhesion ligands. The deficit in 
nasopharyngeal survival and transmissibility conferred by mutations in covR/S may 
explain why such bacteria have not become prevalent in community S. pyogenes 
infections despite being advantageous in invasive infection. 
8.7. SUMMARY 
The models described in this work represent refinements of previous systems to 
study upper respiratory tract infection by S. pyogenes; each model is non-invasive 
and allows longitudinal monitoring of bacterial infection, using the same mice 
throughout the study. This has facilitated research which might have otherwise 
required prohibitively large numbers of animals. 
The direct nasal sampling technique and the co-mingling model of transmission have 
revealed similarities between mouse and human infection, and some differences that 
needed to be accounted for when translating the findings of this research into the 
human setting. The studies have also revealed for the first time that covR/S mutation 
impedes infection of, and transmission from the nasopharynx. 
Through application of BPI to study infection in the nasopharynx this work 
demonstrated that immunisation with a vaccine candidate based on SpyCEP 
provides protection during infection in the nasopharynx. The capacity of BPI to 
directly quantify bacterial numbers during the course of infection enabled vaccine 
efficacy to be assessed based on bacterial clearance rather than host survival. 
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Importantly, the expression of bioluminescence was not in itself neutral to the 
pathogenesis of S. pyogenes. It was found to confer a slight fitness defect in vitro, 
and impaired the competitiveness of S. pyogenes in vivo. Furthermore the change in 
the infectious phenotype caused by the expression of bioluminescence interfered 
with the effects of covR/S mutation in this model.  
BPI has the potential for providing useful insights into the pathogenesis of infection. 
However these insights must be tempered by the knowledge of its flaws, and the 
acknowledgement that its applicability may be limited in certain situations.  BPI is a 
powerful technique, but must be utilised with care and precision if it is to fulfil its 
potential.   
8.8. FURTHER WORK. 
8.8.1. CHARACTERISATION OF THE FVB/N MOUSE STRAIN SUSCEPTIBILITY TO S. 
PYOGENES 
In this work, the FVB/n mouse strain was found to be susceptible to S. pyogenes 
colonisation. However, the reasons for this susceptibility remain unknown. Other 
work investigating the relative susceptibility of different strains of mice to S. 
pyogenes infection such as BALB/k and C3H/HeN have been linked to the variants 
of MHC class II molecules encoded by the H2k region. Whilst this locus of 
susceptibility has been shown to be important in the course of invasive infection, it is 
not known whether this has a significant effect during the course of nasopharyngeal 
infection. Differences in innate immunity, for example in complement or AMP’s, are 
most likely to impact upon susceptibility to infection with bacteria such as S. 
pyogenes. In addition to simple cytometric comparisons of neutrophil numbers, and 
absolute concentrations of complement and AMP, simple ex vivo bacterial killing 
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experiments comparing serum opsonic activity using donor neutrophils could 
address this potentially.  Comparative whole genome sequencing of the FVB/n 
mouse should reveal candidate loci. If a different locus is responsible for the 
susceptibility of the FVB/n strain to S. pyogenes, its characterisation may provide a 
useful insight into the underlying factors governing the susceptibility of humans to S. 
pyogenes infection. In addition to this, without more detailed knowledge of the 
factors governing the susceptibility of the FVB/n mouse, this trait may accidentally be 
bred out of the strain. 
8.8.2. THE STUDY OF THE COMMENSAL BACTERIA WITHIN THE MURINE 
NASOPHARYNX BEFORE AND DURING S. PYOGENES INFECTION 
The presence of commensal bacteria within the nasopharynx was briefly investigated 
during this study with the sole aim of differentiating commensal bacteria from 
exogenously administered S. pyogenes. None of the commensal strains documented 
in this study were fully speciated, and the use of CBA for direct nasal sampling may 
have biased the findings in favour of bacteria that are better able to grow on CBA. 
Certain classes of commensals, such as Haemophilus and Pseudomonas were more 
frequently recovered after the onset of S. pyogenes infection. Whether this was due 
to an actual increase in the presence of these bacteria after infection, or whether it 
was a recovery artefact due to the extensive haemolysis caused by the presence of 
S. pyogenes onto CBA is unclear.  It is believed that S. pyogenes can interact with 
other commensal species such as Streptococcus salivarius via the production of 
signalling peptides [315] and lantibiotics which can inhibit the growth of commensal 
bacteria within the nasopharynx [316]  
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To better investigate this, direct nasal sampling onto a number of different media 
could be performed, and genomic techniques could be utilised to speciate the 
commensals which naturally inhabit the nasopharynx, and observe how the 
presence of S. pyogenes in this region alters the abundance of these commensals 
and determine whether this interaction plays a role in infection. 
8.8.3. THE CHARACTERISATION OF S. PYOGENES INFECTION OF THE 
UROGENITAL TRACT AFTER INFECTION IN THE NASOPHARYNX 
In the course of these studies, colonisation of the mouse urogenital tract was 
observed to occur in some mice as a consequence of nasopharyngeal infection. In 
preliminary studies, mice that had been pre-treated with β-estradiol showed an 
increased susceptibility to urogenital colonisation. There are a number of factors 
which need to be further understood before this could be used to devise a model of 
S. pyogenes vaginitis. The phase of oestrus in which the mouse urogenital tract 
becomes susceptible to infection needs to be characterised. The bacterial content of 
this tract must also be studied, in order to see whether any other bacteria take 
advantage of this susceptibility. Isolates of S. pyogenes from cases of vaginitis would 
need to be tested, in order to determine whether they have a greater tendency to 
colonise this region than other strains, and whether there are any aspects of their 
phenotype which enable their infection of this region.  
S. pyogenes has also been long known to cause puerperal sepsis, an invasive 
disease which generally occurs after childbirth. Sepsis is believed to result from an 
ascending S. pyogenes infection that exploits the recently parturient genital tract as a 
portal of entry. However, strains that cause puerperal sepsis are not generally 
carried in the genital tract prior to childbirth and appear to be acquired shortly before 
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invasive infection occurs, from the respiratory tract of either the patient, family 
member, or healthcare worker[317]. The factors, including strain type, that govern 
transmission from the respiratory tract to the genital tract are therefore important. An 
extension to the characterisation of a mouse model of vaginitis would be to develop 
a mouse model of puerperal sepsis using pregnant mice to dissect the factors which 
underlie the susceptibility to this disease. 
8.8.4. FURTHER STUDIES ON TRANSMISSION, AND THE RELATIVE IMPACT OF 
MOUSE BEHAVIOUR 
The emm75 isolate used in this study was found to be readily transmitted from 
infected mice to uninfected recipients housed in the same cage. Whilst these 
recipient mice carried emm75 S. pyogenes, it appeared that this represented 
asymptomatic carriage as opposed to clinical infection. However, other pharyngitis 
strain types of S. pyogenes, such as the emm1 and emm12 strains studied in this 
work, showed a greater capacity for virulence during nasopharyngeal infection. As 
has been shown in this work, the numbers of bacteria shed from the nose correlate 
with actual bacterial abundance in the nasopharynx. The emm1 and emm12 strains 
may prove to be more transmissible and better able to result in a productive infection 
than the emm75 strain utilised in this study, and may thus be better suited to 
represent the entire transmission and infection cycle of S. pyogenes. Such a 
transmission model could then be used to test whether vaccinated recipients are 
more susceptible to infection than adjuvant vaccinated or unvaccinated recipients. 
The model could also be used to develop a system to study outbreaks that have 
been strongly associated with highly virulent emm types such as emm1. 
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The model was used in this work to demonstrate the relative impairment of a covR/S 
mutation with respect to transmission. The phenotypic effect was dramatic enough to 
be detected in spite of the relative variability in transmission between mice. As a 
result of this variability, mutations which exert more subtle effects may not be as 
readily detectable.  
One of the sources of variability stems from the behaviour of the mice themselves, 
and the manner in which they interact. To control for this, specialised equipment may 
be required. The construction of housing in which a partition prevents infected donor 
mice from physically interacting with recipient mice, but allowing for the free passage 
of air would enable this to some extent.  But even in this situation, the activity of mice 
would be a source of variability. In studies in humans, airborne transmission of 
bacteria such as S. pyogenes and S. aureus was found to be increased during 
physical exercise [101,318]. A number of technologies could be adapted to monitor 
the relative effects of this movement. Piezoelectric sensors could be employed to 
gauge the total movement within a cage during different time periods, and the 
difference this exerts on the production of airborne S. pyogenes could be detected 
using settle plates. Recent advances in motion tracking using high frame rate 
cameras can potentially be used to track the interactions of mice with each other and 
their surroundings and comprehensively control for the effects of movement and 
aggressive behaviours. However, this particular technology has not yet been 
developed for such a purpose.  
The development of a standardised model of transmission that more accurately 
represents the S. pyogenes pathogenic cycle will enable the more effective testing of 
strategies to prevent outbreaks of infection and lead to a greater understanding of 
how this lethal organism spreads within households and institutions.  
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Abstract
Streptococcus pyogenes is a leading cause of pharyngeal infection, with an estimated 616 million cases per year. The human
nasopharynx represents the major reservoir for all S. pyogenes infection, including severe invasive disease. To investigate
bacterial and host factors that influence S. pyogenes infection, we have devised an improved murine model of
nasopharyngeal colonization, with an optimized dosing volume to avoid fulminant infections and a sensitive host strain. In
addition we have utilized a refined technique for longitudinal monitoring of bacterial burden that is non-invasive thereby
reducing the numbers of animals required. The model was used to demonstrate that the two component regulatory system,
CovR/S, is required for optimum infection and transmission from the nasopharynx. There is a fitness cost conferred by covR/
S mutation that is specific to the nasopharynx. This may explain why S. pyogenes with altered covR/S have not become
prevalent in community infections despite possessing a selective advantage in invasive infection.
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Introduction
Streptococcus pyogenes is estimated to cause 616 million cases of
pharyngeal infection per year, and 663,000 cases of invasive
disease [1]. As the human nasopharynx represents the major
reservoir for all types of S. pyogenes infection, it is essential to
develop a better understanding of the factors that influence upper
respiratory tract infection.
Despite their limitations, mice play an important role in
infectious diseases research [2]. The mouse nasopharynx has
structural similarities to the nasal turbinate system in humans [3],
although mice lack tonsils [4]. Instead, mice possess nasal
associated lymphoid tissue (NALT), which shares some similarity
to the tonsils [5] and has been shown to be a target for infection by
S. pyogenes [6]. Indeed, mice have been used by several groups to
investigate S. pyogenes in the upper respiratory tract, although there
is no consensus on which is the most appropriate strain, sex or age
of animal to use [6,7,8,9,10]. Furthermore, the maximum dose
volume posited for establishing infection by previous studies ranges
from 5 ml, as determined by administration of colored dye [8,11],
10 ml as determined by radioactive microspheres [10,12], to 20 ml
volumes [6]. This is an important consideration, as aspiration of
the bacteria into the lungs has the potential to trigger a more
invasive disease and systemic infection.
It is known that phenotypic differences can exist between
nasopharyngeal and invasive S. pyogenes isolates, and these have
been ascribed to altered activity or mutation of the streptococcal
two component regulatory system, covR/S [13]. As a result of
signalling from the sensor kinase, CovS, CovR represses a range of
virulence factors concerned with resistance to phagocytosis, such
as the capsule synthesis operon hasABC, the DNase, sda, and the
CXC chemokine protease, SpyCEP [13,14,15,16,17]. Mutations
in covR/S de-repress these virulence genes, conferring a selective
advantage to S. pyogenes in mouse models of invasive infection,
leading to greater mortality [15,18]. However, the impact of such
mutations on nasopharyngeal infection is unclear. Isolates of S.
pyogenes with covS mutations bind less well to skin cells in vitro and
in vivo than those without the mutation [19]. Furthermore, S.
pyogenes with mutations in covS lack competitiveness in the saliva
relative to wild type [20].
In this work, we set out to produce a longitudinally monitored
murine model of nasopharyngeal infection, by examining the
effect of mouse strain, age and sex on S. pyogenes carriage. We
evaluated S. pyogenes pharyngitis isolates from patients rather than
a previously-described mouse-pathogenic strain that lacks a func-
tional copy of the multigene activator, mga [21,22]. The improved
nasopharyngeal infection model was used to evaluate the impact of
the S. pyogenes CovR/S two component regulatory system on
longevity and transmission of S. pyogenes upper respiratory tract
infection.
Methods
Ethics Statement
In vivo experiments were performed in accordance with the
Animals (scientific Procedures) Act 1986, subject to protocols set
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61655
out in PPL 70/7379 that were approved by the Imperial College
Ethical Review Process (ERP) panel and the UK Home Office.
Bacterial Strains
The bacterial strains used in this study are given in Table 1
[16,23,24]. Streptococcal strains were cultured in Todd Hewitt
Yeast broth (THY) or on Columbia Blood Agar (CBA), while
Luria Bertani (LB) medium was used for culturing C. rodentium
ICC180. All strains were grown at 37uC. For animal experiments,
S. pyogenes was grown without shaking with 5% CO2 overnight,
centrifuged at 18646g, (Sorvall RTH 750 Rotor), washed twice in
phosphate buffered saline (PBS), and re-suspended in PBS to
produce an inoculum of 1–76108 colony forming units (cfu) per
5 ml. Numbers of viable bacteria within the inoculum were
retrospectively assessed by plating of 1026–1028 dilutions of the
inoculum onto agar.
Animals
Male and female 5–10 week old CD1, C57BL/6, A/J, BALB/c,
FVB/n specific-pathogen free mice (Harlan, UK) were maintained
in individually HEPA filtered cages with sterile bedding and free
access to sterilized food and water. GLP Mini Fun Tunnels
(Lillico), or Des. Res. Mini Mouse Houses (Lillico) were provided
in each cage for environmental enrichment.
Intranasal Infection
Pilot experiments were conducted using ,109 cfu in doses of
2.5 ml–20 ml bioluminescent C. rodentium ICC180 [24] to de-
termine the correct dosing strategy to deliver bacteria to the
murine nasopharynx without lung involvement. Bioluminescence
(as photons s21 cm22 steridian [sr] 21) from living animals was
performed as previously described [24] using an IVISH 100 system
(Perkin Elmer).
For streptococcal infection of the nasopharynx, 1–76108 cfu of
S. pyogenes was administered intranasally using a pipette to mice in
a volume of 2.5 ml per nostril under 2–5% isoflurane anaesthesia.
Mice were weighed daily; reduction by 20% of original weight was
a defined humane endpoint.
Intramuscular Infection
66108 cfu S. pyogenes were administered to mice under isoflurane
anaesthesia via injection with a 27 gauge needle into the right
lateral thigh. Numbers of viable bacteria within the inoculum were
assessed by retrospective plating of 1026–1028 dilutions. At 72
hours, the right thigh muscle and ipsilateral inguinal node were
extracted, weighed and homogenized into PBS and then plated
out onto CBA for bacterial enumeration.
Table 1. Bacterial strains used in this study.
Strain Designation Emm type Species Description Ref.
H305 emm1 S. pyogenes Scarlet fever reference strain [23]
H343 emm2 S. pyogenes Pharyngitis isolate [16]
H292 emm81 S. pyogenes Blood isolate [16]
H347 emm75 S. pyogenes Pharyngitis isolate [16]
H494 emm75 S. pyogenes Strain H347 with an inactivated covR/S operon [16]
ICC180 C. rodentium Bioluminescent derivative of ICC169 [24]
doi:10.1371/journal.pone.0061655.t001
Figure 1. Bioluminescence imaging of bacterial distribution after intranasal inoculation with bioluminescent C. rodentium. 109 colony
forming units (cfu) of bioluminescent C. rodentium were administered intranasally to 8 week old CD1 outbred female mice in 20 ml (n = 3), 10 ml
(n = 2), 5 ml (n = 3) and 2.5 ml (n = 2) of PBS. Images were acquired using an IVIS spectrum system, and are displayed as images of peak
bioluminescence, with variations in colour representing light intensity at a given location. Red represents the most intense light emission, while blue
corresponds to the weakest signal. The colour bar indicates relative signal intensity (as photons s21 cm2 sr21). Two representative mice shown for
each group.
doi:10.1371/journal.pone.0061655.g001
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Nasal Sampling
The level of shedding of S. pyogenes from the nasopharynx was
assessed longitudinally using direct nasal sampling. The nares of
each mouse were gently pressed onto the surface of a CBA plate
ten times. Exhaled particulates were streaked out, and the plates
were then incubated overnight at 37uC with 5% CO2 for bacterial
enumeration. In preliminary experiments using naive, non-
infected mice, a-hemolytic streptococci, staphylococci, pseudomo-
nads and corynebacteria were recovered, but no b hemolytic
Group A streptococci were found to naturally colonize the mouse
nasopharyngeal tract.
For experiments where mice had been infected with S. pyogenes,
b-hemolytic colonies were counted for each mouse and confirmed
as S. pyogenes through Gram staining, catalase testing, oxidase
testing, and Lancefield grouping. No other b-haemolytic bacteria
were recovered from the mouse nasopharynx. Kaplan-Meier plots
were created to analyse the duration of S. pyogenes shedding. Nasal
samples were taken for 21 days post inoculation. Mice were
determined to have stopped shedding upon the first instance of
a nasal sample turning up negative.
In some studies, the nasopharynx was dissected and removed at
fixed time points for microbiological culture. To ensure complete
extraction of the nasopharynx, the skin and mandibles were
removed to expose the cranium. This was then sectioned along the
coronal plane at the bregma. The brain tissue within the cranium
anterior to this incision was removed, exposing the posterior aspect
of the nasal cavity, known as the cribriform plate. The orbits were
removed from this tissue via sagittal incisions lateral to the pre-
maxilla. The remaining tissue comprised the entire nasal cavity,
and NALT. This was homogenized into PBS and serial dilutions
plated onto CBA to quantify S. pyogenes from the whole
nasopharynx.
Settle Plates
To detect the presence of airborne bacteria within cages of
infected mice, CBA plates were placed in the upper rack of the
individually HEPA filtered cages (n = 4 plates per cage) and
exposed for defined time periods throughout each experiment.
Plates then incubated overnight at 37uC and the numbers of S.
pyogenes colonies, (identified by Gram staining, catalase testing, and
Lancefield grouping) were enumerated.
Histopathology
The head of each mouse was removed at the atlanto-occipital
joint and sagittally hemi-sected. One half was fixed in formalin
and processed routinely to paraffin wax, while the other was
homogenised and plated to assess S. pyogenes numbers in the
nasopharynx. Paraffin sections were cut at 6 mm and stained
with Haematoxylin and Eosin and Gram stains. The degree of
nasal damage and inflammation was scored as : No significant
abnormality (Intact nasal mucosa and absence of inflammation),
Mild (Focal erosion of the mucosa with local neutrophil
exocytosis across the affected epithelium), Moderate (Focal
necrosis and ulceration of the mucosa with local neutrophilic
exocytosis and surface neutrophilic exudation), Marked (Exten-
sive necrosis and ulceration of the mucosa with widespread
neutrophilic exocytosis and surface neutrophilic exudation) and
Severe (Extensive necrosis and ulceration of the mucosa with
widespread neutrophilic exocytosis and surface neutrophilic
exudation and with extension of necrosis into underlying
stroma). Slides were reviewed and scored by an experienced
histopathologist (KS).
Statistics
For statistical analysis of Kaplan-Meier curves, the Mantel-
Cox Logrank test was applied. For statistical analysis of colony
count comparisons, a non-parametric Kruskal-Wallis test and
Dunn’s post-test were used. P values less than 0.05 were defined
as significant. Statistics were performed using Prism Graphpad
version 5.02. Data are presented as median, 6 interquartile
range.
Results
Volume of Inoculum Determines Distribution within the
Respiratory Tract
Bioluminescence imaging demonstrated that dose volumes of
20 ml volume delivered bacteria to the lungs, whereas this was
not shown with lower volumes (Figure 1). Any dose volume
above 10 ml was deposited in the trachea. Dose volumes of 5 ml
and 2 ml did not distribute bacteria to the lungs. As the optimal
dose volume for nasopharyngeal deposition without lung
involvement or significant nasal clearance was 5 ml (2.5 ml per
nostril), this was the volume used in subsequent experiments.
Figure 2. Correlation between S. pyogenes recovered from nasal
shedding and from nasopharyngeal dissection. Data are pooled
from direct nasal samples taken on days 3, 7, and 14 from five week old
female FVB/n mice during intranasal infection with emm75 S. pyogenes
(1.36108 cfu) were compared to bacterial numbers obtained on
dissection on the same days. (r2.0.95, n = 36). Data shown from
individual mice.
doi:10.1371/journal.pone.0061655.g002
Table 2. Duration of shedding of different strains of S.
pyogenes (76108 cfu per 5 ml dose) in 8 week old male BALB/c
mice after intranasal infection.
Number of mice shedding S. pyogenes
Day 1 Day 2 Day 3
emm1 0/7 0/7 0/7
emm2 1/7 1/7 1/7
emm75 4/7 3/7 2/7
emm81 1/7 0/7 0/7
doi:10.1371/journal.pone.0061655.t002
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Nasopharyngeal Shedding as a Method to Longitudinally
Monitor S. pyogenes Infection in the Upper Respiratory
Tract
To select an appropriate bacterial strain for development of the
model, BALB/c mice were intranasally inoculated with four
clinical S. pyogenes strains of different emm genotypes. An emm75
pharyngitis strain was found to have shed for the longest period
using direct nasal sampling (Table 2) and was used in subsequent
experiments. Importantly, a significant correlation was found
between the numbers of colonies recovered from nasal shedding of
S. pyogenes and bacterial numbers from dissected and homogenised
nasal tissue on the same day (Figure 2, r2.0.95, n = 36). This
longitudinal method of monitoring was therefore employed in
subsequent experiments consistent with the principles of the 3Rs
(Replacement, Refinement, and Reduction) by reducing the
numbers of animals used.
Longevity of Nasopharyngeal Shedding is Greater in FVB/
n Mice
To determine the most appropriate mouse strain for model
development, male mice of different host backgrounds were
infected intranasally with emm75 S. pyogenes, and observed
longitudinally for 72 h using direct nasal sampling. Data were
used to create Kaplan Meier plots to analyse the duration of
shedding for each strain of mouse (Figure 3 A). FVB/n mice
carried S. pyogenes longer and shed significantly more S. pyogenes on
the final day of the time course than all other strains tested
Figure 3. Comparison of nasopharyngeal shedding of S. pyogenes between different mouse strains. Five week old male mice of different
strain backgrounds were inoculated intranasally with emm75 S. pyogenes (1.56108 cfu). Duration and quantity of shedding were determined from
colonies recovered from direct nasal sampling of the mouse nasopharynx. (A) Kaplan-Meier plot showing percentage of mice shedding S. pyogenes in
each group. (B) Bacterial counts shed by FVB/n (n = 8) CD1 (n = 14), BALB/c (n = 14), C57BL/6 (n = 12) and A/J (n = 6) at 72 hours. Individual points
represent individual mice. (Kruskal Wallis with Dunns Post Test p,0.05). Bars indicate the median, ND = no detectable bacteria.
doi:10.1371/journal.pone.0061655.g003
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(Figure 3 B). FVB/n mice carried S. pyogenes were therefore used
for all future studies.
Gender has an Effect on the Nasopharyngeal Carriage of
S. pyogenes that is Dependent on the Age of the Mice
To determine whether gender influenced S. pyogenes infection of
the nasopharynx, peri pubertal (n = 10 per group, 5 per cage, 5
Figure 4. Sex differences in S. pyogenes nasopharyngeal carriage and shedding intensity in 5 week old mice. Male and female FVB/n
mice 5 weeks (A, p.0.05 Mantel–Cox Logrank test, n = 10) of age were infected intranasally with emm75 S. pyogenes (1.16108 cfu) and sampled non-
invasively through direct nasal sampling over 21 days. Shedding intensity maps display the data from direct nasal samples throughout the time
course from the male mice (B) and the female mice (C). Rows indicate individual mice throughout the time course, colours indicate the numbers of S.
pyogenes recovered from direct nasal samples with red indicating the highest recorded levels of carriage ($5000 cfu) and green indicates the lowest
levels of carriage (1 cfu) and blank blocks indicate no recovery of S. pyogenes. Black line indicates survival based on the first loss of carriage.
doi:10.1371/journal.pone.0061655.g004
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Figure 5. Sex differences in S. pyogenes nasopharyngeal carriage and shedding intensity in 10 week old mice. Male and female FVB/n
10 weeks (A, p,0.05 Mantel–Cox Logrank test, n = 10) of age were infected intranasally with emm75 S. pyogenes (1.16108 cfu) and sampled non-
invasively through direct nasal sampling over 21 days. Male mice carried S. pyogenes for significantly longer than the female mice in this age group.
Shedding intensity maps display the data from direct nasal samples throughout the time course from the male mice (B) and the female mice (C).
Rows indicate individual mice throughout the time course, colours indicate the numbers of S. pyogenes recovered from direct nasal samples with red
indicating the highest recorded levels of carriage ($5000 cfu) and green indicates the lowest levels of carriage (1 cfu) and blank blocks indicate no
recovery of S. pyogenes. Black line indicates survival based on the first loss of carriage.
doi:10.1371/journal.pone.0061655.g005
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weeks of age) and post pubertal (n = 10 per group, 5 per cage, 10
weeks of age) male and female FVB/n mice were intranasally
inoculated with S. pyogenes. There was no significant difference in
infection duration between 5 week old males and females over a 21
day period (Figure 4, Logrank p.0.05), whereas 10 week old males
shed S. pyogenes for significantly longer than 10 week old female
mice (Figure 5, Logrank test p,0.05). However, the older males
had to be housed separately to prevent intraspecific aggression and
for this reason further experiments were conducted using female
mice.
Figure 6. Nasopharyngeal infection is adversely affected by covR/Smutation. Five week old female FVB/n mice were inoculated intranasally
with either emm75 S. pyogenes, or DcovR/S S. pyogenes. To determine the duration of shedding, direct nasal samples were taken over a 21 day period.
The wild type strain was shed over a significantly longer time period than the DcovR/S strain (A, 1.56108 cfu per dose, n = 20 per group, Logrank
Mantel Cox p,0.05). Shedding intensity maps display the data from direct nasal samples throughout the time course from the groups infected with
the wild type emm75 strain (B) and the mice infected with the DcovR/S strain (C). Rows indicate individual mice throughout the time course, colours
indicate the numbers of S. pyogenes recovered from direct nasal samples with red indicating the highest recorded levels of carriage ($5000 cfu) and
green indicates the lowest levels of carriage (1 cfu) and blank blocks indicate no recovery of S. pyogenes. Black line indicates survival based on the first
loss of carriage.
doi:10.1371/journal.pone.0061655.g006
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DcovR/S Mutation is Detrimental to Long Term S.
pyogenes Infection of the Nasopharynx
Two groups of FVB/n female mice (n = 20, 5 per cage) were
infected intranasally with 5 ml of 108 cfu of emm75 S. pyogenes or an
isogenic DcovR/S strain and observed over 21 days. Kaplan Meier
analysis of daily nasal samples demonstrated that the DcovR/S
strain was shed from the nasopharynx for a shorter length of time
compared to its wild type counterpart. (Figure 6, Mantel Cox
Logrank p,0.05).
We considered the possibility that the reduced longevity of
infection reflected a general fitness defect in the DcovR/S strain.
However, following intramuscular infection of groups of mice with
each strain, both the DcovR/S strain and wild-type strain survived
equally well within the thigh muscle (n = 12 per group, 6 per cage,
Figure 7 A). Furthermore the DcovR/S strain disseminated to the
ipsilateral inguinal lymph node in greater numbers than the wild-
type (Figure 7 B, p,0.05 Mann-Whitney), consistent with the
predicted phenotype of a DcovR/S strain. Streptococci were
detected in the liver (Figure 7 C) and in the spleen (Figure 7 D),
but these differences were not significant.
Intranasal Administration of S. pyogenes Results in
a Suppurative Upper Respiratory Tract Infection that
Resolves Over 21 Days
5 week old female FVB/n mice infected with emm75 S. pyogenes
demonstrated inflammatory changes affecting the nasal cavity over
the first week of infection (Figure 8, A–D), particularly in the
caudal (ethmoturbinate) region. A moderate to marked suppura-
tive rhinitis with complete erosion or ulceration of the nasal
mucosa and neutrophilic exudate on the mucosal surface was
observed. On days 3 and 7, mice occasionally demonstrated
necrosis of underlying turbinate bone and extension of in-
flammation and infection across the cribriform plate, resulting in
a localized meningoencephalitis affecting the olfactory bulbs (data
not shown). However, by Day 21, the inflammatory damage to the
nasal mucosa had resolved. The S. pyogenes DcovR/S strain elicited
a similar inflammatory response (Figure 8, E–H), albeit over
a slightly shorter time period. Mice demonstrated mild to marked
suppurative rhinitis at days 3 and 7 that resolved by day 14. Both
strains of S. pyogenes could be recovered from cultures of the
nasopharynx from mice even after the inflammation resolved
(Data not shown). Semi quantitative assessment of sections from
mice infected with both the wild type and DcovR/S emm75 strains
were undertaken in comparison with control sections from
uninfected mice; this demonstrated that the observed inflamma-
Figure 7. The effects of covR/S mutation on dissemination from an invasive intramuscular infection. Five week old FVB/n female mice
(n = 12) were infected intramuscularly in the right thigh with either wild type S. pyogenes or an isogenic DcovR/S strain (66108 cfu per dose). After
three days there was no significant difference in bacterial growth within the thigh (A, Mann Whitney U p.0.05), but there was a significant difference
in bacterial numbers that had disseminated to the inguinal node (B, Mann Whitney U p,0.05). No significant difference in dissemination to the liver
(C) and the spleen (D) was found between the wild type and the DcovR/S strains. Median indicated by a black line.
doi:10.1371/journal.pone.0061655.g007
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Figure 8. Histopathological analysis of the caudal nasal cavity during long term nasal infection. Photomicrographs demonstrating five
week old female FVB/n mice infected with either the emm75 S. pyogenes (A–D) or the emm75 DcovR/S strain (E–H) (1.56108 cfu per dose, n = 3 per
group) were taken at days 3, 7, 14 and 21 after inoculation (Haemotoxylin & Eosin staining). n= Neutrophilic Exudate, m= Nasal mucosa, s= Nasal
stroma. Scale bar as shown. Damage to the nasal mucosa with surface neutrophilic exudate was apparent at day 3 post inoculation with both strains
(A & E). The nasal epithelia of mice in both groups were widely eroded or ulcerated by day 7 (B) than those infected with the DcovR/S strain (F). At day
14 the inflammation had begun to resolve in both strains (C & G). By day 21, mice in all groups had histologically normal mucosa (D & H). Control
mice over the time course are shown in (I–L). Semi quantitative analysis of the histopathology was undertaken to determine the severity of infection
and assigned a numerical designation for each time point (n = 3 mice per time point). 2= No significant abnormality,+= Mild,++= Moder-
ate,+++= Marked,++++= Severe and ND = Non diagnostic sections (M).
doi:10.1371/journal.pone.0061655.g008
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tion decreased throughout the time course consistent with the
lowering of the bacterial load (Figure 8 I–M).
Transmission of S. pyogenes within a Mouse Cage is
Dependent on the Proportion of Infected Donor Mice
Present
Preliminary work showed that S. pyogenes shed by infected mice
could lead to the infection of uninfected mice in the same cage.
Transmissibility of S. pyogenes in the nasopharynx was formally
investigated through introducing infected donor mice into cages of
uninfected recipient mice (n = 8 per cage). The effect of varying
the ratio of donor to recipient (D:R) mice present in a cage on
transmission was evaluated.
Within 4 hours of donor introduction transmission occurred to
all recipients. A higher D:R ratio resulted in greater counts of S.
pyogenes cultured from recipient mice in those cages. Recipient
mice in the cage with a D:R ratio of 4:4 had significantly more
bacteria in the nasopharynx compared to mice in the cage with
a D:R ratio of 2:6 (Figure 9 p,0.05).
DcovR/S Mutation is Detrimental to the Transmission of S.
pyogenes in a Mouse Model
Mice were observed over the first three days of infection, when
shedding of the wild-type and the DcovR/S strain were shown to be
similar, to determine whether a mutation in covR/S affects
transmission.
Female FVB/n mice infected with either the wild-type or the
DcovR/S strains were introduced into cages at a D:R ratio of 3:5.
After inoculation, the infected mice were separated for six hours
before being introduced to the recipients, to prevent passive
inoculum transfer. Direct nasal samples were taken from recipient
mice over three days after the introduction of the donor mice.
Recipient mice housed with donor mice carrying wild type S.
pyogenes acquired significantly more bacteria over the time course
than the recipient mice housed with donor mice carrying the
DcovR/S strain (Figure 10 A, AUC analysis, with Mann Whitney U
p,0.05).
There was no statistically significant difference in the abun-
dance of airborne S. pyogenes in the cages of mice infected with the
wild-type compared with the cages of mice infected with the
DcovR/S strain. (Figure 10 B, AUC analysis with Mann Whitney U
p.0.05).
Discussion
To facilitate the investigation of bacterial and host factors that
influence S. pyogenes in nasopharyngeal infection, an improved, new
model of nasopharyngeal colonisation was devised, with an
optimised dosing volume to avoid fulminant infections. A non-
invasive method of longitudinal monitoring was developed that
does not require culling of mice at multiple time points, thus
reducing the numbers of animals used.
An emm75 strain of S. pyogenes was found in preliminary
experiments to be carried better than other emm types by
BALB/c mice, although previous studies have however found
that the BALB/c strain is more resistant to infection than other
strains [9]. A number of mouse strains were therefore tested in this
study, of which the FVB/n was found to be the most susceptible to
S. pyogenes intranasal infection. Emm types 1, 2, 3, 4, 6, 12, 22 and
89 were also successfully carried by FVB/n mice (data not shown),
although in some cases causing a far more severe disease than the
emm75 strain, making them unsuitable for long term infection
studies.
We found that gender had an impact on susceptibility to
carriage in post pubertal mice only. Data were consistent with
other published work demonstrating an increase in susceptibility to
infection in male mice [9,25]. However, the intraspecific
aggression expressed by males of this strain made them difficult
to house in groups, and thus the older individuals were housed
individually. In previous studies, housing mice singly has been
demonstrated to increase immune responses [26,27,28], and
would theoretically increase their resistance to infection.
Histological analysis during infection revealed that nasal
shedding of S. pyogenes was associated with on-going inflammation
that subsided in the second and third weeks of infection. Previous
studies have demonstrated bacterial infection of the mouse NALT
[6]. However this study focussed on the site of infection in the
deeper nasal passages, which demonstrated a suppurative rhinitis.
Studies have shown that S. pyogenes distributes to the ethmoid
sinuses in humans during rhinosinusitis [29,30].
The model was used to demonstrate that a functional covR/S is
required for optimum infection and transmission from the
nasopharynx. The failure of the DcovR/S strain to survive in the
mouse nasopharynx was not due to a consistent fitness burden,
since in invasive infection, the covR/S strain disseminated in
significantly greater numbers than the wild type bacteria to the
inguinal lymph node.
During preliminary experiments, we became aware that in-
dividual mice occasionally became re-infected after clearing the
initial infection. To address transmission, and the factors that may
influence this, co-mingling experiments were conducted. These
demonstrated that transmission occurred as early as 4 hours post
introduction, and the numbers of bacteria recovered from the
nares of the recipients increased as the number of infected donor
mice in the cage was increased. Importantly, such transmission
events may not necessarily constitute a productive infection, as S.
Figure 9. Density of infected carriers determines the burden of
transmitted infection. Five week old female FVB/n donor mice
infected intranasally with S. pyogenes (1.636108 cfu per dose) were
introduced into a cage of naı¨ve recipient female mice. The Donor:
Recipient (D:R) ratio was varied between 4:4, 3:5 and 2:6 between cages.
Recipient mice were sampled at 4, 24, 48, 72 and 96 hours after the
infection and introduction of the donor mice to a cage. Data show
counts from direct nasal sampling from recipient mice only. Donor mice
had .5000 cfu recovered at all time points (not shown). The burden of
transmitted infection was significantly higher in cages with a D:R ratio
of 4:4 compared with cages with a 2:4 ratio. (AUC analysis, followed by
Kruskal Wallis with Dunns Post test p,0.05). Lines indicate the median
and the interquartile range.
doi:10.1371/journal.pone.0061655.g009
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pyogenes did not reach the same abundance in recipient mice as
observed in donor mice.
Co-mingling was then used to examine the impact of covR/S on
transmission. Despite the fact that the infection burden (as
measured by direct nasal sampling) was similar between the two
donor groups in the first 72 h, recipients housed with donor mice
carrying the DcovR/S were demonstrated to have a shorter
shedding duration than the recipient mice housed with the donors
carrying the wild type strain.
Furthermore, despite some differences between the experimen-
tal groups, settle plates placed in each cage revealed no significant
difference in aerosolization between the two strains. This suggests
that the impairment of the covR/S primarily affects the survival of
S. pyogenes in the nasopharynx after the initial transmission event
has taken place.
There is thus a fitness cost conferred by covR/S mutation specific
to the nasopharynx that may explain why such bacteria have not
Figure 10. Transmission of S. pyogenes is hampered by loss of covR/S regulation. Naı¨ve five week old female FVB/n recipients co-mingled at
a D:R ratio of 3:5 with female FVB/n mice infected with either the emm75 wild type strain or it’s isogenic DcovR/S strain (56108 cfu per dose) and
sampled after the introduction of the donor mice. Donor mice had .5000 cfu recovered from direct nasal sampling throughout the experiment. The
DcovR/S strain transmitted significantly less well to recipients compared to the wild type strain (A, n = 15 recipients per group, AUC analysis, followed
by Mann-Whitney U test). Line indicates median, error bars indicate interquartile range. Settle plates exposed to the air in the cages revealed no
significant differences in the bacteria deposited on the surface of the plates by mice infected with the strain, or the DcovR/S strain (B, n = 4 plates per
cage, AUC analysis followed by Mann-Whitney U test p.0.05) Data is shown for individual animals with medians indicated by black line.
doi:10.1371/journal.pone.0061655.g010
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become prevalent in community S. pyogenes pharyngitis despite
being advantageous in invasive infection.
The model described represents a refinement of previous
systems to study upper respiratory tract infection by S. pyogenes; the
model is non-invasive and allows longitudinal monitoring of
bacterial infection, using the same mice throughout the study.
Such a model will facilitate research which might otherwise
require prohibitively large numbers of animals and could be of
importance in future evaluation of vaccines, antimicrobials, as well
as the factors that influence transmission.
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